

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2016321244 B2**

(54) Title
Treatment of retinitis pigmentosa using engineered meganucleases

(51) International Patent Classification(s)
C12N 9/22 (2006.01) **C12N 15/861** (2006.01)

(21) Application No: **2016321244** (22) Date of Filing: **2016.09.08**

(87) WIPO No: **WO17/044649**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/215,460	2015.09.08	US

(43) Publication Date: **2017.03.16**

(44) Accepted Journal Date: **2020.09.24**

(71) Applicant(s)
Precision Biosciences, Inc.

(72) Inventor(s)
Bartsevich, Victor;Jantz, Derek;Smith, James Jefferson;Nicholson, Michael G.

(74) Agent / Attorney
Davies Collison Cave Pty Ltd, Level 15 1 Nicholson Street, MELBOURNE, VIC, 3000, AU

(56) Related Art
WO 2012167192 A2




- (51) International Patent Classification:
C12N 9/22 (2006.01) *C12N 15/861* (2006.01)
- (21) International Application Number:
PCT/US2016/050809
- (22) International Filing Date:
8 September 2016 (08.09.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/215,460 8 September 2015 (08.09.2015) US
- (71) Applicant: **PRECISION BIOSCIENCES, INC.**
[US/US]; 302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC 27701 (US).
- (72) Inventors: **BARTSEVICH, Victor**; 1008 Odyssey Drive, Durham, NC 27713 (US). **JANTZ, Derek**; 215 Hillview Drive, Durham, NC 27703 (US). **SMITH, James Jefferson**; 1808 Camation Drive, Durham, NC 27703 (US). **NICHOLSON, Michael G.**; 1200 Willow Drive, Chapel Hill, NC 27517 (US).
- (74) Agents: **TWOMEY, Michael J.** et al.; Wilmer Cutler Pickering Hale And Dorr LLP, 60 State Street, Boston, MA 02109 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


[Continued on next page]

(54) Title: TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES

A.



B.



C.




Figure 1

(57) Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.



Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The application claims the benefit of priority under 35 U.S.C. §119(e) to co-pending application Ser. No. 62/215,460, filed September 8, 2015, the contents of which are incorporated in their entirety by reference.

FIELD OF THE INVENTION

[0002] The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to recombinant meganucleases engineered to recognize and cleave a recognition sequence found in a human rhodopsin gene allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa.

BACKGROUND OF THE INVENTION

[0003] Retinitis pigmentosa (RP) is an inherited degenerative eye disease that causes severe vision impairment due to the progressive degeneration of photoreceptor cells in the retina. RP is characterized by an initial decline in rod photoreceptor cells, resulting in compromised peripheral and dim light vision. Progressive rod degeneration is followed by abnormalities in the retinal pigment epithelium and deterioration of cone photoreceptor cells. As the disease advances, patients experience nyctalopia, progressive tunnel vision, and eventual blindness. RP affects approximately 1 in 3000 people and can occur alone or together with other systemic disorders. Currently, RP has no effective treatment.

[0004] The genetic causes of RP have been identified as autosomal dominant, autosomal recessive, X-linked, or maternally acquired. The autosomal dominant form of RP represents 30-40% of cases (Ma *et al.* (2105), *Scientific Reports*. 18(5:9236):1-6), and has been associated with mutations in genes expressed in rod photoreceptor cells and the retinal pigment epithelium. The human rhodopsin gene (RHO) was the first gene shown to contribute to the pathogenesis of autosomal dominant RP and remains the most common gene associated with this form of the disease (McWilliam *et al.* (1989) *Genomics*. 5:619-622; Dryja *et al.* (1990) *Nature*. 343:364-366; Farrar *et al.* (1990) *EMBO Journal*. 21:857-864). Indeed, RHO mutations are associated with 30-40% of autosomal dominant RP cases

worldwide, and are observed in approximately 26.5% of cases in the United States (Illing *et al.* (2002) *Journal of Bio. Chem.* 277(37):34150-34160).

[0005] Rhodopsin is an essential photopigment expressed in retinal rod photoreceptor cells that is responsible for the conversion of light stimuli into electrical signals in the first step of phototransduction. Rhodopsin is expressed as a light-sensitive G-protein-coupled receptor that consists of an opsin protein moiety bound to an 11-*cis*-retinal chromophore, and represents the main component of the disk membranes of rod photoreceptor cell outer segments.

[0006] The first RHO mutation shown to contribute to autosomal dominant RP was a C to A mutation at position 68 of the RHO gene coding sequence, which confers a proline to histidine substitution at position 23 (P23H) of the encoded protein. This mutation is referred to herein as the “RHO P23H mutation,” and a RHO allele comprising the mutation is referred to herein as a “mutant RHO P23H allele.” The RHO P23H mutation is the most frequently reported RHO mutation in autosomal dominant RP cases in North America (Mao *et al.* (2011) *Human Gene Therapy.* 22:567-575), and patients having a single mutant RHO P23H allele can develop RP despite the presence of a functional wild-type RHO allele.

[0007] Rhodopsin proteins that comprise the P23H substitution fold improperly, accumulate in the endoplasmic reticulum of rod photoreceptor cells, and do not reconstitute with the 11-*cis*-retinal chromophore. In many cases of autosomal dominant RP, misfolded P23H rhodopsin contributes to rod photoreceptor cell degeneration and death. Accumulated P23H rhodopsin undergoes proteasomal and lysosomal degradation and has been shown to stimulate the ER-associated unfolded protein response, which can induce ER stress and cellular apoptosis (Lin *et al.* (2007), *Science.* 318:944-949; Gorbatyuk *et al.* (2010) *PNAS U.S.A.* 107(13):5961-5966). Misfolding of P23H rhodopsin may also contribute to cell death by interfering with the transport or function of wild-type rhodopsin (Illing *et al.*, 2002, Lin *et al.*, 2007). Furthermore, P23H rhodopsin has been shown to exhibit delayed dephosphorylation, and cell death may result from abnormal cytosolic Ca²⁺ levels (Saito *et al.* (2008) *Clin. Opthamol.* 2:821-828).

[0008] Multiple strategies have been pursued to treat autosomal dominant RP, including nutritional therapies, pharmaceuticals, and gene therapy. Gene therapy approaches have adopted either an indirect or a direct strategy for treating autosomal dominant RP. Indirect approaches have aimed to promote the survival of rod photoreceptor cells without directly affecting the expression of pathogenic mutant proteins. For example, gene therapy has been

used to introduce neurotrophic factors, such as GDNF, and anti-apoptotic proteins, such as XIAP, in retinal cells in order to inhibit apoptosis in rod photoreceptor cells.

[0009] By contrast, direct approaches in gene therapy have sought to modulate the levels of proteins that directly contribute to the pathogenesis of autosomal dominant RP. In the context of RHO-associated autosomal dominant RP, one strategy has been to enhance the proteasomal degradation of P23H rhodopsin, though no significant success has been made in animal models. Another strategy has utilized targeted RNA-based therapy to silence a mutant RHO allele while maintaining expression of the functional wild-type allele. Such approaches have used ribozymes and RNA interference (RNAi) to target specific mRNA transcripts produced by a mutant RHO P23H transgene in rats.

[0010] Further strategies have pursued a “suppression and replacement” approach by non-specifically silencing both the wild-type RHO allele and the mutant RHO allele, while concurrently delivering a replacement copy of wild-type RHO to express the wild-type protein. For example, O’Reilly *et al.* utilized adeno-associated virus (AAV) vectors to deliver and express short hairpin RNAs designed to target and suppress both the wild-type and mutant RHO alleles in heterozygous Pro23His^{+/-} mice, while also delivering and expressing a RHO replacement gene (O’Reilly *et al.* (2007) *Amer. J. of Human Genetics*. 81:127-135). Palfi *et al.* similarly demonstrated the use of AAV vectors to deliver a RHO replacement gene to Rho^{-/-} knockout mice (Palfi *et al.* (2010) *Human Gene Therapy*. 21:311-323). However, in such approaches, toxicity and off-target effects may be induced if RHO replacement levels are too high. Furthermore, off-target effects of RNAi approaches are a known complication, and it has been shown that siRNAs greater than 21 base pairs in length can induce retinal degeneration in animal models (Kleinman *et al.* (2012) *Mol. Ther.* 20(1): 101-108).

[0011] The use of engineered nucleases for cleaving DNA targets in the human RHO gene was previously disclosed in U.S. Patent Publication No. US 2012/0204282 A1 by Zhang (“the Zhang application”). The Zhang application disclosed several approaches for targeting and modulating the expression of mutant RHO alleles. Specifically, the Zhang application discussed the use of engineered DNA binding domains, such as zinc finger proteins (ZFP) and TAL effector (TALE) proteins, as repressors of RHO gene expression. The Zhang application also described fusion proteins comprising a ZFP or TALE binding domain operably linked to a regulatory or functional domain. The functional domain could be a transcriptional repressor domain that downregulates RHO gene expression.

Alternatively, the functional domain could be a transcriptional activation domain. Further, the functional domain could comprise a nuclease domain. When linked to a nuclease domain, the resulting fusion proteins include zinc finger nucleases (ZFNs) and TALE-nucleases (TALENs).

[0012] In addition to ZFNs and TALENs, the Zhang application discusses the use of meganucleases for targeting and inhibiting the expression of wild-type and/or mutant RHO alleles. The Zhang application describes the use of such meganucleases for disrupting RHO gene expression via non-homologous end joining (NHEJ) at the recognition sequence, and for introducing a replacement wild-type RHO gene sequence to express the wild-type rhodopsin protein. However, the recognition sequences in the RHO gene that are identified by the Zhang application are limited to three pairs of ZFN target sites found in the wild-type RHO gene (see, Zhang application at Table 2).

[0013] The use of engineered meganucleases for cleaving DNA targets in the RHO gene was also disclosed in U.S. Patent Publication No. US 2013/0183282 by Lemaire and Arnould (“the Lemaire application”). The Lemaire application disclosed meganucleases designed to target various regions of the RHO gene for use in one of three gene therapy strategies. The first strategy is gene correction, wherein the engineered meganucleases are specific for a recognition sequence in the vicinity of a specified mutation, induce a double-strand break at that site, and rely on homologous recombination of a corresponding non-mutant allelic sequence into the genome. The second strategy disclosed in the Lemaire application is exon knock-in, wherein a functional protein is reconstituted by using a meganuclease to introduce a synthetic wild-type coding sequence into the genome while preventing the expression of the pathologic mutation. The third strategy disclosed in the Lemaire application is gene inactivation by mutagenesis, which relies a meganuclease to induce a double-strand break at a target recognition sequence in the genome, and NHEJ at the cleavage site to induce a mutation.

[0014] Accordingly, there is still a need in the art for methods that can preferentially target and inactivate the RHO P23H allele for treatment of RP.

SUMMARY OF THE INVENTION

[0015] The present invention provides recombinant meganucleases that are engineered to recognize and cleave P23H recognition sequences. The present invention further provides methods comprising the delivery of such a recombinant meganuclease, or genes encoding such a recombinant meganuclease, to the cells of a patient having RP, such that the

recombinant meganuclease (or encoded recombinant meganuclease) preferentially targets and cleaves a P23H recognition sequence present on the mutant RHO P23H allele. NHEJ occurs at the cleavage site, resulting in mutagenesis and disruption of the mutant RHO P23H allele, while the functional wild-type RHO allele remains intact to express wild-type rhodopsin in rod photoreceptor cells of the retina. Preferential inactivation of the mutant RHO P23H allele, and disruption of P23H rhodopsin expression, is expected to delay, prevent, or reverse the progression of RP in patients.

[0016] Thus, in some embodiments, the present invention provides recombinant meganucleases that are engineered to recognize and cleave a P23H recognition sequence, which is present in the mutant RHO P23H allele but not in the wild-type RHO allele. The present invention further provides the use of such a recombinant meganuclease in a method for treating RP, preferably autosomal dominant RP, wherein the mutant RHO P23H allele is preferentially targeted and cleaved. In this manner, expression of P23H rhodopsin is suppressed due to NHEJ at the meganuclease cleavage site, while the functional wild-type RHO allele remains intact to express wild-type rhodopsin in rod photoreceptor cells of the retina.

[0017] Thus, the invention includes the use of site-specific, rare-cutting, homing endonucleases (also called “meganucleases”) that are engineered to recognize specific DNA sequences in a locus of interest. Homing endonucleases are a group of naturally-occurring nucleases which recognize 15-40 base pair cleavage sites commonly found in the genomes of plants and fungi. They are frequently associated with parasitic DNA elements, such as group 1 self-splicing introns and inteins. They naturally promote homologous recombination or gene insertion at specific locations in the host genome by producing a double-stranded break in the chromosome, which recruits the cellular DNA-repair machinery (Stoddard (2006), *Q. Rev. Biophys.* 38:49-95). Homing endonucleases are commonly grouped into four families: the LAGLIDADG (SEQ ID NO:96) family, the GIY-YIG family, the His-Cys box family and the HNH family. These families are characterized by structural motifs, which affect catalytic activity and recognition sequence. For instance, members of the LAGLIDADG (SEQ ID NO:96) family are characterized by having either one or two copies of the conserved LAGLIDADG (SEQ ID NO:96) motif (Chevalier *et al.* (2001), *Nucleic Acids Res.* 29(18): 3757-3774). The LAGLIDADG (SEQ ID NO:96) homing endonucleases with a single copy of the LAGLIDADG (SEQ ID NO:96) motif form homodimers, whereas members with two copies of the LAGLIDADG (SEQ ID NO:96) motif are found as monomers.

[0018] Methods for producing engineered, site-specific recombinant meganucleases are known in the art. I-CreI (SEQ ID NO:95) is a member of the LAGLIDADG (SEQ ID NO:96) family of homing endonucleases which recognizes and cuts a 22 base pair recognition sequence in the chloroplast chromosome of the algae *Chlamydomonas reinhardtii*. Genetic selection techniques have been used to modify the wild-type I-CreI cleavage site preference (Sussman *et al.* (2004), *J. Mol. Biol.* 342: 31-41; Chames *et al.* (2005), *Nucleic Acids Res.* 33: e178; Seligman *et al.* (2002), *Nucleic Acids Res.* 30: 3870-9, Arnould *et al.* (2006), *J. Mol. Biol.* 355: 443-58). More recently, a method of rationally-designing mono-LAGLIDADG (SEQ ID NO:96) homing endonucleases was described which is capable of comprehensively redesigning I-CreI and other homing endonucleases to target widely-divergent DNA sites, including sites in mammalian, yeast, plant, bacterial, and viral genomes (WO 2007/047859).

[0019] As first described in WO 2009/059195, I-CreI and its engineered derivatives are normally dimeric but can be fused into a single polypeptide using a short peptide linker that joins the C-terminus of a first subunit to the N-terminus of a second subunit (see also Li, *et al.* (2009) *Nucleic Acids Res.* 37:1650-62; Grizot, *et al.* (2009) *Nucleic Acids Res.* 37:5405-19.) Thus, a functional “single-chain” meganuclease can be expressed from a single transcript. Such engineered meganucleases exhibit an extremely low frequency of off-target cutting. By delivering a gene encoding a single-chain meganuclease to retinal cells, and preferably to rod photoreceptor cells, it is possible to specifically and preferentially target, cleave, and inactivate the mutant RHO P23H allele, thus suppressing expression of P23H rhodopsin.

[0020] Thus, in one aspect, the invention provides a recombinant meganuclease that recognizes and cleaves a recognition sequence comprising the mutation which encodes P23H substitution in the P23H mutant allele. In some embodiments, the recognition sequence is selected from the SEQ ID NOs:1-4 (*i.e.*, the P23H recognition sequences). The recombinant meganuclease comprises a first subunit and a second subunit, wherein the first subunit recognizes a first recognition half-site of one of the P23H recognition sequences and comprises an (a) an amino acid sequence having at least 80% sequence identity to residues 198-344 of any one of SEQ ID NOs:6-69 or residues 7-153 of any one of SEQ ID NOs:70-93; and (b) a first hypervariable (HVR1) region which determines specificity for the first recognition half-site. The recombinant meganuclease further comprises a second subunit that recognizes a second half-site of one of the P23H recognition sequences and comprises: (a) an

amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs:6-69 or residues 198-344 of any one of SEQ ID NOs:70-93; and (b) a second hypervariable (HVR2) region which determines specificity for the second recognition half-site. In some embodiments, the P23H recognition sequence is SEQ ID NO:1 and the recombinant meganuclease comprises a first subunit and a second subunit, wherein the first subunit recognizes a first recognition half-site of one of SEQ ID NO:1 and comprises (a) an amino acid sequence having at least 80% sequence identity to residues 198-344 of any one of SEQ ID NOs:6-69 or residues 7-153 of any one of SEQ ID NOs:70-93; and (b) a first hypervariable (HVR1) region which determines specificity for the first recognition half-site. The recombinant meganuclease further comprises a second subunit that recognizes a second half-site of SEQ ID NO:1 and comprises: (a) an amino acid sequence having at least 80% sequence identity to residues 7-153 of any one of SEQ ID NOs:6-69 or residues 198-344 of any one of SEQ ID NOs:70-93; and (b) a second hypervariable (HVR2) region which determines specificity for the second recognition half-site.

[0021] In some embodiments, the P23H recognition sequence is SEQ ID NO:1 and the first subunit comprises an amino acid sequence having at least 85%, 90%, or 95% sequence identity to residues 198-344 of any one of SEQ ID NOs:6-69 or residues 7-153 of any one of SEQ ID NOs:70-93, and the second subunit comprises an amino acid sequence having at least 85%, 90%, or 95% sequence identity to residues 7-153 of any one of SEQ ID NOs:6-69 or residues 198-344 of any one of SEQ ID NOs:70-93.

[0022] In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR1 region comprises W or Y at a position corresponding to: (a) position 215 of any one of SEQ ID NOs:6-69; or (b) position 24 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR1 region comprises I at a position corresponding to: (a) position 219 of any one of SEQ ID NOs:6-69; or (b) position 28 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR1 region comprises V at a position corresponding to: (a) position 259 of any one of SEQ ID NOs:6-69; or (b) position 68 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR1 region comprises one or more of W or Y, I, and V at positions corresponding to (a) positions 215, 219, and 259, respectively, of any one of SEQ ID NOs:6-69; or (b) positions 24, 28, and 68, respectively, of any one of SEQ ID NOs:70-93.

[0023] In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises Y or M at a position corresponding to (a) position 24 of any one of SEQ ID NOs:6-69; or (b) position 215 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises F at a position corresponding to (a) position 28 of any one of SEQ ID NOs:6-69; or (b) position 219 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises H at a position corresponding to (a) position 44 of any one of SEQ ID NOs:6-69; or (b) position 235 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises S at a position corresponding to (a) position 46 of any one of SEQ ID NOs:6-69; or (b) position 237 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises W at a position corresponding to (a) position 70 of any one of SEQ ID NOs:6-69; or (b) position 261 of any one of SEQ ID NOs:70-93. In other embodiments, the P23H recognition sequence is SEQ ID NO:1 and the HVR2 region comprises one or more of Y or M, F, H, S, and W at positions corresponding to (a) positions 24, 28, 44, 46, and 70, respectively, of any one of SEQ ID NOs:6-69; or (b) positions 215, 219, 235, 237, and 261, respectively, of any one of SEQ ID NOs:70-93.

[0024] In some embodiments, the recombinant meganuclease is a single-chain meganuclease comprising a linker, wherein the linker covalently joins the first subunit and the second subunit.

[0025] In some embodiments, the P23H recognition sequence is SEQ ID NO:1 and the first subunit comprises residues 198-344 of any one of SEQ ID NOs:6-69 or residues 7-153 of any one of SEQ ID NOs:70-93. In some embodiments, the P23H recognition sequence is SEQ ID NO:1 and the second subunit comprises residues 7-153 of any one of SEQ ID NOs:6-69 or residues 198-344 of any one of SEQ ID NOs:70-93.

[0026] In some specific embodiments, the P23H recognition sequence is SEQ ID NO:1 and the meganuclease comprises the amino acid sequence of any one of SEQ ID NOs:6-93.

[0027] In some embodiments, the recombinant meganuclease preferentially recognizes and cleaves one of the P23H recognition sequences (SEQ ID NOs:1-4) relative to the corresponding 22 base pair recognition sequence present in the wild-type RHO allele (*e.g.*, SEQ ID NO: 1 relative to SEQ ID NO:5).

[0028] In another aspect, the invention provides an isolated polynucleotide comprising a nucleic acid sequence encoding a recombinant meganuclease described herein.

[0029] In another aspect, the invention provides a recombinant DNA construct comprising an isolated polynucleotide, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein. In some embodiments, the recombinant DNA construct encodes a viral vector. In some such embodiments, the viral vector can be a retroviral vector, a lentiviral vector, an adenoviral vector, or an adeno-associated viral (AAV) vector. In some particular embodiment, the recombinant DNA construct encodes a recombinant AAV vector.

[0030] In another aspect, the invention provides a viral vector comprising an isolated polynucleotide, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein. In some embodiments, the viral vector can be a retroviral vector, a lentiviral vector, an adenoviral vector, or an AAV vector. In some particular embodiments, the viral vector can be a recombinant AAV vector.

[0031] In another aspect, the invention provides a pharmaceutical composition for treatment of a subject having RP, preferably autosomal dominant RP caused by the P23H mutation. The pharmaceutical composition can comprise a pharmaceutically acceptable carrier and: (a) a nucleic acid encoding a recombinant meganuclease described herein, wherein the recombinant meganuclease is expressed in a target cell *in vivo*; or (b) a recombinant meganuclease protein described herein; wherein the recombinant meganuclease has specificity for one of the P23H recognition sequences (SEQ ID NOs:1-4) in the target cell.

[0032] In some embodiments, the nucleic acid encoding the recombinant meganuclease can be an mRNA.

[0033] In other embodiments, the pharmaceutical composition comprises a recombinant DNA construct comprising the nucleic acid.

[0034] In some embodiments, the pharmaceutical composition comprises a viral vector comprising the nucleic acid. In one such embodiment, the viral vector can be a retroviral vector, a lentiviral vector, an adenoviral vector, or an AAV vector. In some particular embodiments, the viral vector can be a recombinant AAV vector.

[0035] In another aspect, the invention provides a recombinant meganuclease described herein for use as a medicament. The invention further provides the use of a recombinant meganuclease described herein in the manufacture of a medicament for treating RP,

preferably autosomal dominant RP caused by the P23H mutation, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele.

[0036] In another aspect, the invention provides an isolated polynucleotide for use as a medicament, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein. The invention further provides the use of an isolated polynucleotide in the manufacture of a medicament for treating RP, preferably autosomal dominant RP caused by the P23H mutation, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele, wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein.

[0037] In another aspect, the invention provides a recombinant AAV vector for use as a medicament, wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein. The invention further provides the use of a recombinant AAV vector in the manufacture of a medicament for treating RP, preferably autosomal dominant RP caused by the P23H mutation, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele wherein the recombinant AAV vector comprises an isolated polynucleotide, and wherein the isolated polynucleotide comprises a nucleic acid sequence encoding a recombinant meganuclease described herein.

[0038] In another aspect, the invention provides a method for treating RP caused by the P23H mutation in a subject in need thereof, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele. The method comprises contacting the DNA of a target cell of said subject with a recombinant meganuclease described herein that recognizes and cleaves the a recognition sequence including the P23H mutation (e.g, SEQ ID NOs:1-4). The target cell of the subject comprises the P23H recognition sequence in a RHO gene allele, and cleavage of the recognition sequence inhibits expression of the RHO gene allele.

[0039] In some embodiments, the method is for treating autosomal dominant RP caused by the P23H mutation, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele.

[0040] In some embodiments, the target cell in the subject is a retinal target cell. In preferred embodiments, the retinal cell is a rod photoreceptor cell.

[0041] In some embodiments of the method, a nucleic acid encoding the recombinant meganuclease is introduced into the target cell. In some such embodiments, the nucleic acid can be an mRNA. In other such embodiments, the nucleic acid can be introduced into the cell using a recombinant DNA construct. In yet other such embodiments, the nucleic acid can be introduced into the target cell using a viral vector such as a retroviral vector, a lentiviral vector, an adenoviral vector, or an AAV vector. In some particular embodiment, a gene encoding the recombinant meganuclease is delivered to the target cell using a recombinant AAV vector.

[0042] In other embodiments of the method, a recombinant meganuclease protein of the invention is introduced into the target cell.

[0043] In the various embodiments of the method, the recombinant meganuclease protein, or a nucleic acid encoding the recombinant meganuclease, can be administered to the subject in a pharmaceutical composition described herein.

[0044] In another aspect, the invention provides a method for producing a genetically-modified cell. The method comprises: (a) obtaining a cell comprising at least one P23H RHO allele; and (b) introducing into the cell: (i) a nucleic acid sequence encoding a recombinant meganuclease of the invention, wherein the recombinant meganuclease is expressed in the cell; or (ii) a recombinant meganuclease protein; wherein the recombinant meganuclease has specificity for a P23H recognition sequence present on the P23H RHO allele(s); and wherein the recombinant meganuclease recognizes and cleaves the P23H recognition sequence; and wherein expression of the P23H RHO allele is disrupted by non-homologous end joining at the cleavage site. Preferably the cell is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele prior to the modification.

[0045] In some embodiments of the method, the cell can be a eukaryotic cell. In some such embodiments, the eukaryotic cell can be a pluripotent cell. In such embodiments, the pluripotent cell can be an induced pluripotent stem (iPS) cell. In some particular embodiments, the iPS cell can be a human iPS cell.

[0046] In other embodiments of the method, the nucleic acid can be an mRNA.

[0047] In some embodiment of the method, the nucleic acid can be introduced into the cell using a recombinant DNA construct.

[0048] In some embodiments of the method, the nucleic acid can be introduced into the cell using a viral vector. In some such embodiments, the viral vector can be a retroviral

vector, a lentiviral vector, an adenoviral vector, or an AAV vector. In some particular embodiments, the viral vector can be a recombinant AAV vector.

[0049] In another aspect, the invention provides a genetically-modified cell, wherein the genetically-modified cell comprises a wild-type RHO allele and a disrupted P23H allele, wherein the genetically-modified cell expresses a wild-type RHO protein and does not express a P23H RHO protein, and wherein the genetically-modified cell is produced according to the methods of the invention described herein. In some embodiments, the disrupted P23H allele includes a deletion mutation caused by cleavage with the meganuclease and NHEJ. In some particular embodiments, the genetically-modified cell can be a pluripotent cell, an iPS cell, or a human iPS cell.

[0050] In another aspect, the invention provides a pharmaceutical composition for treatment of a subject having RP caused by the P23H mutation, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele. In different embodiments, the pharmaceutical composition can comprise a pharmaceutically acceptable carrier and any genetically-modified cell of the invention, and/or any genetically-modified cell produced according to the methods of the invention, which comprises a wild-type RHO allele that expresses wild-type RHO protein and a disrupted P23H allele which does not express P23H RHO protein. In some embodiments, the disrupted P23H allele includes a deletion mutation caused by cleavage with the meganuclease and NHEJ.

[0051] In another aspect, the invention provides a method for treating RP caused by the P23H mutation in a subject in need thereof, and preferably for a subject that is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele. The method comprises administering to the subject a pharmaceutical composition described herein which comprises a pharmaceutically acceptable carrier and a genetically-modified cell of the invention, which comprises a wild-type RHO allele that expresses wild-type RHO protein and a disrupted P23H allele which does not express P23H RHO protein. In some embodiments, the disrupted P23H allele includes a deletion mutation caused by cleavage with the meganuclease and NHEJ.

[0052] In some embodiments of the method, the genetically-modified cell can be delivered to a target tissue. Such target tissues can include the eye, and particularly the retina.

[0053] Further, in some embodiments of the method, the genetically-modified cell can be a genetically-modified iPS cell. In such embodiments, the genetically-modified iPS cell can

differentiate into a cell which expresses wild-type RHO protein when it is delivered to the target tissue. In some particular embodiments, the genetically-modified iPS cell can differentiate into a retinal cell, and particularly into a rod photoreceptor cell, which expresses the wild-type rhodopsin protein but not the P23H rhodopsin protein.

BRIEF DESCRIPTION OF THE FIGURES

[0054] Figure 1. P23H recognition sequence. A) Alignment of the 22 base pair P23H recognition sequence of SEQ ID NO:1 with the corresponding 22 base pair recognition sequence present in the wild-type human RHO gene allele (SEQ ID NO:5). These sequences span nucleotides 49 to 70 of the P23H mutant or wild-type RHO gene coding sequences (SEQ ID NOs:98 and 97, respectively). The C68A nucleotide substitution within the P23H recognition sequence is highlighted. B) The P23H recognition sequence of SEQ ID NO:1 comprises two recognition half-sites, referred to as RHO1 and RHO2. Each recognition half-site comprises 9 base pairs as shown. Half-sites in the recognition sequence are separated by a 4 base pair central region. C) The recombinant meganuclease of the invention comprises two subunits, wherein the first subunit binds to the a first half-site (*e.g.*, RHO1) of a P23H recognition sequence (*e.g.*, SEQ ID NO:1) and the second subunit binds to a second half-site (*e.g.*, RHO2). In embodiments where the recombinant meganuclease is a single-chain meganuclease, the first subunit can be positioned as either the N-terminal or C-terminal subunit. Likewise, the second subunit can be positioned as either the N-terminal or C-terminal subunit.

[0055] Figures 2A-2F. Amino acid alignment of RHO1-binding subunits. A-F) Recombinant meganucleases encompassed by the invention comprise one subunit that binds the 9 base pair RHO1 recognition half-site of SEQ ID NO:1. Amino acid sequence alignments are provided for the RHO1-binding subunits (SEQ ID NOs:102-188) of the recombinant meganucleases set forth in SEQ ID NOs:6-93. As shown, the RHO1-binding subunit of SEQ ID NOs:6-69 comprises residues 198-344, whereas the RHO1-binding subunit of SEQ ID NOs:70-93 comprises residues 7-153. Each RHO1-binding subunit comprises a 56 amino acid hypervariable region as indicated. Variable residues within the hypervariable region are shaded, with the most frequent amino acids at each position further highlighted; the most prevalent residues are bolded, whereas the second most prevalent are bolded and italicized. Residues outside of the hypervariable region are identical in each subunit (but this is not required), with the exception of a Q or E residue at position 80 or

position 271 (see, U.S. Patent No. 8,021,867). Nearly all RHO1-binding subunits provided in Figure 2A-2F share at least 90% sequence identity to the RHO1-binding subunit (residues 198-344) of the RHO2-L3-59 meganuclease (SEQ ID NO:102). Residue numbers shown are those of SEQ ID NOs:6-93.

[0056] Figures 3A-3F. Amino acid alignment of RHO2-binding subunits. A-F) Recombinant meganucleases encompassed by the invention comprise one subunit that binds the 9 base pair RHO2 recognition half-site of SEQ ID NO:1. Amino acid sequence alignments are provided for the RHO2-binding subunits (SEQ ID NOs:190-277) of the recombinant meganucleases set forth in SEQ ID NOs:6-93. As shown, the RHO2-binding subunit of SEQ ID NOs:6-69 comprises residues 7-153, whereas the RHO2-binding subunit of SEQ ID NOs:70-93 comprises residues 198-344. Each RHO2-binding subunit comprises a 56 amino acid hypervariable region as indicated. Variable residues within the hypervariable region are shaded, with the most frequent amino acids at each position further highlighted; the most prevalent residues are bolded, whereas the second most prevalent are bolded and italicized. Residues outside of the hypervariable region are identical in each subunit (but this is not required), with the exception of a Q or E residue at position 80 or position 271 (see, U.S. Patent No. 8,021,867). Nearly all RHO2-binding subunits provided in Figures 3A-3F share at least 90% sequence identity to the RHO2-binding subunit (residues 7-153) of the RHO2-L3-59 meganuclease (SEQ ID NO:190). Residue numbers shown are those of SEQ ID NOs:6-93.

[0057] Figure 4. Schematic of reporter assay in CHO cells for evaluating recombinant meganucleases targeting a P23H recognition sequence. For the recombinant meganucleases described herein, a CHO cell line was produced in which a reporter cassette was integrated stably into the genome of the cell. The reporter cassette comprised, in 5' to 3' order: an SV40 Early Promoter; the 5' 2/3 of the GFP gene; the recognition sequence for an engineered meganuclease of the invention, for example a P23H recognition sequence of any one of SEQ ID NOs:1-4; the recognition sequence for the CHO-23/24 meganuclease (WO 2012/167192); and the 3' 2/3 of the GFP gene. Cells stably transfected with this cassette did not express GFP in the absence of a DNA break-inducing agent. Meganucleases were introduced by transduction of plasmid DNA or mRNA encoding each meganuclease. When a DNA break was induced at either of the meganuclease recognition sequences, the duplicated regions of the GFP gene recombined with one another to produce a functional GFP gene. The

percentage of GFP-expressing cells could then be determined by flow cytometry as an indirect measure of the frequency of genome cleavage by the meganucleases.

[0058] Figure 5. Efficiency of recombinant meganucleases for recognizing and cleaving a P23H recognition sequence in a CHO cell reporter assay. A)-J) Each of the recombinant meganucleases set forth in SEQ ID NOs:6-93 were engineered to target a P23H recognition sequence and were screened for efficacy in the CHO cell reporter assay. The results shown provide the percentage of GFP-expressing cells observed in each assay, which indicates the efficacy of each meganuclease for cleaving the P23H recognition sequence or the CHO-23/24 recognition sequence. A negative control (RHO 1-2 bs) was further included in each assay.

[0059] Figure 6. Time course of recombinant meganuclease efficacy in CHO cell reporter assay. Recombinant meganucleases encompassed by the invention were evaluated in the CHO reporter assay, with the percentage of GFP-expressing cells determined 1, 4, 6, and 8 days after introduction of meganuclease-encoding mRNA into the CHO reporter cells. A CHO-23/24 meganuclease was included at each time point as a positive control.

[0060] Figure 7. Selectivity of recombinant meganucleases. A)-F) The selectivity of recombinant meganucleases for a P23H recognition sequence (SEQ ID NO:1) versus the corresponding wild-type RHO recognition sequence (SEQ ID NO:5) was determined using the CHO cell reporter assay. Recombinant meganucleases encompassed by the invention were introduced into cells comprising a P23H recognition sequence ("RHO 1-2 cells," gray bars) or the corresponding wild-type RHO recognition sequence ("RHO 3-4 cells," black bars) to determine if they could discriminate between the mutant and wild-type targets.

[0061] Figure 8. Generation and expression of recombinant AAV vectors. A) Diagram of recombinant AAV vector genome shown with inverted terminal repeats (ITRs) at the 5' and 3' ends. The vector comprises the coding sequence for the recombinant meganuclease RHO-1/2-L2-49 (SEQ ID NO:8) operably linked to a cytomegalovirus-early (CMV) promoter. The nuclease expression cassette was incorporated into a "packaging" plasmid that was used in conjunction with an Ad helper plasmid to produce recombinant AAV capable of delivering genes encoding the RHO-1/2-L2-49 meganuclease. B) Immunoblot of RHO-1/2-L2-49 meganuclease expression in recombinant AAV-transduced CHO cells after 24 hours.

[0062] Figure 9. Efficiency and selectivity of a RHO-1/2-L2-49 meganuclease for a P23H recognition sequence (SEQ ID NO:1) when expressed by recombinant AAV in a CHO cell reporter assay. CHO cells harboring the wild-type recognition sequence (SEQ ID NO:5; "RHO 3-4 cells", black bars) or the P23H recognition sequence (SEQ ID NO:1; "RHO 1-2

cells,” gray bars) were transduced with three different doses of AAV2 vector encoding the RHO-1/2-L2-49 meganuclease operably linked to a CMV promoter.

[0063] Figure 10. RHO-1/2-L2-49 meganuclease stability in CHO reporter cells following treatment with cycloheximide.

[0064] Figure 11. A) Vector map of the pDS CMV RHO2_L3_59 plasmid (SEQ ID NO:278). B) Vector map of the pDS CMV RHO2_L5_14 plasmid (SEQ ID NO:279).

[0065] Figure 12. CHO GFP reporter assay demonstrating specificity of RHO 1-2 meganucleases for RHO 1-2 recognition sequence. CHO-K cells (controls), WT RHO cells (comprising wild-type RHO sequence of SEQ ID NO:5), or P23H RHO cells (comprising P23H RHO sequence of SEQ ID NO:1) were transduced with low, medium, or high titers of recombinant AAV vectors encoding a GFP protein, the RHO2-L3-59 meganuclease (SEQ ID NO:6), or the RHO2-L5-14 meganuclease (SEQ ID NO:7). The percent of GFP-positive cells was determined in each cell line following transduction as a measure of recognition sequence cleavage.

[0066] Figure 13. Western blot analysis of meganuclease expression in CHO RHO 1-2 cells following transduction of recombinant AAV vectors. P23H RHO cells, comprising the RHO 1-2 recognition sequence, were transduced with $1e8$, $1e9$, or $2e9$ viral genomes per cell of recombinant AAV vectors encoding the RHO2-L3-59 meganuclease (SEQ ID NO:6) or the RHO2-L5-14 meganuclease (SEQ ID NO:7). Cell lysates were analyzed for expression of GFP as a measure of RHO 1-2 recognition sequence cleavage (top panel), meganuclease expression (bottom panel), and β -actin as a loading control. Lanes 1-6 were transduced to express the RHO2-L3-59 meganuclease. Lanes 7-12 were transduced to express the RHO2-L5-14 meganuclease.

[0067] Figure 14. Vector map of the pDS GRK1 RHO2_L5_14 plasmid (SEQ ID NO:281).

[0068] Figure 15. Western blot analysis of meganuclease expression in mouse retinal cells following subretinal AAV injection. Wild-type mice were administered a recombinant AAV vector encoding the RHO2-L5-14 meganuclease (SEQ ID NO:7) by subretinal injection. Retinal cells were obtained from the left (OS) and right (OD) eye of five mice and cell lysates were analyzed by Western blot for the expression of the RHO2-L5-14 meganuclease and β -actin.

BRIEF DESCRIPTION OF THE SEQUENCES

- [0069] SEQ ID NO:1 sets forth the nucleotide sequence of one P23H recognition sequence (RHO-1/2).
- [0070] SEQ ID NO:2 sets forth the nucleotide sequence of one P23H recognition sequence (RHO-9/10).
- [0071] SEQ ID NO:3 sets forth the nucleotide sequence of one P23H recognition sequence (RHO-11/12).
- [0072] SEQ ID NO:4 sets forth the nucleotide sequence of one P23H recognition sequence (RHO-13/14).
- [0073] SEQ ID NO:5 sets forth the nucleotide sequence of the corresponding recognition sequence found in the wild-type RHO allele (*i.e.*, the RHO 3-4 recognition sequence).
- [0074] SEQ ID NO: 6 sets forth the amino acid sequence of the RHO2-L3-59 meganuclease.
- [0075] SEQ ID NO: 7 sets forth the amino acid sequence of the RHO2-L5-14 meganuclease.
- [0076] SEQ ID NO: 8 sets forth the amino acid sequence of the RHO-1/2-L2-49 meganuclease.
- [0077] SEQ ID NO: 9 sets forth the amino acid sequence of the RHO 1-2x.179 meganuclease.
- [0078] SEQ ID NO: 10 sets forth the amino acid sequence of the RHO 1-2x.4 meganuclease.
- [0079] SEQ ID NO: 11 sets forth the amino acid sequence of the RHO 1-2x.207 meganuclease.
- [0080] SEQ ID NO: 12 sets forth the amino acid sequence of the RHO 1-2x.277 meganuclease.
- [0081] SEQ ID NO: 13 sets forth the amino acid sequence of the RHO 1-2x.292 meganuclease.
- [0082] SEQ ID NO: 14 sets forth the amino acid sequence of the RHO 1-2x.324 meganuclease.
- [0083] SEQ ID NO: 15 sets forth the amino acid sequence of the RHO 1-2x.371 meganuclease.
- [0084] SEQ ID NO: 16 sets forth the amino acid sequence of the RHO 1-2x.164 meganuclease.

- [0085] SEQ ID NO: 17 sets forth the amino acid sequence of the RHO 1-2x.181 meganuclease.
- [0086] SEQ ID NO: 18 sets forth the amino acid sequence of the RHO 1-2x.184 meganuclease.
- [0087] SEQ ID NO: 19 sets forth the amino acid sequence of the RHO-1/2-L1-21 meganuclease.
- [0088] SEQ ID NO: 20 sets forth the amino acid sequence of the RHO-1/2-L1-43 meganuclease.
- [0089] SEQ ID NO: 21 sets forth the amino acid sequence of the RHO-1/2-L1-45 meganuclease.
- [0090] SEQ ID NO: 22 sets forth the amino acid sequence of the RHO-1/2-L1-60 meganuclease.
- [0091] SEQ ID NO: 23 sets forth the amino acid sequence of the RHO-1/2-L1-61 meganuclease.
- [0092] SEQ ID NO: 24 sets forth the amino acid sequence of the RHO-1/2-L1-58 meganuclease.
- [0093] SEQ ID NO: 25 sets forth the amino acid sequence of the RHO-1/2-L1-7 meganuclease.
- [0094] SEQ ID NO: 26 sets forth the amino acid sequence of the RHO-1/2-L1-13 meganuclease.
- [0095] SEQ ID NO: 27 sets forth the amino acid sequence of the RHO-1/2-L1-18 meganuclease.
- [0096] SEQ ID NO: 28 sets forth the amino acid sequence of the RHO-1/2-L1-70 meganuclease.
- [0097] SEQ ID NO: 29 sets forth the amino acid sequence of the RHO-1/2-L1-86 meganuclease.
- [0098] SEQ ID NO: 30 sets forth the amino acid sequence of the RHO-1/2-L2-13 meganuclease.
- [0099] SEQ ID NO: 31 sets forth the amino acid sequence of the RHO-1/2-L2-24 meganuclease.
- [0100] SEQ ID NO: 32 sets forth the amino acid sequence of the RHO-1/2-L2-37 meganuclease.

[0101] SEQ ID NO: 33 sets forth the amino acid sequence of the RHO-1/2-L2-58 meganuclease.

[0102] SEQ ID NO: 34 sets forth the amino acid sequence of the RHO-1/2-L2-31 meganuclease.

[0103] SEQ ID NO: 35 sets forth the amino acid sequence of the RHO-1/2-L2-29 meganuclease.

[0104] SEQ ID NO: 36 sets forth the amino acid sequence of the RHO-1/2-L2-61 meganuclease.

[0105] SEQ ID NO: 37 sets forth the amino acid sequence of the RHO2-L3-2 meganuclease.

[0106] SEQ ID NO: 38 sets forth the amino acid sequence of the RHO2-L3-3 meganuclease.

[0107] SEQ ID NO: 39 sets forth the amino acid sequence of the RHO2-L3-5 meganuclease.

[0108] SEQ ID NO: 40 sets forth the amino acid sequence of the RHO2-L3-10 meganuclease.

[0109] SEQ ID NO: 41 sets forth the amino acid sequence of the RHO2-L3-11 meganuclease.

[0110] SEQ ID NO: 42 sets forth the amino acid sequence of the RHO2-L3-12 meganuclease.

[0111] SEQ ID NO: 43 sets forth the amino acid sequence of the RHO2-L3-13 meganuclease.

[0112] SEQ ID NO: 44 sets forth the amino acid sequence of the RHO2-L3-28 meganuclease.

[0113] SEQ ID NO: 45 sets forth the amino acid sequence of the RHO2-L3-29 meganuclease.

[0114] SEQ ID NO: 46 sets forth the amino acid sequence of the RHO2-L3-57 meganuclease.

[0115] SEQ ID NO: 47 sets forth the amino acid sequence of the RHO2-L3-80 meganuclease.

[0116] SEQ ID NO: 48 sets forth the amino acid sequence of the RHO2-L3-85 meganuclease.

- [0117] SEQ ID NO: 49 sets forth the amino acid sequence of the RHO2-L3-86 meganuclease.
- [0118] SEQ ID NO: 50 sets forth the amino acid sequence of the RHO2-L3-92 meganuclease.
- [0119] SEQ ID NO: 51 sets forth the amino acid sequence of the RHO2-L3-4 meganuclease.
- [0120] SEQ ID NO: 52 sets forth the amino acid sequence of the RHO2-L3-20 meganuclease.
- [0121]** SEQ ID NO: 53 sets forth the amino acid sequence of the RHO2-L3-72 meganuclease.
- [0122] SEQ ID NO: 54 sets forth the amino acid sequence of the RHO1-L1-4 meganuclease.
- [0123] SEQ ID NO: 55 sets forth the amino acid sequence of the RHO1-L1-8 meganuclease.
- [0124] SEQ ID NO: 56 sets forth the amino acid sequence of the RHO1-L1-13 meganuclease.
- [0125] SEQ ID NO: 57 sets forth the amino acid sequence of the RHO1-L1-19 meganuclease.
- [0126] SEQ ID NO: 58 sets forth the amino acid sequence of the RHO1-L1-58 meganuclease.
- [0127] SEQ ID NO: 59 sets forth the amino acid sequence of the RHO1-L1-69 meganuclease.
- [0128] SEQ ID NO: 60 sets forth the amino acid sequence of the RHO1-L1-80 meganuclease.
- [0129] SEQ ID NO: 61 sets forth the amino acid sequence of the RHO1-L1-82 meganuclease.
- [0130] SEQ ID NO: 62 sets forth the amino acid sequence of the RHO1-L1-73 meganuclease.
- [0131] SEQ ID NO: 63 sets forth the amino acid sequence of the RHO1-L1-85 meganuclease.
- [0132] SEQ ID NO: 64 sets forth the amino acid sequence of the RHO1-L1-86 meganuclease.

- [0133] SEQ ID NO: 65 sets forth the amino acid sequence of the RHO-1/2-L4-10 meganuclease.
- [0134] SEQ ID NO: 66 sets forth the amino acid sequence of the RHO-1/2-L4-29 meganuclease.
- [0135] SEQ ID NO: 67 sets forth the amino acid sequence of the RHO-1/2-L4-65 meganuclease.
- [0136] SEQ ID NO: 68 sets forth the amino acid sequence of the RHO-1/2-L4-66 meganuclease.
- [0137] SEQ ID NO: 69 sets forth the amino acid sequence of the RHO-1/2-L4-85 meganuclease.
- [0138] SEQ ID NO: 70 sets forth the amino acid sequence of the RHO 1-2x.216 meganuclease.
- [0139]** SEQ ID NO: 71 sets forth the amino acid sequence of the RHO 1-2x.241 meganuclease.
- [0140] SEQ ID NO: 72 sets forth the amino acid sequence of the RHO 1-2x.94 meganuclease.
- [0141] SEQ ID NO: 73 sets forth the amino acid sequence of the RHO 1-2x.95 meganuclease.
- [0142] SEQ ID NO: 74 sets forth the amino acid sequence of the RHO 1-2x.1 meganuclease.
- [0143] SEQ ID NO: 75 sets forth the amino acid sequence of the RHO 1-2x.60 meganuclease.
- [0144] SEQ ID NO: 76 sets forth the amino acid sequence of the RHO 1-2x.74 meganuclease.
- [0145] SEQ ID NO: 77 sets forth the amino acid sequence of the RHO 1-2x.88 meganuclease.
- [0146] SEQ ID NO: 78 sets forth the amino acid sequence of the RHO 1-2x.294 meganuclease.
- [0147] SEQ ID NO: 79 sets forth the amino acid sequence of the RHO 1-2x.302 meganuclease.
- [0148] SEQ ID NO: 80 sets forth the amino acid sequence of the RHO 1-2x.306 meganuclease.

- [0149] SEQ ID NO: 81 sets forth the amino acid sequence of the RHO 1-2x.338 meganuclease.
- [0150]** SEQ ID NO: 82 sets forth the amino acid sequence of the RHO 1-2x.348 meganuclease.
- [0151] SEQ ID NO: 83 sets forth the amino acid sequence of the RHO 1-2x.356 meganuclease.
- [0152] SEQ ID NO: 84 sets forth the amino acid sequence of the RHO 1-2x.364 meganuclease.
- [0153] SEQ ID NO: 85 sets forth the amino acid sequence of the RHO 1-2x.142 meganuclease.
- [0154] SEQ ID NO: 86 sets forth the amino acid sequence of the RHO 1-2x.177 meganuclease.
- [0155] SEQ ID NO: 87 sets forth the amino acid sequence of the RHO 1-2x.148 meganuclease.
- [0156] SEQ ID NO: 88 sets forth the amino acid sequence of the RHO 1-2x.20 meganuclease.
- [0157] SEQ ID NO: 89 sets forth the amino acid sequence of the RHO 1-2x.55 meganuclease.
- [0158] SEQ ID NO: 90 sets forth the amino acid sequence of the RHO 1-2x.197 meganuclease.
- [0159]** SEQ ID NO: 91 sets forth the amino acid sequence of the RHO 1-2x.252 meganuclease.
- [0160] SEQ ID NO: 92 sets forth the amino acid sequence of the RHO 1-2x.372 meganuclease.
- [0161] SEQ ID NO: 93 sets forth the amino acid sequence of the RHO 1-2x.151 meganuclease.
- [0162] SEQ ID NO:94 sets forth the amino acid sequence of the wild-type I-CreI meganuclease.
- [0163] SEQ ID NO:95 sets forth the amino acid sequence of the LAGLIDADG motif of the I-CreI meganuclease.
- [0164] SEQ ID NO:96 sets forth the nucleic acid sequence of the coding region for wild-type human rhodopsin.

- [0165] SEQ ID NO:97 sets forth the nucleic acid sequence of the coding region for mutant P23H rhodopsin.
- [0166] SEQ ID NO:98 sets forth the nucleic acid sequence of the wild-type human rhodopsin gene.
- [0167]** SEQ ID NO:99 sets forth the nucleic acid sequence of the human rhodopsin gene comprising a C68A mutation that encodes a P23H substitution in rhodopsin.
- [0168] SEQ ID NO:100 sets forth the amino acid sequence of wild-type human rhodopsin.
- [0169] SEQ ID NO:101 sets forth the amino acid sequence of mutant P23H rhodopsin.
- [0170] SEQ ID NO: 102 sets forth residues 198-344 of the RHO2-L3-59 meganuclease.
- [0171] SEQ ID NO: 103 sets forth residues 198-344 of the RHO2-L5-14 meganuclease.
- [0172] SEQ ID NO: 104 sets forth residues 198-344 of the RHO-1/2-L2-49 meganuclease.
- [0173] SEQ ID NO: 105 sets forth residues 198-344 of the RHO 1-2x.179 meganuclease.
- [0174] SEQ ID NO: 106 sets forth residues 198-344 of the RHO 1-2x.4 meganuclease.
- [0175]** SEQ ID NO: 107 sets forth residues 198-344 of the RHO 1-2x.207 meganuclease.
- [0176] SEQ ID NO: 108 sets forth residues 198-344 of the RHO 1-2x.277 meganuclease.
- [0177] SEQ ID NO: 109 sets forth residues 198-344 of the RHO 1-2x.292 meganuclease.
- [0178] SEQ ID NO: 110 sets forth residues 198-344 of the RHO 1-2x.324 meganuclease.
- [0179] SEQ ID NO: 111 sets forth residues 198-344 of the RHO 1-2x.371 meganuclease.
- [0180] SEQ ID NO: 112 sets forth residues 198-344 of the RHO 1-2x.164 meganuclease.
- [0181] SEQ ID NO: 113 sets forth residues 198-344 of the RHO 1-2x.181 meganuclease.
- [0182] SEQ ID NO: 114 sets forth residues 198-344 of the RHO 1-2x.184 meganuclease.
- [0183] SEQ ID NO: 115 sets forth residues 198-344 of the RHO-1/2-L1-21 meganuclease.
- [0184]** SEQ ID NO: 116 sets forth residues 198-344 of the RHO-1/2-L1-43 meganuclease.
- [0185] SEQ ID NO: 117 sets forth residues 198-344 of the RHO-1/2-L1-45 meganuclease.
- [0186] SEQ ID NO: 118 sets forth residues 198-344 of the RHO-1/2-L1-60 meganuclease.
- [0187] SEQ ID NO: 119 sets forth residues 198-344 of the RHO-1/2-L1-61 meganuclease.

- [0188] SEQ ID NO: 120 sets forth residues 198-344 of the RHO-1/2-L1-58 meganuclease.
- [0189] SEQ ID NO: 121 sets forth residues 198-344 of the RHO-1/2-L1-7 meganuclease.
- [0190] SEQ ID NO: 122 sets forth residues 198-344 of the RHO-1/2-L1-13 meganuclease.
- [0191] SEQ ID NO: 123 sets forth residues 198-344 of the RHO-1/2-L1-18 meganuclease.
- [0192] SEQ ID NO: 124 sets forth residues 198-344 of the RHO-1/2-L1-70 meganuclease.
- [0193] SEQ ID NO: 125 sets forth residues 198-344 of the RHO-1/2-L1-86 meganuclease.
- [0194] SEQ ID NO: 126 sets forth residues 198-344 of the RHO-1/2-L2-13 meganuclease.
- [0195]** SEQ ID NO: 127 sets forth residues 198-344 of the RHO-1/2-L2-24 meganuclease.
- [0196] SEQ ID NO: 128 sets forth residues 198-344 of the RHO-1/2-L2-37 meganuclease.
- [0197] SEQ ID NO: 129 sets forth residues 198-344 of the RHO-1/2-L2-58 meganuclease.
- [0198] SEQ ID NO: 130 sets forth residues 198-344 of the RHO-1/2-L2-31 meganuclease.
- [0199] SEQ ID NO: 131 sets forth residues 198-344 of the RHO-1/2-L2-29 meganuclease.
- [0200] SEQ ID NO: 132 sets forth residues 198-344 of the RHO-1/2-L2-61 meganuclease.
- [0201] SEQ ID NO: 133 sets forth residues 198-344 of the RHO2-L3-2 meganuclease.
- [0202] SEQ ID NO: 134 sets forth residues 198-344 of the RHO2-L3-3 meganuclease.
- [0203] SEQ ID NO: 135 sets forth residues 198-344 of the RHO2-L3-5 meganuclease.
- [0204] SEQ ID NO: 136 sets forth residues 198-344 of the RHO2-L3-10 meganuclease.
- [0205]** SEQ ID NO: 137 sets forth residues 198-344 of the RHO2-L3-11 meganuclease.
- [0206] SEQ ID NO: 138 sets forth residues 198-344 of the RHO2-L3-12 meganuclease.
- [0207] SEQ ID NO: 139 sets forth residues 198-344 of the RHO2-L3-13 meganuclease.
- [0208] SEQ ID NO: 140 sets forth residues 198-344 of the RHO2-L3-28 meganuclease.

- [0209] SEQ ID NO: 141 sets forth residues 198-344 of the RHO2-L3-29 meganuclease.
- [0210] SEQ ID NO: 142 sets forth residues 198-344 of the RHO2-L3-57 meganuclease.
- [0211] SEQ ID NO: 143 sets forth residues 198-344 of the RHO2-L3-80 meganuclease.
- [0212] SEQ ID NO: 144 sets forth residues 198-344 of the RHO2-L3-85 meganuclease.
- [0213] SEQ ID NO: 145 sets forth residues 198-344 of the RHO2-L3-86 meganuclease.
- [0214]** SEQ ID NO: 146 sets forth residues 198-344 of the RHO2-L3-92 meganuclease.
- [0215] SEQ ID NO: 147 sets forth residues 198-344 of the RHO2-L3-4 meganuclease.
- [0216] SEQ ID NO: 148 sets forth residues 198-344 of the RHO2-L3-20 meganuclease.
- [0217] SEQ ID NO: 149 sets forth residues 198-344 of the RHO2-L3-72 meganuclease.
- [0218] SEQ ID NO: 150 sets forth residues 198-344 of the RHO1-L1-4 meganuclease.
- [0219] SEQ ID NO: 151 sets forth residues 198-344 of the RHO1-L1-8 meganuclease.
- [0220] SEQ ID NO: 152 sets forth residues 198-344 of the RHO1-L1-13 meganuclease.
- [0221] SEQ ID NO: 153 sets forth residues 198-344 of the RHO1-L1-19 meganuclease.
- [0222] SEQ ID NO: 154 sets forth residues 198-344 of the RHO1-L1-58 meganuclease.
- [0223] SEQ ID NO: 155 sets forth residues 198-344 of the RHO1-L1-69 meganuclease.
- [0224]** SEQ ID NO: 156 sets forth residues 198-344 of the RHO1-L1-80 meganuclease.
- [0225] SEQ ID NO: 157 sets forth residues 198-344 of the RHO1-L1-82 meganuclease.
- [0226] SEQ ID NO: 158 sets forth residues 198-344 of the RHO1-L1-73 meganuclease.
- [0227] SEQ ID NO: 159 sets forth residues 198-344 of the RHO1-L1-85 meganuclease.
- [0228] SEQ ID NO: 160 sets forth residues 198-344 of the RHO1-L1-86 meganuclease.
- [0229] SEQ ID NO: 161 sets forth residues 198-344 of the RHO-1/2-L4-10 meganuclease.
- [0230] SEQ ID NO: 162 sets forth residues 198-344 of the RHO-1/2-L4-29 meganuclease.
- [0231] SEQ ID NO: 163 sets forth residues 198-344 of the RHO-1/2-L4-65 meganuclease.
- [0232] SEQ ID NO: 164 sets forth residues 198-344 of the RHO-1/2-L4-66 meganuclease.
- [0233] SEQ ID NO: 165 sets forth residues 198-344 of the RHO-1/2-L4-85 meganuclease.
- [0234] SEQ ID NO: 166 sets forth residues 7-153 of the RHO 1-2x.216 meganuclease.
- [0235] SEQ ID NO: 167 sets forth residues 7-153 of the RHO 1-2x.241 meganuclease.
- [0236]** SEQ ID NO: 168 sets forth residues 7-153 of the RHO 1-2x.94 meganuclease.

- [0237] SEQ ID NO: 169 sets forth residues 7-153 of the RHO 1-2x.95 meganuclease.
- [0238] SEQ ID NO: 170 sets forth residues 7-153 of the RHO 1-2x.1 meganuclease.
- [0239] SEQ ID NO: 171 sets forth residues 7-153 of the RHO 1-2x.60 meganuclease.
- [0240] SEQ ID NO: 172 sets forth residues 7-153 of the RHO 1-2x.74 meganuclease.
- [0241] SEQ ID NO: 173 sets forth residues 7-153 of the RHO 1-2x.88 meganuclease.
- [0242] SEQ ID NO: 174 sets forth residues 7-153 of the RHO 1-2x.294 meganuclease.
- [0243] SEQ ID NO: 175 sets forth residues 7-153 of the RHO 1-2x.302 meganuclease.
- [0244] SEQ ID NO: 176 sets forth residues 7-153 of the RHO 1-2x.306 meganuclease.
- [0245] SEQ ID NO: 177 sets forth residues 7-153 of the RHO 1-2x.338 meganuclease.
- [0246] SEQ ID NO: 178 sets forth residues 7-153 of the RHO 1-2x.348 meganuclease.
- [0247] SEQ ID NO: 179 sets forth residues 7-153 of the RHO 1-2x.356 meganuclease.
- [0248] SEQ ID NO: 180 sets forth residues 7-153 of the RHO 1-2x.364 meganuclease.
- [0249]** SEQ ID NO: 181 sets forth residues 7-153 of the RHO 1-2x.142 meganuclease.
- [0250] SEQ ID NO: 182 sets forth residues 7-153 of the RHO 1-2x.177 meganuclease.
- [0251] SEQ ID NO: 183 sets forth residues 7-153 of the RHO 1-2x.148 meganuclease.
- [0252] SEQ ID NO: 184 sets forth residues 7-153 of the RHO 1-2x.20 meganuclease.
- [0253] SEQ ID NO: 185 sets forth residues 7-153 of the RHO 1-2x.55 meganuclease.
- [0254] SEQ ID NO: 186 sets forth residues 7-153 of the RHO 1-2x.197 meganuclease.
- [0255] SEQ ID NO: 187 sets forth residues 7-153 of the RHO 1-2x.252 meganuclease.
- [0256] SEQ ID NO: 188 sets forth residues 7-153 of the RHO 1-2x.372 meganuclease.
- [0257] SEQ ID NO: 189 sets forth residues 7-153 of the RHO 1-2x.151 meganuclease.
- [0258] SEQ ID NO: 190 sets forth residues 7-153 of the RHO2-L3-59 meganuclease.
- [0259] SEQ ID NO: 191 sets forth residues 7-153 of the RHO2-L5-14 meganuclease.
- [0260] SEQ ID NO: 192 sets forth residues 7-153 of the RHO-1/2-L2-49 meganuclease.
- [0261] SEQ ID NO: 193 sets forth residues 7-153 of the RHO 1-2x.179 meganuclease.
- [0262]** SEQ ID NO: 194 sets forth residues 7-153 of the RHO 1-2x.4 meganuclease.
- [0263] SEQ ID NO: 195 sets forth residues 7-153 of the RHO 1-2x.207 meganuclease.
- [0264] SEQ ID NO: 196 sets forth residues 7-153 of the RHO 1-2x.277 meganuclease.
- [0265] SEQ ID NO: 197 sets forth residues 7-153 of the RHO 1-2x.292 meganuclease.
- [0266] SEQ ID NO: 198 sets forth residues 7-153 of the RHO 1-2x.324 meganuclease.
- [0267] SEQ ID NO: 199 sets forth residues 7-153 of the RHO 1-2x.371 meganuclease.
- [0268] SEQ ID NO: 200 sets forth residues 7-153 of the RHO 1-2x.164 meganuclease.
- [0269] SEQ ID NO: 201 sets forth residues 7-153 of the RHO 1-2x.181 meganuclease.

- [0270] SEQ ID NO: 202 sets forth residues 7-153 of the RHO 1-2x.184 meganuclease.
- [0271] SEQ ID NO: 203 sets forth residues 7-153 of the RHO-1/2-L1-21 meganuclease.
- [0272] SEQ ID NO: 204 sets forth residues 7-153 of the RHO-1/2-L1-43 meganuclease.
- [0273] SEQ ID NO: 205 sets forth residues 7-153 of the RHO-1/2-L1-45 meganuclease.
- [0274]** SEQ ID NO: 206 sets forth residues 7-153 of the RHO-1/2-L1-60 meganuclease.
- [0275] SEQ ID NO: 207 sets forth residues 7-153 of the RHO-1/2-L1-61 meganuclease.
- [0276] SEQ ID NO: 208 sets forth residues 7-153 of the RHO-1/2-L1-58 meganuclease.
- [0277] SEQ ID NO: 209 sets forth residues 7-153 of the RHO-1/2-L1-7 meganuclease.
- [0278] SEQ ID NO: 210 sets forth residues 7-153 of the RHO-1/2-L1-13 meganuclease.
- [0279] SEQ ID NO: 211 sets forth residues 7-153 of the RHO-1/2-L1-18 meganuclease.
- [0280] SEQ ID NO: 212 sets forth residues 7-153 of the RHO-1/2-L1-70 meganuclease.
- [0281] SEQ ID NO: 213 sets forth residues 7-153 of the RHO-1/2-L1-86 meganuclease.
- [0282] SEQ ID NO: 214 sets forth residues 7-153 of the RHO-1/2-L2-13 meganuclease.
- [0283] SEQ ID NO: 215 sets forth residues 7-153 of the RHO-1/2-L2-24 meganuclease.
- [0284] SEQ ID NO: 216 sets forth residues 7-153 of the RHO-1/2-L2-37 meganuclease.
- [0285] SEQ ID NO: 217 sets forth residues 7-153 of the RHO-1/2-L2-58 meganuclease.
- [0286]** SEQ ID NO: 218 sets forth residues 7-153 of the RHO-1/2-L2-31 meganuclease.
- [0287] SEQ ID NO: 219 sets forth residues 7-153 of the RHO-1/2-L2-29 meganuclease.
- [0288] SEQ ID NO: 220 sets forth residues 7-153 of the RHO-1/2-L2-61 meganuclease.
- [0289] SEQ ID NO: 221 sets forth residues 7-153 of the RHO2-L3-2 meganuclease.
- [0290] SEQ ID NO: 222 sets forth residues 7-153 of the RHO2-L3-3 meganuclease.
- [0291] SEQ ID NO: 223 sets forth residues 7-153 of the RHO2-L3-5 meganuclease.
- [0292] SEQ ID NO: 224 sets forth residues 7-153 of the RHO2-L3-10 meganuclease.
- [0293] SEQ ID NO: 225 sets forth residues 7-153 of the RHO2-L3-11 meganuclease.
- [0294] SEQ ID NO: 226 sets forth residues 7-153 of the RHO2-L3-12 meganuclease.
- [0295] SEQ ID NO: 227 sets forth residues 7-153 of the RHO2-L3-13 meganuclease.
- [0296] SEQ ID NO: 228 sets forth residues 7-153 of the RHO2-L3-28 meganuclease.
- [0297] SEQ ID NO: 229 sets forth residues 7-153 of the RHO2-L3-29 meganuclease.
- [0298] SEQ ID NO: 230 sets forth residues 7-153 of the RHO2-L3-57 meganuclease.
- [0299] SEQ ID NO: 231 sets forth residues 7-153 of the RHO2-L3-80 meganuclease.
- [0300] SEQ ID NO: 232 sets forth residues 7-153 of the RHO2-L3-85 meganuclease.
- [0301] SEQ ID NO: 233 sets forth residues 7-153 of the RHO2-L3-86 meganuclease.
- [0302] SEQ ID NO: 234 sets forth residues 7-153 of the RHO2-L3-92 meganuclease.

- [0303] SEQ ID NO: 235 sets forth residues 7-153 of the RHO2-L3-4 meganuclease.
- [0304] SEQ ID NO: 236 sets forth residues 7-153 of the RHO2-L3-20 meganuclease.
- [0305]** SEQ ID NO: 237 sets forth residues 7-153 of the RHO2-L3-72 meganuclease.
- [0306] SEQ ID NO: 238 sets forth residues 7-153 of the RHO1-L1-4 meganuclease.
- [0307] SEQ ID NO: 239 sets forth residues 7-153 of the RHO1-L1-8 meganuclease.
- [0308] SEQ ID NO: 240 sets forth residues 7-153 of the RHO1-L1-13 meganuclease.
- [0309] SEQ ID NO: 241 sets forth residues 7-153 of the RHO1-L1-19 meganuclease.
- [0310] SEQ ID NO: 242 sets forth residues 7-153 of the RHO1-L1-58 meganuclease.
- [0311] SEQ ID NO: 243 sets forth residues 7-153 of the RHO1-L1-69 meganuclease.
- [0312] SEQ ID NO: 244 sets forth residues 7-153 of the RHO1-L1-80 meganuclease.
- [0313] SEQ ID NO: 245 sets forth residues 7-153 of the RHO1-L1-82 meganuclease.
- [0314] SEQ ID NO: 246 sets forth residues 7-153 of the RHO1-L1-73 meganuclease.
- [0315] SEQ ID NO: 244 sets forth residues 7-153 of the RHO1-L1-85 meganuclease.
- [0316] SEQ ID NO: 248 sets forth residues 7-153 of the RHO1-L1-86 meganuclease.
- [0317] SEQ ID NO: 249 sets forth residues 7-153 of the RHO-1/2-L4-10 meganuclease.
- [0318] SEQ ID NO: 250 sets forth residues 7-153 of the RHO-1/2-L4-29 meganuclease.
- [0319]** SEQ ID NO: 251 sets forth residues 7-153 of the RHO-1/2-L4-65 meganuclease.
- [0320] SEQ ID NO: 252 sets forth residues 7-153 of the RHO-1/2-L4-66 meganuclease.
- [0321] SEQ ID NO: 253 sets forth residues 7-153 of the RHO-1/2-L4-85 meganuclease.
- [0322] SEQ ID NO: 254 sets forth residues 198-344 of the RHO 1-2x.216 meganuclease.
- [0323] SEQ ID NO: 255 sets forth residues 198-344 of the RHO 1-2x.241 meganuclease.
- [0324] SEQ ID NO: 256 sets forth residues 198-344 of the RHO 1-2x.94 meganuclease.
- [0325] SEQ ID NO: 257 sets forth residues 198-344 of the RHO 1-2x.95 meganuclease.
- [0326] SEQ ID NO: 258 sets forth residues 198-344 of the RHO 1-2x.1 meganuclease.
- [0327]** SEQ ID NO: 259 sets forth residues 198-344 of the RHO 1-2x.60 meganuclease.
- [0328] SEQ ID NO: 260 sets forth residues 198-344 of the RHO 1-2x.74 meganuclease.
- [0329] SEQ ID NO: 261 sets forth residues 198-344 of the RHO 1-2x.88 meganuclease.
- [0330] SEQ ID NO: 262 sets forth residues 198-344 of the RHO 1-2x.294 meganuclease.
- [0331] SEQ ID NO: 263 sets forth residues 198-344 of the RHO 1-2x.302 meganuclease.
- [0332] SEQ ID NO: 264 sets forth residues 198-344 of the RHO 1-2x.306 meganuclease.
- [0333] SEQ ID NO: 265 sets forth residues 198-344 of the RHO 1-2x.338 meganuclease.
- [0334] SEQ ID NO: 266 sets forth residues 198-344 of the RHO 1-2x.348 meganuclease.
- [0335] SEQ ID NO: 267 sets forth residues 198-344 of the RHO 1-2x.356 meganuclease.

- [0336] SEQ ID NO: 268 sets forth residues 198-344 of the RHO 1-2x.364 meganuclease.
- [0337]** SEQ ID NO: 269 sets forth residues 198-344 of the RHO 1-2x.142 meganuclease.
- [0338] SEQ ID NO: 270 sets forth residues 198-344 of the RHO 1-2x.177 meganuclease.
- [0339] SEQ ID NO: 271 sets forth residues 198-344 of the RHO 1-2x.148 meganuclease.
- [0340] SEQ ID NO: 272 sets forth residues 198-344 of the RHO 1-2x.20 meganuclease.
- [0341] SEQ ID NO: 273 sets forth residues 198-344 of the RHO 1-2x.55 meganuclease.
- [0342] SEQ ID NO: 274 sets forth residues 198-344 of the RHO 1-2x.197 meganuclease.
- [0343] SEQ ID NO: 275 sets forth residues 198-344 of the RHO 1-2x.252 meganuclease.
- [0344] SEQ ID NO: 276 sets forth residues 198-344 of the RHO 1-2x.372 meganuclease.
- [0345] SEQ ID NO: 277 sets forth residues 198-344 of the RHO 1-2x.151 meganuclease.
- [0346] SEQ ID NO: 278 sets forth the nucleic acid sequence of the pDS CMV RHO2_L3_59 plasmid.
- [0347] SEQ ID NO: 279 sets forth the nucleic acid sequence of the pDS CMV RHO2_L5_14 plasmid.
- [0348] SEQ ID NO: 280 sets forth the nucleic acid sequence of the pDS GRK1 RHO2_L3_59 plasmid.
- [0349]** SEQ ID NO: 281 sets forth the nucleic acid sequence of the pDS GRK1 RHO2_L5_14 plasmid.

DETAILED DESCRIPTION OF THE INVENTION

1.1 References and Definitions

[0350] The patent and scientific literature referred to herein establishes knowledge that is available to those of skill in the art. The issued US patents, allowed applications, published foreign applications, and references, including GenBank database sequences, which are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference.

[0351] The present invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. For example, features illustrated with respect to one embodiment can be incorporated into other embodiments, and features illustrated with respect to a particular embodiment can be deleted from that embodiment. In addition, numerous variations and additions to the embodiments suggested herein will be apparent to

those skilled in the art in light of the instant disclosure, which do not depart from the instant invention.

[0352] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

[0353] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety.

[0354] As used herein, “a,” “an,” or “the” can mean one or more than one. For example, “a” cell can mean a single cell or a multiplicity of cells.

[0355] As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “and/or” and not the exclusive sense of “either/or.”

[0356] As used herein, the term “meganuclease” refers to an endonuclease that binds double-stranded DNA at a recognition sequence that is greater than 12 base pairs. Preferably, the recognition sequence for a meganuclease of the invention is 22 base pairs. A meganuclease can be an endonuclease that is derived from I-CreI, and can refer to an engineered variant of I-CreI that has been modified relative to natural I-CreI with respect to, for example, DNA-binding specificity, DNA cleavage activity, DNA-binding affinity, or dimerization properties. Methods for producing such modified variants of I-CreI are known in the art (*e.g.* WO 2007/047859). A meganuclease as used herein binds to double-stranded DNA as a heterodimer. A meganuclease may also be a “single-chain meganuclease” in which a pair of DNA-binding domains are joined into a single polypeptide using a peptide linker.

[0357] As used herein, the term “single-chain meganuclease” refers to a polypeptide comprising a pair of meganuclease subunits joined by a linker. A single-chain meganuclease has the organization: N-terminal subunit – Linker – C-terminal subunit. The two meganuclease subunits will generally be non-identical in amino acid sequence and will recognize non-identical DNA sequences. Thus, single-chain meganucleases typically cleave pseudo-palindromic or non-palindromic recognition sequences. A single-chain meganuclease may be referred to as a “single-chain heterodimer” or “single-chain heterodimeric meganuclease” although it is not, in fact, dimeric. For clarity, unless otherwise specified, the term “meganuclease” can refer to a dimeric or single-chain meganuclease. Methods for

producing single—chain meganuclease variants of I-CreI are known in the art (*e.g.*, WO 2009/059195; Li, *et al.* (2009) *Nucleic Acids Res.* 37:1650-62; Grizot, *et al.* (2009) *Nucleic Acids Res.* 37:5405-19). The term “homing endonuclease” is synonymous with the term “meganuclease.”

[0358] As used herein, the term “linker” refers to an exogenous peptide sequence used to join two meganuclease subunits into a single polypeptide. A linker may have a sequence that is found in natural proteins, or may be an artificial sequence that is not found in any natural protein. A linker may be flexible and lacking in secondary structure or may have a propensity to form a specific three-dimensional structure under physiological conditions. A linker can include, without limitation, those encompassed by U.S. Patent No. 8,445,251. In some embodiments, a linker may have an amino acid sequence comprising residues 154-195 of any one of SEQ ID NOs:6-93.

[0359] As used herein, with respect to a protein, the term “recombinant” means having an altered amino acid sequence as a result of the application of genetic engineering techniques to nucleic acids which encode the protein, and cells or organisms which express the protein. With respect to a nucleic acid, the term “recombinant” means having an altered nucleic acid sequence as a result of the application of genetic engineering techniques. Genetic engineering techniques include, but are not limited to, PCR and DNA cloning technologies; transfection, transformation and other gene transfer technologies; homologous recombination; site-directed mutagenesis; and gene fusion. In accordance with this definition, a protein having an amino acid sequence identical to a naturally-occurring protein, but produced by cloning and expression in a heterologous host, is not considered recombinant.

[0360] As used herein, the term “wild-type” refers to the most common naturally occurring allele (*i.e.*, polynucleotide sequence) in the allele population of the same type of gene, wherein a polypeptide encoded by the wild-type allele has its original functions. The term “wild-type” also refers a polypeptide encoded by a wild-type allele. Wild-type alleles (*i.e.*, polynucleotides) and polypeptides are distinguishable from mutant or variant alleles and polypeptides, which comprise one or more mutations and/or substitutions relative to the wild-type sequence(s). Whereas a wild-type allele or polypeptide can confer a normal phenotype in an organism, a mutant or variant allele or polypeptide can, in some instances, confer an altered phenotype. The mutant RHO P23H allele and the P23H rhodopsin protein are distinguishable from the wild-type RHO allele and rhodopsin protein. Further, wild-type

homing endonucleases are distinguishable from recombinant or non-naturally-occurring meganucleases.

[0361] As used herein with respect to recombinant proteins, the term “modification” means any insertion, deletion or substitution of an amino acid residue in the recombinant sequence relative to a reference sequence (*e.g.*, a wild-type or a native sequence).

[0362] As used herein, the term “recognition sequence” refers to a DNA sequence that is bound and cleaved by a meganuclease. In the case of a recombinant meganuclease of the invention, a recognition sequence comprises a pair of inverted, 9 base pair “half-sites” or “recognition half-sites” which are separated by four base pairs. In the case of a single-chain meganuclease, the N-terminal subunit of the protein contacts a first half-site and the C-terminal subunit of the protein contacts a second half-site. Cleavage by a meganuclease produces four base pair 3’ “overhangs”. “Overhangs”, or “sticky ends” are short, single-stranded DNA segments that can be produced by meganuclease cleavage of a double-stranded DNA sequence. In the case of meganucleases of the present invention, the overhang comprises bases 10-13 of the 22 base pair recognition sequence.

[0363] As used herein, the term “target site” or “target sequence” refers to a region of the chromosomal DNA of a cell comprising a recognition sequence for a meganuclease.

[0364] As used herein, the term “DNA-binding affinity” or “binding affinity” means the tendency of a meganuclease to non-covalently associate with a reference DNA molecule (*e.g.*, a recognition sequence or an arbitrary sequence). Binding affinity is measured by a dissociation constant, K_d . As used herein, a meganuclease has “altered” binding affinity if the K_d of the recombinant meganuclease for a reference recognition sequence is increased or decreased by a statistically significant ($p < 0.05$) amount relative to a reference meganuclease.

[0365] As used herein, the term “homologous recombination” or “HR” refers to the natural, cellular process in which a double-stranded DNA-break is repaired using a homologous DNA sequence as the repair template (see, *e.g.* Cahill *et al.* (2006), *Front. Biosci.* 11:1958-1976). The homologous DNA sequence may be an endogenous chromosomal sequence or an exogenous nucleic acid that was delivered to the cell.

[0366] As used herein, the term “non-homologous end-joining” or “NHEJ” refers to the natural, cellular process in which a double-stranded DNA-break is repaired by the direct joining of two non-homologous DNA segments (see, *e.g.* Cahill *et al.* (2006), *Front. Biosci.* 11:1958-1976). DNA repair by non-homologous end-joining is error-prone and frequently results in the untemplated addition or deletion of DNA sequences at the site of repair. In

some instances, cleavage at a target recognition sequence results in NHEJ at a target recognition site. Nuclease-induced cleavage of a target site in the coding sequence of a gene followed by DNA repair by NHEJ can introduce mutations into the coding sequence, such as frameshift mutations, that disrupt gene function. Thus, engineered nucleases such as meganucleases can be used to effectively knock-out a gene in a population of cells.

[0367] As used herein with respect to both amino acid sequences and nucleic acid sequences, the terms “percent identity,” “sequence identity,” “percentage similarity,” “sequence similarity” and the like refer to a measure of the degree of similarity of two sequences based upon an alignment of the sequences which maximizes similarity between aligned amino acid residues or nucleotides, and which is a function of the number of identical or similar residues or nucleotides, the number of total residues or nucleotides, and the presence and length of gaps in the sequence alignment. A variety of algorithms and computer programs are available for determining sequence similarity using standard parameters. As used herein, sequence similarity is measured using the BLASTp program for amino acid sequences and the BLASTn program for nucleic acid sequences, both of which are available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/), and are described in, for example, Altschul *et al.* (1990), *J. Mol. Biol.* 215:403-410; Gish and States (1993), *Nature Genet.* 3:266-272; Madden *et al.* (1996), *Meth. Enzymol.* 266:131-141; Altschul *et al.* (1997), *Nucleic Acids Res.* 25:33 89-3402; Zhang *et al.* (2000), *J. Comput. Biol.* 7(1-2):203-14. As used herein, percent similarity of two amino acid sequences is the score based upon the following parameters for the BLASTp algorithm: word size=3; gap opening penalty=-11; gap extension penalty=-1; and scoring matrix=BLOSUM62. As used herein, percent similarity of two nucleic acid sequences is the score based upon the following parameters for the BLASTn algorithm: word size=11; gap opening penalty=-5; gap extension penalty=-2; match reward=1; and mismatch penalty=-3. Similarly, the percent identity can be established based upon an alignment of the sequences which maximizes identity between aligned amino acid residues or nucleotides, and which is a function of the number of identical residues or nucleotides divided by the number of total residues or nucleotides in the larger of the two sequences.

[0368] As used herein with respect to modifications of two proteins or amino acid sequences, the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins

corresponds to or aligns with the amino acid position of the modification in the second protein when the two proteins are subjected to standard sequence alignments (*e.g.*, using the BLASTp program). Thus, the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.

[0369] As used herein, the term “recognition half-site,” “recognition sequence half-site,” or simply “half-site” means a nucleic acid sequence in a double-stranded DNA molecule which is recognized by a monomer of a homodimeric or heterodimeric meganuclease, or by one subunit of a single-chain meganuclease.

[0370] As used herein, the term “preferentially” refers to the specificity of a recombinant meganuclease for recognizing and cleaving a particular target recognition sequence in the genome relative to a second, reference recognition sequence. By way of example, a recombinant meganuclease of the invention may preferentially recognize and cleave a P23H recognition sequence (*e.g.*, SEQ ID NO:1) with greater efficiency than it recognizes and cleaves the corresponding wild-type recognition sequence (*e.g.*, SEQ ID NO:5), as determined by methods known in the art, including those methods provided in the examples herein. In some embodiments, a recombinant meganuclease of the invention may recognize and cleave a P23H recognition sequence with greater than about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% more efficiency than it recognizes and cleaves the corresponding wild-type recognition sequence. In other embodiments, a recombinant meganuclease of the invention may recognize and cleave a P23H recognition sequence with greater than about 1-fold, 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, or 1000-fold more efficiency than it recognizes and cleaves the corresponding wild-type recognition sequence.

[0371] As used herein, the term “hypervariable region” refers to a localized sequence within a meganuclease monomer or subunit that comprises amino acids with relatively high variability. A hypervariable region can comprise about 50-60 contiguous residues, about 53-57 contiguous residues, or preferably about 56 residues. In some embodiments, the residues of a hypervariable region may correspond to positions 24-79 or positions 215-270 of any one of SEQ ID NOs:6-93. A hypervariable region can comprise one or more residues that contact DNA bases in a recognition sequence and can be modified to alter base preference of the monomer or subunit. A hypervariable region can also comprise one or more residues that

bind to the DNA backbone when the meganuclease associates with a double-stranded DNA recognition sequence. Such residues can be modified to alter the binding affinity of the meganuclease for the DNA backbone and the target recognition sequence. In different embodiments of the invention, a hypervariable region may comprise between 1-20 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity. In particular embodiments, a hypervariable region comprises between about 15-18 residues that exhibit variability and can be modified to influence base preference and/or DNA-binding affinity. In some embodiments, variable residues within a hypervariable region correspond to one or more of positions 24, 26, 28, 29, 30, 32, 33, 38, 39, 40, 42, 44, 46, 68, 70, 73, 75, and 77 of any one of SEQ ID NOs:6-93. In other embodiments, variable residues within a hypervariable region correspond to one or more of positions 215, 217, 219, 220, 221, 223, 224, 229, 230, 231, 233, 235, 237, 259, 261, 264, 266, and 268 of any one of SEQ ID NOs:6-93.

[0372] As used herein, the terms “RHO,” “RHO gene,” “rhodopsin gene,” and “wild-type RHO allele” are used interchangeably and refer to the human rhodopsin gene, preferably the gene identified by NCBI Reference Sequence NG_009115.1 (SEQ ID NO:98). The terms “mutant RHO allele” and “mutant RHO P23H allele” are used interchangeably and refer to a RHO allele sequence comprising a C68A mutation (SEQ ID NO:99), which results in a P23H substitution in the encoded protein. The terms “rhodopsin” and “wild-type rhodopsin” are used interchangeably and refer to the protein encoded by the wild-type rhodopsin gene, particularly the protein identified by NCBI Reference Sequence NP_000530.1 (SEQ ID NO:100). The term “P23H rhodopsin” refers to the mutant rhodopsin protein comprising a P23H substitution, particularly the protein set forth in SEQ ID NO:101.

[0373] The terms “recombinant DNA construct,” “recombinant construct,” “expression cassette,” “expression construct,” “chimeric construct,” “construct,” and “recombinant DNA fragment” are used interchangeably herein and are nucleic acid fragments. A recombinant construct comprises an artificial combination of nucleic acid fragments, including, without limitation, regulatory and coding sequences that are not found together in nature. For example, a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source and arranged in a manner different than that found in nature. Such a construct may be used by itself or may be used in conjunction with a vector.

[0374] As used herein, a “vector” or “recombinant DNA vector” may be a construct that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. If a vector is used then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art. Vectors can include, without limitation, plasmid vectors and recombinant AAV vectors, or any other vector known in that art suitable for delivering a gene encoding a meganuclease of the invention to a target cell. The skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleotides or nucleic acid sequences of the invention.

[0375] As used herein, a “vector” can also refer to a viral vector. Viral vectors can include, without limitation, retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors (AAV).

[0376] As used herein, a “target cell” refers to a cell that comprises at least one RHO allele comprising a P23H recognition sequence (*e.g.*, one of SEQ ID NOs:1-4). Such target cells can express mutant RHO P23H protein. Target cells can include, without limitation, cells of the eye, preferably cells in the posterior segment of the eye, and even more preferably cells of the retina, including rod photoreceptor cells comprising a P23H recognition sequence in at least one RHO gene allele.

[0377] As used herein, a “control” or “control cell” refers to a cell that provides a reference point for measuring changes in genotype or phenotype of a genetically-modified cell. A control cell may comprise, for example: (a) a wild-type cell, *i.e.*, of the same genotype as the starting material for the genetic alteration which resulted in the genetically-modified cell; (b) a cell of the same genotype as the genetically-modified cell but which has been transformed with a null construct (*i.e.*, with a construct which has no known effect on the trait of interest); or, (c) a cell genetically identical to the genetically-modified cell but which is not exposed to conditions or stimuli or further genetic modifications that would induce expression of altered genotype or phenotype.

[0378] As used herein with respect to modifications of two proteins or amino acid sequences, the term “corresponding to” is used to indicate that a specified modification in the first protein is a substitution of the same amino acid residue as in the modification in the second protein, and that the amino acid position of the modification in the first proteins corresponds to or aligns with the amino acid position of the modification in the second

protein when the two proteins are subjected to standard sequence alignments (*e.g.*, using the BLASTp program). Thus, the modification of residue “X” to amino acid “A” in the first protein will correspond to the modification of residue “Y” to amino acid “A” in the second protein if residues X and Y correspond to each other in a sequence alignment, and despite the fact that X and Y may be different numbers.

[0379] As used herein, the terms “treatment” or “treating a subject” refers to the administration of recombinant meganuclease of the invention, or a nucleic acid encoding recombinant meganuclease of the invention, to a subject having RP for the purpose of providing partial or complete relief of one or more symptoms of RP. In some aspects, recombinant meganuclease of the invention, or a nucleic acid encoding the same, is administered during treatment in the form of a pharmaceutical composition of the invention. Preferably the subject is heterozygous for the P23H mutant allele and a functional, normal or wild-type allele.

[0380] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values ≥ 0 and ≤ 2 if the variable is inherently continuous.

2.1 Principle of Targeting and Inactivating the Mutant RHO P23H Allele

[0381] The present invention is based, in part, on the hypothesis that autosomal dominant RP can be corrected or prevented by targeting, cleaving, and inactivating a mutant RHO P23H allele, which encodes the pathogenic P23H rhodopsin protein. Surprisingly, recombinant meganucleases can be engineered to recognize and cleave a P23H recognition sequence (*e.g.*, one of SEQ ID NOs:1-4) present in the mutant RHO P23H allele. Such recombinant meganucleases can preferentially target and cleave the mutant RHO P23H allele relative to the corresponding wild-type allele (SEQ ID NO:96). NHEJ at the cleavage site results in mutagenesis and disruption of the mutant RHO P23H allele, while the functional wild-type RHO allele remains intact to express wild-type rhodopsin in rod photoreceptor cells

of the retina. Preferential inactivation of the mutant RHO P23H allele, and disruption of P23H rhodopsin expression, is expected to prevent, delay, or reverse the progression of RP in patients.

2.2 Meganucleases for Recognizing and Cleaving the P23H Recognition Sequence

[0382] Meganucleases can make a site-specific DNA break in the genome of a living cell, and such a DNA break can result in permanent modification of the genome via mutagenic NHEJ repair or via homologous recombination with a transgenic DNA sequence. NHEJ can produce mutagenesis at the cleavage site, resulting in inactivation of the allele. NHEJ-associated mutagenesis may inactivate an allele via generation of early stop codons, frameshift mutations producing aberrant non-functional proteins, or could trigger mechanisms such as nonsense-mediated mRNA decay. The use of meganucleases to induce mutagenesis via NHEJ can be used to target a specific mutation or a sequence present in a wild-type allele.

[0383] In preferred embodiments, the nucleases used to practice the invention are single-chain meganucleases. A single-chain meganuclease comprises an N-terminal subunit and a C-terminal subunit joined by a linker peptide. Each of the two domains recognizes half of the recognition sequence (*i.e.*, a recognition half-site) and the site of DNA cleavage is at the middle of the recognition sequence near the interface of the two subunits. DNA strand breaks are offset by four base pairs such that DNA cleavage by a meganuclease generates a pair of four base pair, 3' single-strand overhangs.

[0384] Recombinant meganucleases of the invention have been engineered to recognize and cleave a P23H recognition sequence (*e.g.*, one of SEQ ID NOs:1-4). Such meganucleases preferentially cleave the P23H recognition sequence on the mutant RHO P23H allele relative to the corresponding wild-type RHO recognition sequence (SEQ ID NO:96). Exemplary recombinant meganucleases of the invention are provided in SEQ ID NOs:6-93, which are collectively referred to herein as “RHO 1-2 meganucleases” or “RHO 1/2 meganucleases.”

[0385] Recombinant meganucleases of the invention comprise a first subunit, comprising a first hypervariable (HVR1) region, and a second subunit, comprising a second hypervariable (HVR2) region. Further, the first subunit binds to a first recognition half-site in a P23H recognition sequence (*e.g.*, the RHO1 half-site), and the second subunit binds to a second recognition half-site in the P23H recognition sequence (*e.g.*, the RHO2 half-site). In embodiments where the recombinant meganuclease is a single-chain meganuclease, the first

and second subunits can be oriented such that the first subunit is positioned as the N-terminal subunit, and the second subunit is positioned as the C-terminal subunit (*e.g.*, SEQ ID NOs:70-93). In alternative embodiments, the first and second subunits can be oriented such that the first subunit is positioned as the C-terminal subunit, and the second subunit is positioned as the N-terminal subunit (*e.g.*, SEQ ID NOs:6-69). Exemplary recombinant meganucleases of the invention are provided in Table 1.

Table 1. Exemplary recombinant meganucleases engineered to recognize and cleave the P23H recognition sequence (SEQ ID NO:1)

Meganuclease	AA SEQ ID	RHO1 Subunit Residues	RHO1 Subunit SEQ ID	*RHO1 Subunit %	RHO2 Subunit Residues	RHO2 Subunit SEQ ID	*RHO2 Subunit %
RHO2-L3-59	6	198-344	102	100	7-153	187	100
RHO2-L5-14	7	198-344	103	100	7-153	188	96.6
RHO-1/2-L2-49	8	198-344	104	100	7-153	189	96.6
RHO 1-2x.179	9	198-344	105	100	7-153	190	93.2
RHO 1-2x.4	10	198-344	106	92.52	7-153	191	91.16
RHO 1-2x.207	11	198-344	107	93.2	7-153	192	91.84
RHO 1-2x.277	12	198-344	108	93.2	7-153	193	91.84
RHO 1-2x.292	13	198-344	109	94.56	7-153	194	90.48
RHO 1-2x.324	14	198-344	110	92.52	7-153	195	91.16
RHO 1-2x.371	15	198-344	111	93.2	7-153	196	91.16
RHO 1-2x.164	16	198-344	112	91.16	7-153	197	90.48
RHO 1-2x.181	17	198-344	113	95.24	7-153	198	90.48
RHO 1-2x.184	18	198-344	114	90.48	7-153	199	88.44
RHO-1/2-L1-21	19	198-344	115	100	7-153	200	93.2
RHO-1/2-L1-43	20	198-344	116	100	7-153	201	92.52
RHO-1/2-L1-45	21	198-344	117	100	7-153	202	92.52
RHO-1/2-L1-60	22	198-344	118	100	7-153	203	92.52
RHO-1/2-L1-61	23	198-344	119	100	7-153	204	92.52
RHO-1/2-L1-58	24	198-344	120	100	7-153	205	92.52
RHO-1/2-L1-7	25	198-344	121	100	7-153	206	92.52
RHO-1/2-L1-13	26	198-344	122	100	7-153	207	92.52
RHO-1/2-L1-18	27	198-344	123	100	7-153	208	92.52
RHO-1/2-L1-70	28	198-344	124	100	7-153	209	92.52
RHO-1/2-L1-86	29	198-344	125	100	7-153	210	92.52
RHO-1/2-L2-13	30	198-344	126	100	7-153	211	95.24
RHO-1/2-L2-24	31	198-344	127	100	7-153	212	95.24
RHO-1/2-L2-37	32	198-344	128	100	7-153	213	93.88
RHO-1/2-L2-58	33	198-344	129	100	7-153	214	93.2
RHO-1/2-L2-31	34	198-344	130	100	7-153	215	93.2

Meganuclease	AA SEQ ID	RHO1 Subunit Residues	RHO1 Subunit SEQ ID	*RHO1 Subunit %	RHO2 Subunit Residues	RHO2 Subunit SEQ ID	*RHO2 Subunit %
RHO-1/2-L2-29	35	198-344	131	100	7-153	216	93.2
RHO-1/2-L2-61	36	198-344	132	100	7-153	217	93.88
RHO2-L3-2	37	198-344	133	100	7-153	218	94.56
RHO2-L3-3	38	198-344	134	100	7-153	219	95.24
RHO2-L3-5	39	198-344	135	100	7-153	220	96.6
RHO2-L3-10	40	198-344	136	100	7-153	221	94.56
RHO2-L3-11	41	198-344	137	100	7-153	222	95.24
RHO2-L3-12	42	198-344	138	100	7-153	223	95.24
RHO2-L3-13	43	198-344	139	100	7-153	224	95.24
RHO2-L3-28	44	198-344	140	100	7-153	225	95.24
RHO2-L3-29	45	198-344	141	100	7-153	226	94.56
RHO2-L3-57	46	198-344	142	100	7-153	227	95.24
RHO2-L3-80	47	198-344	143	100	7-153	228	95.92
RHO2-L3-85	48	198-344	144	100	7-153	229	95.24
RHO2-L3-86	49	198-344	145	100	7-153	230	94.56
RHO2-L3-92	50	198-344	146	100	7-153	231	95.24
RHO2-L3-4	51	198-344	147	100	7-153	232	94.56
RHO2-L3-20	52	198-344	148	100	7-153	233	94.56
RHO2-L3-72	53	198-344	149	100	7-153	234	95.92
RHO1-L1-4	54	198-344	150	96.6	7-153	235	96.6
RHO1-L1-8	55	198-344	151	95.24	7-153	236	96.6
RHO1-L1-13	56	198-344	152	95.24	7-153	237	96.6
RHO1-L1-19	57	198-344	153	95.24	7-153	238	96.6
RHO1-L1-58	58	198-344	154	95.92	7-153	239	96.6
RHO1-L1-69	59	198-344	155	95.92	7-153	240	96.6
RHO1-L1-80	60	198-344	156	95.92	7-153	241	96.6
RHO1-L1-82	61	198-344	157	95.92	7-153	245	96.6
RHO1-L1-73	62	198-344	158	96.6	7-153	246	96.6
RHO1-L1-85	63	198-344	159	96.6	7-153	247	96.6
RHO1-L1-86	64	198-344	160	96.6	7-153	248	96.6
RHO-1/2-L4-10	65	198-344	161	95.24	7-153	249	95.24
RHO-1/2-L4-29	66	198-344	162	95.24	7-153	250	95.24
RHO-1/2-L4-65	67	198-344	163	95.92	7-153	251	94.56
RHO-1/2-L4-66	68	198-344	164	97.28	7-153	252	95.24
RHO-1/2-L4-85	69	198-344	165	96.6	7-153	253	94.56
RHO 1-2x.216	70	7-153	166	93.2	198-344	254	91.16
RHO 1-2x.241	71	7-153	167	93.88	198-344	255	91.16
RHO 1-2x.94	72	7-153	168	91.84	198-344	256	91.16
RHO 1-2x.95	73	7-153	169	91.16	198-344	257	91.16
RHO 1-2x.1	74	7-153	170	93.2	198-344	258	90.48

Meganuclease	AA SEQ ID	RHO1 Subunit Residues	RHO1 Subunit SEQ ID	*RHO1 Subunit %	RHO2 Subunit Residues	RHO2 Subunit SEQ ID	*RHO2 Subunit %
RHO 1-2x.60	75	7-153	171	93.2	198-344	259	90.48
RHO 1-2x.74	76	7-153	172	93.88	198-344	260	90.48
RHO 1-2x.88	77	7-153	173	91.16	198-344	261	90.48
RHO 1-2x.294	78	7-153	174	93.88	198-344	262	90.48
RHO 1-2x.302	79	7-153	175	93.2	198-344	263	90.48
RHO 1-2x.306	80	7-153	176	92.52	198-344	264	90.48
RHO 1-2x.338	81	7-153	177	93.2	198-344	265	90.48
RHO 1-2x.348	82	7-153	178	92.52	198-344	266	90.48
RHO 1-2x.356	83	7-153	179	91.16	198-344	267	90.48
RHO 1-2x.364	84	7-153	180	93.2	198-344	268	90.48
RHO 1-2x.142	85	7-153	181	93.2	198-344	269	90.48
RHO 1-2x.177	86	7-153	182	94.56	198-344	270	90.48
RHO 1-2x.148	87	7-153	183	91.84	198-344	271	93.2
RHO 1-2x.20	88	7-153	184	93.2	198-344	272	89.12
RHO 1-2x.55	89	7-153	185	92.52	198-344	273	92.52
RHO 1-2x.197	90	7-153	186	95.24	198-344	274	91.84
RHO 1-2x.252	91	7-153	187	93.2	198-344	275	88.44
RHO 1-2x.372	92	7-153	188	94.56	198-344	276	91.84
RHO 1-2x.151	93	7-153	189	94.56	198-344	277	90.48

*“RHO1 Subunit %” and “RHO2 Subunit %” represent the amino acid sequence identity between the RHO1-binding and RHO2-binding subunit regions of each meganuclease and the RHO1-binding and RHO2-binding subunit regions, respectively, of the RHO2-L3-59 meganuclease.

2.3 Methods for Delivering and Expressing Recombinant Meganucleases

[0386] Treating RP using the invention requires that a recombinant meganuclease can be expressed in cells in the appropriate tissues. The target tissue(s) for delivery of recombinant meganucleases of the invention are cells of the eye, preferably cells in the posterior segment of the eye, and even more preferably cells of the retina, including rod photoreceptor cells. Recombinant meganucleases can be delivered as purified protein or as RNA or DNA encoding the meganucleases. In one embodiment, recombinant meganuclease proteins, or mRNA or vector encoding recombinant meganucleases, are supplied to target cells (e.g., cells in the retina) via injection directly to the target tissue. For example, delivery of RNA, DNA, or recombinant AAV vectors to the eye via subretinal or intravitreal injection is described in the art (see for example, Martin *et al.* (2002) *Methods*. 28:267-275; Hauswirth *et al.* (2008) *Human Gene Therapy*. 19(10):979-990; Johnson *et al.* (2008) *Molecular Vision*. 14:2211-2226). Alternatively, meganuclease protein, mRNA, or DNA can be delivered systemically via the circulatory system.

[0387] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are formulated for systemic administration, or administration to target tissues, in a pharmaceutical carrier in accordance with known techniques. See, *e.g.*, Remington, *The Science And Practice of Pharmacy* (21st ed. 2005). In the manufacture of a pharmaceutical formulation according to the invention, proteins/RNA/mRNA are typically admixed with a pharmaceutically acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier can be a solid or a liquid, or both, and can be formulated with the compound as a unit-dose formulation.

[0388] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are coupled to a cell penetrating peptide or targeting ligand to facilitate cellular uptake. Examples of cell penetrating peptides known in the art include poly-arginine (Jearawiriyapaisarn, *et al.* (2008) *Mol Ther.* 16:1624-9), TAT peptide from the HIV virus (Hudecz *et al.* (2005), *Med. Res. Rev.* 25: 679-736), MPG (Simeoni, *et al.* (2003) *Nucleic Acids Res.* 31:2717-2724), Pep-1 (Deshayes *et al.* (2004) *Biochemistry* 43: 7698-7706, and HSV-1 VP-22 (Deshayes *et al.* (2005) *Cell Mol Life Sci.* 62:1839-49). In an alternative embodiment, recombinant meganucleases, or DNA/mRNA encoding recombinant meganucleases, are coupled covalently or non-covalently to an antibody that recognizes a specific cell-surface receptor expressed on target cells such that the meganuclease protein/DNA/mRNA binds to and is internalized by the target cells. Alternatively, recombinant meganuclease protein/DNA/mRNA can be coupled covalently or non-covalently to the natural ligand (or a portion of the natural ligand) for such a cell-surface receptor. (McCall, *et al.* (2014) *Tissue Barriers.* 2(4):e944449; Dinda, *et al.* (2013) *Curr Pharm Biotechnol.* 14:1264-74; Kang, *et al.* (2014) *Curr Pharm Biotechnol.* 15(3):220-30; Qian *et al.* (2014) *Expert Opin Drug Metab Toxicol.* 10(11):1491-508). Examples of targeting ligands to direct delivery to cells in the eye include RGD (Pollinger *et al.* (2013) *PNAS.* 110(15): 6115-6120), transferrin (Lajunen *et al.* (2014) *Eur J Pharm Sci.* 62: 23-32), and hyaluronic acid (Martens *et al.* (2015) *J Control Release.* 202: 83-92).

[0389] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are encapsulated within biodegradable hydrogels for injection or implantation within the desired region of the eye (*e.g.*, intravitreal or subconjunctival injection). Hydrogels can provide sustained and tunable release of the

therapeutic payload to the desired region of the eye without the need for frequent injections, and stimuli-responsive materials (*e.g.*, temperature- and pH-responsive hydrogels) can be designed to release the payload in response to environmental or externally applied cues (Kang Derwent *et al.* (2008) *Trans Am Ophthalmol Soc.* 106:206-214).

[0390] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are coupled covalently or, preferably, non-covalently to a nanoparticle or encapsulated within such a nanoparticle using methods known in the art (Sharma, *et al.* (2014) *Biomed Res Int.* 2014). A nanoparticle is a nanoscale delivery system whose length scale is $<1\ \mu\text{m}$, preferably $<100\ \text{nm}$. Such nanoparticles may be designed using a core composed of metal, lipid, polymer, or biological macromolecule, and multiple copies of the recombinant meganuclease proteins, mRNA, or DNA can be attached to or encapsulated with the nanoparticle core. This increases the copy number of the protein/mRNA/DNA that is delivered to each cell and, so, increases the intracellular expression of each recombinant meganuclease to maximize the likelihood that the target recognition sequences will be cut. The surface of such nanoparticles may be further modified with polymers or lipids (*e.g.*, chitosan, cationic polymers, or cationic lipids) to form a core-shell nanoparticle whose surface confers additional functionalities to enhance cellular delivery and uptake of the payload (Jian *et al.* (2012), *Biomaterials.* 33(30): 7621-30). Nanoparticles may additionally be advantageously coupled to targeting molecules to direct the nanoparticle to the appropriate cell type and/or increase the likelihood of cellular uptake. Examples of such targeting molecules include antibodies specific for cell-surface receptors and the natural ligands (or portions of the natural ligands) for cell surface receptors.

[0391] In some embodiments, the meganuclease proteins or DNA/mRNA encoding the meganucleases are encapsulated within liposomes or complexed using cationic lipids (*see, e.g.*, Lipofectamine™, Life Technologies Corp., Carlsbad, CA; Zuris *et al.* (2015), *Nat Biotechnol.* 33: 73-80; Mishra *et al.* (2011), *J Drug Deliv.* 2011:863734). The liposome and lipoplex formulations can protect the payload from degradation, enhance accumulation and retention at the target site, and facilitate cellular uptake and delivery efficiency through fusion with and/or disruption of the cellular membranes of the target cells.

[0392] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are encapsulated within polymeric scaffolds (*e.g.*, PLGA) or complexed using cationic polymers (*e.g.*, PEI, PLL) (Tamboli *et al.* (2011), *Ther Deliv.* 2(4): 523-536). Polymeric carriers can be designed to provide tunable drug release

rates through control of polymer erosion and drug diffusion, and high drug encapsulation efficiencies can offer protection of the therapeutic payload until intracellular delivery to the desired target cell population.

[0393] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are combined with amphiphilic molecules that self-assemble into micelles (Tong *et al.* (2007), *J Gene Med.* 9(11): 956-66). Polymeric micelles may include a micellar shell formed with a hydrophilic polymer (*e.g.*, polyethyleneglycol) that can prevent aggregation, mask charge interactions, and reduce nonspecific interactions within the vitreous fluid.

[0394] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are formulated into an emulsion or a nanoemulsion (*i.e.*, having an average particle diameter of < 1nm) for administration and/or delivery to the target cell. The term “emulsion” refers to, without limitation, any oil-in-water, water-in-oil, water-in-oil-in-water, or oil-in-water-in-oil dispersions or droplets, including lipid structures that can form as a result of hydrophobic forces that drive apolar residues (*e.g.*, long hydrocarbon chains) away from water and polar head groups toward water, when a water immiscible phase is mixed with an aqueous phase. These other lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases. Emulsions are composed of an aqueous phase and a lipophilic phase (typically containing an oil and an organic solvent). Emulsions also frequently contain one or more surfactants. Nanoemulsion formulations are well known, *e.g.*, as described in US Patent Application Nos. 2002/0045667 and 2004/0043041, and US Pat. Nos. 6,015,832, 6,506,803, 6,635,676, and 6,559,189, each of which is incorporated herein by reference in its entirety.

[0395] In some embodiments, recombinant meganuclease proteins, or DNA/mRNA encoding recombinant meganucleases, are covalently attached to, or non-covalently associated with, multifunctional polymer conjugates, DNA dendrimers, and polymeric dendrimers (Mastorakos *et al.* (2015), *Nanoscale.* 7(9): 3845-56; Cheng *et al.* (2008), *J Pharm Sci.* 97(1): 123-43). The dendrimer generation can control the payload capacity and size, and can provide a high drug payload capacity. Moreover, display of multiple surface groups can be leveraged to improve stability, reduce nonspecific interactions, and enhance cell-specific targeting and drug release.

[0396] In some embodiments, genes encoding a recombinant meganuclease are delivered using a viral vector. Such vectors are known in the art and include lentiviral vectors,

adenoviral vectors, and adeno-associated virus (AAV) vectors (reviewed in Vannucci, *et al.* (2013), *New Microbiol.* 36:1-22). In some embodiments, the viral vectors are injected directly into target tissues (Bosch, *et al.* (2000), *Mol Ther.* 1:63-70; Greig *et al.* (2014), *PLoS One.* Nov 13;9(11):e112268). In alternative embodiments, the viral vectors are delivered systemically via the circulatory system. It is known in the art that different AAV vectors tend to localize to different tissues. In retinal target tissues, effective transduction of retinal photoreceptor cells has been shown, for example, with AAV serotypes 1, 2, 5, 8, and 9 (Petr-Silva *et al.* (2014), *Clinical Ophthalmology.* 8:127-136). AAV vectors can also be self-complementary such that they do not require second-strand DNA synthesis in the host cell (McCarty *et al.* (2001), *Gene Ther.* 8:1248-54).

[0397] In one embodiment, a viral vector used for meganuclease gene delivery is a self-limiting viral vector. A self-limiting viral vector can have limited persistence time in a cell or organism due to the presence of a recognition sequence for a recombinant meganuclease within the vector. Thus, a self-limiting viral vector can be engineered to provide coding for a promoter, a recombinant meganuclease described herein, and a meganuclease recognition site within the ITRs. The self-limiting viral vector delivers the meganuclease gene to a cell, tissue, or organism, such that the meganuclease is expressed and able to cut the genome of the cell at an endogenous recognition sequence within the genome. The delivered meganuclease will also find its target site within the self-limiting viral vector itself, and cut the vector at this target site. Once cut, the 5' and 3' ends of the viral genome will be exposed and degraded by exonucleases, thus killing the virus and ceasing production of the recombinant meganuclease.

[0398] If the recombinant meganuclease genes are delivered in DNA form (*e.g.* plasmid) and/or via a viral vector (*e.g.* AAV) they must be operably linked to a promoter. In some embodiments, this can be a viral promoter such as endogenous promoters from the viral vector (*e.g.* the LTR of a lentiviral vector) or the well-known cytomegalovirus- or SV40 virus-early promoters. In a preferred embodiment, meganuclease genes are operably linked to a promoter that drives gene expression preferentially in the target cells. Examples of retina and/or rod photoreceptor cell-specific promoters include, without limitation, the human rhodopsin kinase promoter, the proximal mouse opsin promoter (mOP), the human G-protein-coupled receptor protein kinase 1 promoter (hGRK1), and the human interphotoreceptor retinoid-binding protein (IRBP) promoter (Khani *et al.* (2007), *Invest. Ophthalmol. Vis. Sci.* 48(9):3954-3961); Beltran *et al.* (2010), *Gene Therapy.* 17(9):1162-

1174); Yokoyama *et al.* (1992), *Exp. Eye Res.* 55(2):225-233), as well as rod photoreceptor cell-specific promoters disclosed in U.S. Patent Publication No. US 2014/0287510.

[0399] In some embodiments, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant meganuclease of the invention, or a pharmaceutically acceptable carrier and an isolated polynucleotide comprising a nucleic acid encoding a recombinant meganuclease of the invention. Such pharmaceutical compositions can be prepared in accordance with known techniques. See, *e.g.*, Remington, *The Science And Practice of Pharmacy* (21st ed. 2005). In the manufacture of a pharmaceutical formulation according to the invention, endonuclease polypeptides (or DNA/RNA encoding the same) are typically admixed with a pharmaceutically acceptable carrier and the resulting composition is administered to a subject. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the subject. In some embodiments, pharmaceutical compositions of the invention can further comprise one or more additional agents or biological molecules useful in the treatment of a disease in the subject. Likewise, the additional agent(s) and/or biological molecule(s) can be co-administered as a separate composition.

[0400] It is envisioned that a single treatment will permanently inactivate the mutant P23H RHO allele in a percentage of patient target cells. If the frequency of P23H allele inactivation is low, however, or if a large percentage of target cells need to be corrected, it may be necessary to perform multiple treatments on each patient.

2.4 Recombinant Meganuclease Variants

[0401] Embodiments of the invention encompass the recombinant meganucleases described herein, and variants thereof. Further embodiments of the invention encompass isolated polynucleotides comprising a nucleic acid sequence encoding the recombinant meganucleases described herein, and variants of such polynucleotides.

[0402] In particular, the invention provides variants of the meganucleases of SEQ ID Nos:6-93 in which the hypervariable regions have been modified such that the meganucleases preferentially recognize and cleave one of SEQ ID NOs: 2-4 relative to the corresponding wild-type sequences in the wild-type RHO gene (SEQ ID NO: 98). Such additional variants meganucleases can be produced by routine experimentation according to the methods described in WO2007/047859, U.S. Pat. No. 8,021,867, U.S. Pat. No. 8,119,361, U.S. Pat.

No.8,119,381, U.S. Pat. No. 8,124,369, U.S. Pat. No. 8,129,134, U.S. Pat. No.8,133,697, U.S. Pat. No. 8,143,015, U.S. Pat. No. 8,143,016, U.S. Pat. No. 8,148,098, U.S. Pat. No.8,163,514, U.S. Pat. No. 8,304,222, U.S. Pat. No. 8,377,674 and U.S. Pat. No. 8,445,251, and discussed below.

[0403] As used herein, “variants” is intended to mean substantially similar sequences. A “variant” polypeptide is intended to mean a polypeptide derived from the “native” polypeptide by deletion or addition of one or more amino acids at one or more internal sites in the native protein and/or substitution of one or more amino acids at one or more sites in the native polypeptide. As used herein, a “native” polynucleotide or polypeptide comprises a parental sequence from which variants are derived. Variant polypeptides encompassed by the embodiments are biologically active. That is, they continue to possess the desired biological activity of the native protein; *i.e.*, the ability to preferentially recognize and cleave a P23H recognition sequence (*e.g.*, one of SEQ ID NOs:1-4), as described herein. Such variants may result, for example, from human manipulation. Biologically active variants of a native polypeptide of the embodiments (*e.g.*, SEQ ID NOs:6-93), or biologically active variants of the RHO1- and RHO2-binding subunits described herein (*e.g.*, SEQ ID NOs:99-274), will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%, sequence identity to the amino acid sequence of the native polypeptide or native subunit, as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a polypeptide or subunit of the embodiments may differ from that polypeptide or subunit by as few as about 1-40 amino acid residues, as few as about 1-20, as few as about 1-10, as few as about 5, as few as 4, 3, 2, or even 1 amino acid residue.

[0404] The polypeptides of the embodiments may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants can be prepared by mutations in the DNA. Methods for mutagenesis and polynucleotide alterations are well known in the art. See, for example, Kunkel (1985), *Proc. Natl. Acad. Sci. USA* 82:488-492; Kunkel *et al.* (1987), *Methods in Enzymol.* 154:367-382; U.S. Pat. No. 4,873,192; Walker and Gastra, eds. (1983), *Techniques in Molecular Biology* (MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be

found in the model of Dayhoff *et al.* (1978), *Atlas of Protein Sequence and Structure* (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be optimal.

[0405] A substantial number of amino acid modifications to the DNA recognition domain of the wild-type I-CreI meganuclease have previously been identified (*e.g.*, U.S. Pat. No. 8,021,867) which, singly or in combination, result in recombinant meganucleases with specificities altered at individual bases within the DNA recognition sequence half-site, such that the resulting rationally-designed meganucleases have half-site specificities different from the wild-type enzyme. Table 2 provides potential substitutions that can be made in a recombinant meganuclease monomer or subunit to enhance specificity based on the base present at each half-site position (-1 through -9) of a recognition half-site.

Table 2.

Posn.	Favored Sense-Strand Base										
	A	C	G	T	A/T	A/C	A/G	C/T	G/T	A/G/T	A/C/G/T
-1	Y75 L75* C75* Y139* C46* A46*	R70* H75* R75* H46* K46* R46*	K70 E70* E75* E46* D46*	Q70* C70 L70 Y75* Q75* H75* H139 Q46* H46*				T46*			G70 A70 S70 G46*
-2	Q70 T44* A44* V44* I44* L44* N44*	E70 D70 K44* R44*	H70 D44* E44*	Q44*	C44*						
-3	Q68 C24* I24*	E68 F68 K24* R24*	R68	M68 C68 L68 F68		H68		Y68	K68		
-4	A26* Q77	E77 K26*	R77 E26*					S77 Q26*			S26*
-5		E42	R42			K28*	C28*				M66

	Favored Sense-Strand Base									
							Q42			K66
-6	Q40 C28*	E40 R28*	R40	C40 I40 V40 C79 I79 V79 Q28*	A40 A79 A28* H28*					S40 S28*
-7	N30* Q38	E38 K30* R30*	K38 R38 E30*	I38 L38			C38			H38 N38 Q30*
-8	F33 Y33	E33 D33	F33 H33	L33 V33 I33 F33 C33		R32*	R33			
-9		E32	R32 K32	L32 V32 A32 C32				D32 I32		S32 N32 H32 Q32 T32

[0406] For polynucleotides, a “variant” comprises a deletion and/or addition of one or more nucleotides at one or more sites within the native polynucleotide. One of skill in the art will recognize that variants of the nucleic acids of the embodiments will be constructed such that the open reading frame is maintained. For polynucleotides, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides of the embodiments. Variant polynucleotides include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis but which still encode a recombinant meganuclease of the embodiments. Generally, variants of a particular polynucleotide of the embodiments will have at least about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein. Variants of a particular polynucleotide of the embodiments (*i.e.*, the reference polynucleotide) can also be evaluated by comparison of the

percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide.

[0407] The deletions, insertions, and substitutions of the protein sequences encompassed herein are not expected to produce radical changes in the characteristics of the polypeptide. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by screening the polypeptide for its ability to preferentially recognize and cleave a P23H recognition sequence (*e.g.*, one of SEQ ID NOs:1-4).

EXAMPLES

[0408] This invention is further illustrated by the following examples, which should not be construed as limiting. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are intended to be encompassed in the scope of the claims that follow the examples below.

EXAMPLE 1

Evaluation of meganucleases that recognize and cleave a P23H recognition sequence

1. Meganucleases that recognize and cleave a P23H recognition sequence

[0409] Recombinant meganucleases (SEQ ID NOs:6-93), collectively referred to herein as “RHO 1-2 meganucleases,” were engineered to recognize and cleave one of the P23H recognition sequences (*i.e.*, SEQ ID NO:1), which is present in the mutant RHO P23H allele (see, Figure 1A). Each RHO 1-2 recombinant meganuclease comprises an N-terminal nuclease-localization signal derived from SV40, a first meganuclease subunit, a linker sequence, and a second meganuclease subunit. A first subunit in each RHO 1-2 meganuclease binds to the RHO1 recognition half-site of SEQ ID NO:1, while a second subunit binds to the RHO2 recognition half-site (see, Figure 1B).

[0410] As illustrated in Figures 2 and 3, RHO1-binding subunits and RHO2-binding subunits each comprise a 56 base pair hypervariable region, referred to as HVR1 and HVR2, respectively. RHO1-binding subunits are identical outside of the HVR1 region except at position 80 or position 271 (comprising a Q or E residue), and are highly conserved within

the HVR1 region. Similarly, RHO2-binding subunits are also identical outside of the HVR2 region except at position 80 or position 271 (comprising a Q or E residue), and are highly conserved within the HVR2 region.

[0411] The RHO1-binding regions of SEQ ID NOs:6-93 are illustrated in Figures 2A-2F and are provided as SEQ ID NOs:102-189, respectively. Nearly all of SEQ ID NOs:102-189 share at least 90% sequence identity to SEQ ID NO:102, which is the RHO1-binding region of the meganuclease RHO2-L3-59 (SEQ ID NO:6). RHO2-binding regions of SEQ ID NOs:6-93 are illustrated in Figures 3A-3F and are provided as SEQ ID NOs:190-277, respectively. Nearly all of SEQ ID NOs:190-277 share at least 90% sequence identity to SEQ ID NO:190, which is the RHO2-binding region of the meganuclease RHO2-L3-59 (SEQ ID NO:6).

2. Cleavage of a P23H recognition sequence in a CHO cell reporter assay

[0412] To determine whether RHO 1-2 meganucleases could recognize and cleave the P23H recognition sequence of SEQ ID NO:1, each RHO 1-2 meganuclease was evaluated using the CHO cell reporter assay previously described (see WO2012/167192, Figure 4). To perform the assay, a pair of CHO cell reporter lines were produced which carried a non-functional Green Fluorescent Protein (GFP) gene expression cassette integrated into the genome of the cell. The GFP gene in each cell line was interrupted by a pair of recognition sequences such that intracellular cleavage of either recognition sequence by a meganuclease would stimulate a homologous recombination event resulting in a functional GFP gene. In both cell lines, one of the recognition sequences was derived from the RHO gene (either SEQ ID NO:1 or SEQ ID NO:5) and the second recognition sequence was specifically recognized by a control meganuclease called “CHO-23/24”. CHO reporter cells comprising the P23H recognition sequence of SEQ ID NO:1 and the CHO-23/24 recognition sequence are referred to herein as “RHO 1-2 cells.” RHO 1-2 cells were transfected with plasmid DNA encoding one of the RHO 1-2 meganucleases (SEQ ID NOs:6-93) or encoding the CHO-23/34 meganuclease. Approximately 4×10^5 CHO cells were transfected with 50 ng of plasmid DNA in a 96-well plate using Lipofectamine 2000 (ThermoFisher) according to the manufacturer’s instructions. At 48 hours post-transfection, cells were evaluated by flow cytometry to determine the percentage of GFP-positive cells compared to an untransfected negative control (RHO 1-2 bs). All RHO 1-2 meganucleases were found to produce GFP-positive cells in cell lines comprising the P23H recognition sequence at frequencies

significantly exceeding the negative control and comparable to or exceeding the CHO-23/24 positive control, indicating that each RHO 1-2 meganuclease was able to efficiently recognize and cleave the intended P23H recognition sequence in a cell (see, Figure 5).

[0413] The efficacy of RHO 1-2 recombinant meganucleases was also determined in a time-dependent manner 1, 4, 6, and 8 days after introduction of the meganucleases into RHO 1-2 cells. In this study, RHO 1-2 cells (1.0×10^6) were electroporated with 1×10^6 copies of meganuclease mRNA per cell using a BioRad Gene Pulser Xcell according to the manufacturer's instructions. At 48 hours post-transfection, cells were evaluated by flow cytometry to determine the percentage of GFP-positive cells. A CHO-23/24 meganuclease was also included at each time point as a positive control. As shown in Figure 6, the efficacy of RHO 1-2 meganucleases persisted over the 8 day period evaluated.

3. Conclusions

[0414] These studies demonstrated that RHO 1-2 meganucleases (SEQ ID NOs:6-93) encompassed by the invention can target and cleave the P23H recognition sequence of SEQ ID NO:1 in cells.

EXAMPLE 2

Specificity of meganucleases for a P23H recognition sequence

1. CHO reporter cells comprising a corresponding wild-type RHO sequence

[0415] To determine the specificity of RHO 1-2 meganucleases (SEQ ID NOs:6-93) for the P23H recognition sequence of SEQ ID NO:1, a CHO reporter cell line was generated as previously described that comprises the corresponding wild-type RHO recognition sequence (SEQ ID NO:5), referred to herein as the "RHO 3-4 recognition sequence," and the CHO-23/24 recognition sequence. The resulting cells are referred to herein as "RHO 3-4 cells."

2. Specificity of RHO 1-2 meganucleases

[0416] RHO 1-2 meganucleases were introduced into RHO 1-2 cells or RHO 3-4 cells to determine if the recombinant meganucleases could discriminate between the P23H recognition sequence of SEQ ID NO:1 and the corresponding wild-type recognition sequence (SEQ ID NO:5). RHO 1-2 meganuclease mRNA was introduced into RHO 1-2 cells or RHO 3-4 cells via electroporation of mRNA as previously described, and the percent GFP-positive

cells was determined after 3-5 days. As shown in Figure 7, each of the RHO 1-2 meganucleases tested preferentially cleaved the P23H recognition sequence relative to the RHO 3-4 recognition sequence, as evidenced by higher percentages of GFP-positive RHO 1-2 cells than RHO 3-4 cells (see, Figure 7A-7E). In subsequent experiments, it was shown that recombinant meganucleases could be developed that preferentially target and cleave the wild-type RHO 3-4 recognition sequence (SEQ ID NO:5). This set of meganucleases, when evaluated using the CHO cell reporter assay described above, were found to yield a higher percentage of GFP-positive RHO 3-4 cells than RHO 1-2 cells (see, Figure 7F).

3. Conclusions

[0417] We have demonstrated that RHO 1-2 meganucleases encompassed by the invention preferentially cleave the P23H recognition sequence of SEQ ID NO:1 relative to the corresponding wild-type RHO 3-4 recognition sequence (SEQ ID NO:5).

EXAMPLE 3

Generation and expression of recombinant AAV vectors for expressing recombinant meganucleases

1. Recombinant AAV vectors for expressing RHO 1-2 meganucleases

[0418] Recombinant AAV vectors were designed to express RHO 1-2 meganucleases in CHO reporter cells. As shown in Figure 8A, the recombinant AAV vectors comprise, from 5' to 3', a first inverted terminal repeat (ITR), a CMV promoter operably linked to a nucleotide sequence encoding a meganuclease, and a second inverted terminal repeat. In this study, a coding sequence for the RHO-1/2-L2-49 meganuclease was incorporated into the recombinant AAV vector.

2. Expression of a RHO 1-2 meganuclease following recombinant AAV transduction

[0419] A recombinant AAV vector (rAAV-RHO-1/2) was prepared for expression of the RHO-1/2-L2-49 meganuclease in RHO 1-2 cells using a standard triple-transfection protocol in HEK-293 cells (Drittanti *et al.* (2001), *J Gene Med.* 3:59-71). RHO 1-2 CHO reporter cells were transduced with the rAAV-RHO-1/2 vector at three concentrations of virus. At 24 hours post-transduction, cells were lysed and analyzed by Western blot using a polyclonal

meganuclease-specific antibody or a β -actin-specific control antibody. As shown in Figure 8B, RHO-1/2-L2-49 expression was observed at all three concentrations of virus.

3. Specificity of AAV-delivered RHO 1-2 meganuclease

[0420] The rAAV-RHO-1/2 vector was transduced into RHO 1-2 cells or RHO 3-4 cells to demonstrate the specificity of AAV-delivered RHO-1/2-L2-49 meganuclease for recognizing and cleaving the P23H recognition sequence of SEQ ID NO:1 relative to the corresponding wild-type RHO 3-4 recognition sequence (SEQ ID NO:5). As shown in Figure 9, after three days post-transduction, the AAV-delivered RHO-1/2-L2-49 meganuclease induced a higher percentage of GFP-positive RHO 1-2 cells than RHO 3-4 cells at all concentrations of virus used, indicating that the meganuclease preferentially recognizes and cleaves the mutant sequence.

4. Persistence of AAV-delivered RHO 1-2 meganuclease expression

[0421] RHO 1-2 cells, transduced with the recombinant AAV vector encoding the RHO-1/2-L2-49 meganuclease or GFP, were treated with cycloheximide to halt protein translation and determine the stability of the expressed proteins in cells. Cells were lysed at various times (0, 1.5, 6, and 22 hours) post-cycloheximide treatment, and protein levels of RHO-1/2-L2-49, GFP, and β -actin were determined by Western Blot analysis. As shown in Figure 10, RHO-1/2-L2-49 protein persisted significantly longer than GFP, with no reduction in meganuclease protein apparent after 22 hours.

5. Conclusions

[0422] This study indicates that RHO 1-2 meganucleases encompassed by the invention can be expressed in cells using recombinant AAV vectors, and that such meganucleases can preferentially recognize and cleave the P23H recognition sequence of SEQ ID NO:1 relative to the corresponding wild-type RHO 3-4 sequence (SEQ ID NO:5). Furthermore, this study demonstrates that RHO 1-2 meganuclease proteins are stable in cells when expressed using recombinant AAV vectors.

EXAMPLE 4

Cleavage of RHO 1-2 recognition sequence in reporter cells with RHO 1-2 meganucleases delivered by AAV

1. Production of recombinant AAV vectors

[0423] The purpose of this study was to demonstrate that RHO 1-2 meganucleases could be expressed in mammalian cells by viral transduction, and to further demonstrate their ability to cleave the RHO 1-2 recognition sequence.

[0424] For this experiment, two recombinant AAV2 vectors were produced by the triple-transfection method previously described. The two donor plasmids were pDS CMV RHO2_L3_59 (SEQ ID NO:248) and pDS CMV RHO2_L5_14 (SEQ ID NO:249), which encoded the RHO2-L3-59 and RHO2-L5-14 meganucleases, respectively (Figure 11). These plasmids comprise a CMV promoter and enhancer driving expression of the nuclease, an SV40 polyA sequence, AAV ITR (inverted terminal repeat) sequences required for genome replication, and are suitable for the production of self-complimentary AAV genomes (scAAV). The capsid from AAV serotype 2 was used to generate these vectors. Recombinant scAAV was produced using the triple-transfection method in HEK 293 cells and purified over a CsCl gradient. Viral titer was determined by RT-PCR and slot-blot methods.

2. Transduction of reporter cells and analysis of cleavage efficiency

[0425] To determine whether these AAV particles could deliver functional RHO 1-2 meganucleases capable of recognizing and specifically cleaving the RHO 1-2 recognition sequence (SEQ ID NO:1) and not the RHO 3-4 recognition sequence (SEQ ID NO:5), they were tested in previously described CHO reporter lines (see WO2012/167192). To perform the assay, a pair of CHO cell reporter lines were produced which carried a non-functional Green Fluorescent Protein (GFP) gene expression cassette integrated into the genome of the cell. The GFP gene in each cell line was interrupted by either the RHO 1-2 or RHO 3-4 recognition sequence such that intracellular cleavage of the recognition sequence by a meganuclease would stimulate a homologous recombination event resulting in a functional GFP gene. CHO reporter cells comprising the RHO 1-2 recognition sequence are referred to in this experiment as “P23H RHO cells.” CHO reporter cells comprising the RHO 3-4 recognition sequence are referred to in this experiment as “WT RHO cells.” Wild-type control cells that do not harbor the GFP reporter cassette are referred to in this experiment as “CHO K cells.”

[0426] WT RHO cells, P23H RHO cells, or wild-type CHO K cells (negative control) were infected with recombinant scAAV described above. Reporter cells were infected at

three MOIs: 1×10^8 , 1×10^9 or 2×10^9 (“low,” “medium,” and “high,” respectively). At 48 hours post-infection, cells were evaluated by flow cytometry to determine the percentage of GFP-positive cells compared to wild-type control CHO cells. As shown in Figure 12, control wild-type CHO cells infected with either the RHO2-L3-59 or RHO2-L5-14 scAAV provided background GFP expression, less than 1%. Cells harboring the wild-type RHO 3-4 target (“WT RHO cells”) did not display GFP expression significantly higher than the control cells, indicating that the RHO 1-2 meganucleases are not capable of cleaving the RHO 3-4 recognition sequence. In P23H RHO cells, both the RHO2-L3-59 and RHO2-L5-14 meganucleases resulted in significant GFP expression in a dose-dependent manner, with levels approaching 10% GFP+ in the highest dose.

[0427] Western blot analysis was used to confirm both GFP and meganuclease expression in the P23H RHO cells. Whole cell lysates were prepared only from P23H RHO and WT RHO cells infected with the three different doses of scAAV. Lysates for duplicates were harvested to provide a measure of reproducibility. Equivalent amounts of lysates (determined by protein concentration) were resolved by SDS-PAGE, transferred to a membrane and probed using antibodies against either GFP, the I-CreI meganuclease, or for loading control, β -actin. RHO 1-2 meganucleases are detectable with the polyclonal antibody against I-CreI.

[0428] As shown in Figure 13, western blot analysis clearly demonstrates detection of GFP in a dose-dependent manner, confirming the flow cytometry data shown in Figure 12 and described above. Western blot analysis also shows expression of the RHO 1-2 meganucleases, also in a dose-dependent manner. The blot does suggest that RHO2-L5-14 expressed to higher levels than RHO2-L3-59. β -actin levels were consistent, indicating proper gel loading.

3. Conclusions

[0429] Together, these data demonstrate recombinant scAAV carrying expression cassettes for RHO 1-2 meganucleases of the invention are able to infect CHO reporter lines, resulting in expression of the RHO 1-2 meganucleases which are then able to specifically cleave the P23H RHO 1-2 recognition sequence (SEQ ID NO:1) and not the WT RHO 3-4 recognition

EXAMPLE 5

In vivo cleavage of P23H allele in mouse model of RP

1. Production of recombinant AAV vectors and sub-retinal delivery to mouse eye

[0430] The purpose of this study was to determine whether RHO 1-2 meganucleases of the invention could target and cleave the RHO 1-2 recognition sequence *in vivo* within photoreceptor cells of a mouse retina.

[0431] Recombinant scAAV were prepared using the triple-transfection method as described above and were tested in a murine model of retinitis pigmentosa. In this model, transgenic mice carry a single copy of the human P23H mutant RHO gene in addition to the endogenous murine RHO alleles. While these mice do not exhibit a retinitis pigmentosa phenotype, they are useful for molecular analysis of *in vivo* cleavage of the RHO 1-2 recognition sequence. Since RHO2-L5-14 performed better in the GFP reporter CHO lines, only scAAV encoding RHO2-L5-14 was used to infect mice (though the present experiments could be performed using the RHO2-L3-59 meganuclease, including the production of an scAAV using the donor plasmid set forth in SEQ ID NO:280). The pDS GRK1 RHO2_L5_14 donor plasmid (SEQ ID NO: 281) used in the scAAV triple transfection protocol is illustrated in Figure 14. As shown, the RHO2-L5-14 meganuclease was under the control of a rod cell-specific GRK1 promoter. As a control, a recombinant scAAV encoding a GFP expression cassette was also prepared. The capsid from AAV serotype 5 was used to generate these recombinant scAAV vectors.

[0432] One of the P23H transgenic mice was used to test whether sub-retinal injection of an AAV encoding a RHO2-L5-14 expression cassette could result in cleavage at the RHO 1-2 recognition sequence. Briefly, at postnatal day 30, a mouse was placed under general anesthesia by intraperitoneal injection of Ketamine 100 mg/kg and Xylazine 10 mg/kg. Pupils were dilated with Tropicamide (0.5%) and 1% Proparacaine. Under an ophthalmic surgery microscope, with a 30-gauge needle a small incision was made through the cornea adjacent to the limbus. A 33-gauge blunt needle fitted to a Hamilton syringe was inserted through the incision. All injections were made sub-retinally within the nasal quadrant of the retina. The mouse received 1 μ L of scAAV encoding RHO2-L5-14 in one eye and 1 μ L of scAAV encoding GFP in the other eye (both viral preparations were at a concentration of 7×10^{12} particles/mL). Visualization during injection was aided by the addition of fluorescein to the vector suspensions. Fundus and OCT examination were performed to confirm the successful sub-retinal delivery.

[0433] The mouse was euthanized with isoflurane and eyes were enucleated at 30 days post-injection. The retinas were carefully dissected free from the other ocular tissues under surgical microscope. DNA was isolated from dissected retinas by using DNA isolation

kit (Qiagen). Briefly, retinas were digested with lysis buffer containing protease K at 55°C for 2hrs. After lysis, crude extract was passed through the column and bound DNA washed several times. The DNA was eluted and concentration was estimated by NanoDrop (Thermo).

[0434] To determine the presence and relative frequency of mutations at the RHO 1-2 recognition sequence, the RHO 1-2 locus was PCR-amplified and subjected to deep sequencing analysis. Briefly, PCR primers were designed to amplify a ~200bp region spanning the RHO 1-2 recognition sequence and gel-purified PCR bands were subjected to deep sequencing analysis using an Illumina MiSeq instrument.

2. Results

[0435] Deep sequencing of the PCR bands provided over 5×10^5 sequences per sample. Retinas injected with scAAV encoding GFP showed about 4×10^3 sequences with indels (insertions or deletions) at the RHO 1-2 recognition sequence, establishing the background at 0.54%. In DNA isolated from a mouse retina that had been injected with AAV encoding the RHO2-L5-14 meganuclease, indels were detected at 3.92%, approximately 7-fold higher than background (Table 3). In other experiments (data not shown), control mice showed a lower frequency of indels, typically around 0.01%.

Table 3.

	Sequences with indels	Sequences with no indels	% Indel
AAV-GFP	4155	766145	0.54
AAV-RHO 1-2L5.14	22330	547763	3.92

3. Conclusions

[0436] The deep sequencing data demonstrates that sub-retinal injection with an AAV encoding the RHO2-L5-14 meganuclease resulted in mutation of the P23H RHO 1-2 recognition sequence in a murine model of retinitis pigmentosa following cleavage and non-homologous end joining.

EXAMPLE 6

In vivo expression of RHO 1-2 meganucleases in retinal cells

1. Western blot analysis of retinal cells

[0437] To confirm that the RHO2-L5-14 meganuclease could be expressed in the retinal cells of wild-type mice following AAV delivery, five wild-type mice were administered scAAV encoding RHO2-L5-14 by sub-retinal injection as described above. Both the OS (left) and OD (right) eyes were infected. 30 days following injection, retinas were dissected, whole cell lysates were prepared and western blot analysis was performed, using the anti-I-CreI antibody as described above.

[0438] Western blot analysis showed that in most retinas, RHO2L-5-14 expression is readily detected (Figure 15, lanes 3, 5, 7 and 10). In other retinas, expression was considerably less, but still detectable (Figure 15, lanes 1, 4, and 6). The remaining retinas had almost undetectable levels of expression (Figure 15, lanes 2, 8 and 9). Sub-retinal injection relies on precise delivery to a very small area behind the eye. Although this procedure is fairly common in adult patients, it is not a common lab practice in mouse models. Therefore, the difference in expression was attributed to the difficulty of murine sub-retinal injections.

2. Conclusions

[0439] Western blot analysis demonstrated that scAAV encoding RHO2L-5-14 delivered sub-retinally to mice resulted in expression of the RHO 1-2 meganuclease. Taken together with indel data from a murine model for the human P23H RHO gene, these data suggest that AAV delivery of a RHO 1-2 meganuclease is effective in causing deletions in the P23H RHO allele.

[0440] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0441] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An engineered meganuclease that recognizes and cleaves a P23H recognition sequence consisting of SEQ ID NO: 1, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit recognizes a first recognition half-site of said P23H recognition sequence and comprises a first hypervariable (HVR1) region,

and wherein said second subunit recognizes a second recognition half-site of said P23H recognition sequence and comprises a second hypervariable (HVR2) region, and wherein said engineered meganuclease comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 7.

2. The engineered meganuclease of claim 1, wherein said first subunit comprises an amino acid sequence having at least 97% sequence identity to residues 198-344 of SEQ ID NO: 7, and wherein said second subunit comprises an amino acid sequence having at least 97% sequence identity to residues 7-153 of SEQ ID NO: 7.

3. The engineered meganuclease of claim 1 or claim 2, wherein said first subunit comprises residues 198-344 of any one of SEQ ID NO: 7.




4. The engineered meganuclease of any one of claims 1-3, wherein said second subunit comprises residues 7-153 of SEQ ID NO: 7.

5. The engineered meganuclease of any one of claims 1-4, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 7.

6. The engineered meganuclease of any one of claims 1-5, wherein said engineered meganuclease preferentially recognizes and cleaves a P23H recognition sequence consisting of SEQ ID NO: 1 relative to a recognition sequence consisting of SEQ ID NO: 5.

7. An isolated polynucleotide comprising a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-6.

8. A recombinant DNA construct comprising said isolated polynucleotide of claim 7.
9. The recombinant DNA construct of claim 8, wherein said recombinant DNA construct encodes a recombinant adeno-associated virus (AAV) vector.
10. A recombinant AAV vector comprising a polynucleotide, wherein said polynucleotide comprises a nucleic acid sequence encoding said engineered meganuclease of any one of claims 1-6, wherein said nucleic acid sequence encoding said engineered meganuclease is operably linked to a promoter.
11. The recombinant AAV vector of claim 10, wherein said recombinant AAV vector is serotype 5.
12. The recombinant AAV vector of claim 10, wherein said recombinant AAV vector is serotype 2.
13. The recombinant AAV vector of any one of claims 10-12, wherein said recombinant AAV vector is a self-complementary AAV vector.
14. The recombinant AAV vector of any one of claims 10-13, wherein said promoter is a retina cell-specific promoter.
15. The recombinant AAV vector of any one of claims 10-14, wherein said promoter is a rod photoreceptor cell-specific promoter.
16. The recombinant AAV vector of claim 15, wherein said promoter is a human G-protein-coupled receptor protein kinase 1 (GRK1) promoter.

A.**B.****C.****Figure 1**

RHO1 Half-Site Binding Sequences

SEQ ID NO:		Hypervariable Region 1 (HVR1)	271
102	RHO2-L3-59	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
103	RHO2-L5-14	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
104	RHO-1/2-L2-49	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
105	RHO 1-2x.179	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
106	RHO 1-2x.4	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
107	RHO 1-2x.207	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
108	RHO 1-2x.277	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
109	RHO 1-2x.292	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
110	RHO 1-2x.324	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
111	RHO 1-2x.371	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
112	RHO 1-2x.164	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
113	RHO 1-2x.181	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
114	RHO 1-2x.184	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
115	RHO-1/2-L1-21	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
116	RHO-1/2-L1-43	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
117	RHO-1/2-L1-45	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
118	RHO-1/2-L1-60	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
119	RHO-1/2-L1-61	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
120	RHO-1/2-L1-58	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
121	RHO-1/2-L1-7	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
122	RHO-1/2-L1-13	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
123	RHO-1/2-L1-18	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
124	RHO-1/2-L1-70	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
125	RHO-1/2-L1-86	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
126	RHO-1/2-L2-13	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
127	RHO-1/2-L2-24	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
128	RHO-1/2-L2-37	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
129	RHO-1/2-L2-58	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
130	RHO-1/2-L2-31	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
131	RHO-1/2-L2-29	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE
132	RHO-1/2-L2-61	KEFLLYLAGFVDGDSI	WASIIPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGVDQGGSVSEYRLSE

Figure 2A

RHO1 Half-Site Binding Sequences (cont.)

SEQ ID NO:		Hypervariable Region 1 (HVR1)	271
133	RHO2-L3-2	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
134	RHO2-L3-3	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
135	RHO2-L3-5	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
136	RHO2-L3-10	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
137	RHO2-L3-11	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
138	RHO2-L3-12	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
139	RHO2-L3-13	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
140	RHO2-L3-28	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
141	RHO2-L3-29	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
142	RHO2-L3-57	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
143	RHO2-L3-80	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
144	RHO2-L3-85	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
145	RHO2-L3-86	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
146	RHO2-L3-92	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
147	RHO2-L3-4	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
148	RHO2-L3-20	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
149	RHO2-L3-72	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
150	RHO1-L1-4	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
151	RHO1-L1-8	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
152	RHO1-L1-13	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
153	RHO1-L1-19	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
154	RHO1-L1-58	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
155	RHO1-L1-69	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
156	RHO1-L1-80	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
157	RHO1-L1-82	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
158	RHO1-L1-73	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
159	RHO1-L1-85	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
160	RHO1-L1-86	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	
161	RHO-1/2-L4-10	KEFL YLAGFVDGDSI WASI IPEQGYKFKHRLRLSFTVAQKTQRRWFLDKLVDEIGVGYVVDQGSVSEYRLSE	

Figure 2B

RHO1 Half-Site Binding Sequences (cont.)

SEQ ID NO:		Hypervariable Region 1 (HVR1)	
162	RHO-1/2-14-29	KEFLLYLAGFVDGDSIYAAIIPERAGREFKHRLRLYFTVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	271
163	RHO-1/2-14-65	KEFLLYLAGFVDGDSIYASIPPEPTASEFKHRLRLYFTVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
164	RHO-1/2-14-66	KEFLLYLAGFVDGDSIYASINPEPSYREFKHRLRLSFTVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
165	RHO-1/2-14-85	KEFLLYLAGFVDGDSIYASIPPEHOYREFKHRLRLSFTVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
7			80
166	RHO 1-2x.216	KEFLLYLAGFVDGDSIYAAIPDQKXKFKHRLRLYFAVCQKTQRRWFLDKLVDDEIGVGYYVDHGVSSEYRLSQ	
167	RHO 1-2x.241	KEFLLYLAGFVDGDSIYATIEPAQRIKFKHRLRLIKFAVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
168	RHO 1-2x.94	KEFLLYLAGFVDGDSIYATINPDQTNKFKHRLRLIFFAVCQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
169	RHO 1-2x.95	KEFLLYLAGFVDGDSIYACIEPAQNSKFKHRLRLRFEVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
170	RHO 1-2x.1	KEFLLYLAGFVDGDSIYASITPCQSYKFKHRLRLKFSVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
171	RHO 1-2x.60	KEFLLYLAGFVDGDSIYATIMPEQTVKFKHRLRLRFEFAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
172	RHO 1-2x.74	KEFLLYLAGFVDGDSIYATIQPEQAFKFKHRLRLRFEFVHQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
173	RHO 1-2x.88	KEFLLYLAGFVDGDSIYATIEPSCQTKFKHRLRLRFEFSVYQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
174	RHO 1-2x.294	KEFLLYLAGFVDGDSIYASITPCQSYKFKHRLRLKFSVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
175	RHO 1-2x.302	KEFLLYLAGFVDGDSIYATITPSQNLKFKHRLRLYFVEVCQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
176	RHO 1-2x.306	KEFLLYLAGFVDGDSIYASICTQAQKFKHRLRLRFAVFQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
177	RHO 1-2x.338	KEFLLYLAGFVDGDSIYASIEPAQSYKFKHRLQLKFAVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
178	RHO 1-2x.348	KEFLLYLAGFVDGDSIYAAIMPTQSYKFKHRLRLAFSVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
179	RHO 1-2x.356	KEFLLYLAGFVDGDSIYATITPNQRTKFKHRLKLAFAVYQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
180	RHO 1-2x.364	KEFLLYLAGFVDGDSIYAAIVPMVQSTKFKHRLRLYFTVHQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
181	RHO 1-2x.142	KEFLLYLAGFVDGDSIYATICPVQSLKFKHRLRLRFAVCQKTQRRWFLDKLVDDEIGVGYYVDHGVSSEYRLSE	
182	RHO 1-2x.177	KEFLLYLAGFVDGDSIYASILEQQRNKKFKHRLKLKFSVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
183	RHO 1-2x.148	KEFLLYLAGFVDGDSIYATIHPCQCTKFKHRLRLYFEVYQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
184	RHO 1-2x.20	KEFLLYLAGFVDGDSIYATIDPQQRKFKHRLRLRFEFSVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
185	RHO 1-2x.55	KEFLLYLAGFVDGDSIYAAIVPDQAEKFKHRLRLRFAVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	
186	RHO 1-2x.197	KEFLLYLAGFVDGDSIYASILEQQRNKKFKHRLKLKFSVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
187	RHO 1-2x.252	KEFLLYLAGFVDGDSIYAAIVPDQAEKFKHRLRLRFAVSQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
188	RHO 1-2x.372	KEFLLYLAGFVDGDSIYATIEPDQGYKFKHRLTLKFSVAQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSE	
189	RHO 1-2x.151	KEFLLYLAGFVDGDSIYASILEQQRKFKHRLKLKFSFTVCQKTQRRWFLDKLVDDEIGVGYYVDQGSVSEYRLSQ	

Figure 2C

RHO1 Half-Site Binding Sequences (cont.)

	272	344
RHO2-L3-59	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L5-14	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-49	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.179	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.4	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.207	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.277	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.292	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.324	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.371	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.164	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.181	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO 1-2x.184	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-21	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-43	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-45	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-60	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-61	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-58	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-7	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-13	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-18	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-70	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L1-86	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-13	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-24	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-37	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-58	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-31	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-29	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L2-61	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIIEQLPSAKESPDKFLEVC	FWVDQIAALNDSKTRKTTSETVRAVL

Figure 2D

RHO1 Half-Site Binding Sequences (cont.)

	272		344
RHO2-L3-2	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-3	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-5	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-10	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-11	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-12	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-13	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-28	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-29	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-57	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-80	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-85	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-86	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-92	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-4	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-20	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO2-L3-72	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-4	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-8	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-13	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-19	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-58	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-69	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-80	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-82	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-73	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-85	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO1-L1-86	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		
RHO-1/2-14-10	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVLD		

Figure 2E

RHO1 Half-Site Binding Sequences (cont.)

		272		344
RHO-1/2-L4-29	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO-1/2-L4-65	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO-1/2-L4-66	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO-1/2-L4-85	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
		81		153
RHO 1-2x.216	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.241	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.94	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.95	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.1	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.60	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.74	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.88	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.294	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.302	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.306	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.338	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.348	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.356	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.364	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.142	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.177	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.148	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.20	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.55	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.197	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.252	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.372	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			
RHO 1-2x.151	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL			

Figure 2f

RHO2 Half-Site Binding Sequences

SEQ ID NO: 190 RHO2-L3-59 7
Hypervariable Region 2 (HVR2) 80

190	RHO2-L3-59	KEFLLYLAGFVDGDSI	YARI	FKGQHWKFKKH	YIRLTFTVAQKTQRRWFLDKLVDEIGVG	YVTDWGSVSHYXLS
191	RHO2-L5-14	KEFLLYLAGFVDGDSI	YARI	FKGQHWKFKKH	YIRLTFTVQKTQRRWFLDKLVDEIGVG	YVTDGVSAYXLS
192	RHO-1/2-L2-49	KEFLLYLAGFVDGDSI	YARI	FKGQHWKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
193	RHO 1-2x.179	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
194	RHO 1-2x.4	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
195	RHO 1-2x.207	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
196	RHO 1-2x.277	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
197	RHO 1-2x.292	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
198	RHO 1-2x.324	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
199	RHO 1-2x.371	KEFLLYLAGFVDGDSI	YARI	PKQSSKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
200	RHO 1-2x.164	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
201	RHO 1-2x.181	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
202	RHO 1-2x.184	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
203	RHO-1/2-L1-21	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
204	RHO-1/2-L1-43	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
205	RHO-1/2-L1-45	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
206	RHO-1/2-L1-60	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
207	RHO-1/2-L1-61	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
208	RHO-1/2-L1-58	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
209	RHO-1/2-L1-7	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
210	RHO-1/2-L1-13	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
211	RHO-1/2-L1-18	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
212	RHO-1/2-L1-70	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
213	RHO-1/2-L1-86	KEFLLYLAGFVDGDSI	YARI	EPQQTAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDGVSQYXLS
214	RHO-1/2-L2-13	KEFLLYLAGFVDGDSI	YARI	LGQHWKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
215	RHO-1/2-L2-24	KEFLLYLAGFVDGDSI	YARI	LGQHWKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
216	RHO-1/2-L2-37	KEFLLYLAGFVDGDSI	YARI	YNAQYKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
217	RHO-1/2-L2-58	KEFLLYLAGFVDGDSI	YARI	ERRQNEFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
218	RHO-1/2-L2-31	KEFLLYLAGFVDGDSI	YARI	ERRQCVFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
219	RHO-1/2-L2-29	KEFLLYLAGFVDGDSI	YARI	YRQCAKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS
220	RHO-1/2-L2-61	KEFLLYLAGFVDGDSI	YARI	EPQSSKFKKH	YIRLTFTFHVSKTQRRWFLDKLVDEIGVG	YVTDWGSVSGYXLS

Figure 3A

RHO2 Half-Site Binding Sequences (cont.)

SEQ ID		Hypervariable Region 2 (HVR2)	7	8
NO:				
221	RHO2-L3-2	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVSDTGSQSNYYLSE
222	RHO2-L3-3	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVNDYGSTSNYYLSE
223	RHO2-L3-5	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	AQKTQRRWFLDKLVDEIGVGYVTDHGNSNYYLSE
224	RHO2-L3-10	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	TQKTQRRWFLDKLVDEIGVGYVSDYGSMSNYYLSE
225	RHO2-L3-11	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	TQKTQRRWFLDKLVDEIGVGYVTDHGCSNYYLSE
226	RHO2-L3-12	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVNDYGSMSNYYLSE
227	RHO2-L3-13	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDFGSQSYLSE
228	RHO2-L3-28	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	TQKTQRRWFLDKLVDEIGVGYVSDYGSTSNYYLSE
229	RHO2-L3-29	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	TQKTQRRWFLDKLVDEIGVGYVTDYGSISNYYLSE
230	RHO2-L3-57	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDYGSQSNYYLSE
231	RHO2-L3-80	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDGSSSNYYLSE
232	RHO2-L3-85	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVDHGCSQSNYYLSE
233	RHO2-L3-86	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVCDNGNSNYYLSE
234	RHO2-L3-92	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVADYGSTSNYYLSE
235	RHO2-L3-4	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVADYGSMSNYYLSE
236	RHO2-L3-20	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVCDSGSMAYLSE
237	RHO2-L3-72	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDGSSSNYYLSE
238	RHO1-L1-4	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
239	RHO1-L1-8	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
240	RHO1-L1-13	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
241	RHO1-L1-19	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
242	RHO1-L1-58	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
243	RHO1-L1-69	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
244	RHO1-L1-80	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
245	RHO1-L1-82	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
246	RHO1-L1-73	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
247	RHO1-L1-85	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
248	RHO1-L1-86	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDWGSGYYLSE
249	RHO-1/2-L4-10	KEFLLYLAGFVDDGSIYARI	FKGQHWKFKKHIRLTFNV	SQKTQRRWFLDKLVDEIGVGYVTDGCSNYYLSE

Figure 3B

RHO2 Half-Site Binding Sequences (cont.)

SEQ ID NO:		Hypervariable Region 2 (HVR2)	
250	RHO-1/2-14-29	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	80
251	RHO-1/2-14-65	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
252	RHO-1/2-14-66	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
253	RHO-1/2-14-85	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
198			271
254	RHO 1-2x.216	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
255	RHO 1-2x.241	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
256	RHO 1-2x.94	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
257	RHO 1-2x.95	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
258	RHO 1-2x.1	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
259	RHO 1-2x.60	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
260	RHO 1-2x.74	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
261	RHO 1-2x.88	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
262	RHO 1-2x.294	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
263	RHO 1-2x.302	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
264	RHO 1-2x.306	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
265	RHO 1-2x.338	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
266	RHO 1-2x.348	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
267	RHO 1-2x.356	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
268	RHO 1-2x.364	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
269	RHO 1-2x.142	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
270	RHO 1-2x.177	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
271	RHO 1-2x.148	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
272	RHO 1-2x.20	KEFLLYLAGFVDGDSIYACIEPKQTSKFKHRLCLRFHVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
273	RHO 1-2x.55	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
274	RHO 1-2x.197	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSE	
275	RHO 1-2x.252	KEFLLYLAGFVDGDSIYACIEPKQTSKFKHRLCLRFHVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
276	RHO 1-2x.372	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	
277	RHO 1-2x.151	KEFLLYLAGFVDGDSIYARIFFKQHWKFKHHYIRLTFQVSQKTQRRWFLDKLVDEIGVGYYVDDSGCSNYFLSQ	

Figure 3C

RHO2 Half-Site Binding Sequences (cont.)

153

81

RHO2-I3-59	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO2-I5-14	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-I2-49	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.179	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.4	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.207	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.277	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.292	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.324	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.371	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.164	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.181	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO 1-2x.184	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-21	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-43	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-45	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-60	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-61	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-58	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-7	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-13	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-18	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-70	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L1-86	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-13	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-24	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-37	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-58	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-31	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-29	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD
RHO-1/2-L2-61	IKPLHNFLTQLQPFLLKLKQKQANLVLKIIEQLPSAKESPDKFLEVC	TVAVLD

Figure 3D

RHO2 Half-Site Binding Sequences (cont.)

	81		153
RHO2-L3-2	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-3	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-5	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-10	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-11	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-12	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-13	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-28	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-29	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-57	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-80	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-85	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-86	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-92	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-4	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-20	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO2-L3-72	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-4	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-8	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-13	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-19	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-58	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-69	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-80	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-82	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-73	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-85	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO1-L1-86	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL
RHO-1/2-L4-10	IKPLHNFLTQLQPFLLKQKQANLVLKII	EQLP	SAKESPDKFFLEVCTWVDQIAALNDSKTRKTTSETVRAVL

Figure 3E

RHO2 Half-Site Binding Sequences (cont.)

RHO-1/2-L4-29	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL	81	153
RHO-1/2-L4-65	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO-1/2-L4-66	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO-1/2-L4-85	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 216	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL	272	344
RHO 1-2x. 241	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 94	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 95	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 1	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 60	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 74	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 88	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 294	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 302	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 306	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 338	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 348	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 356	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 364	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 142	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 177	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 148	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 20	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 55	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 197	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 252	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 372	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		
RHO 1-2x. 151	IKPLHNFLTQLQPFLLKQKQANLVLKIIIEQLPSAKESPDKFLEVCTWVDQIAALNDSKTRKTTSETVRAVL		

Figure 3F





Figure 4

**Figure 5**




Figure 5 (cont.)




Figure 5 (cont.)





Figure 5 (cont.)

I.



J.




Figure 5 (cont.)




Figure 6




Figure 7







Figure 7 (cont.)

23/32

E.**F.****Figure 7 (cont.)**

A.



B.




Figure 8




Figure 9




Figure 10




Figure 11




Figure 11 (cont.)





Figure 12



1. RHO P23H CHO reporter AAV2CMV L3 1e8
2. RHO P23H CHO reporter AAV2CMV L3 1e8
3. RHO P23H CHO reporter AAV2CMV L3 1e9
4. RHO P23H CHO reporter AAV2CMV L3 1e9
5. RHO P23H CHO reporter AAV2CMV L3 2e9
6. RHO P23H CHO reporter AAV2CMV L3 2e9
7. RHO P23H CHO reporter AAV2CMV L5 1e8
8. RHO P23H CHO reporter AAV2CMV L5 1e8
9. RHO P23H CHO reporter AAV2CMV L5 1e9
10. RHO P23H CHO reporter AAV2CMV L5 1e9
11. RHO P23H CHO reporter AAV2CMV L5 2e9
12. RHO P23H CHO reporter AAV2CMV L5 2e9

Figure 13





Figure 14



- 1-Mouse 1 OD retina injected with AAV5GRKL5
- 2-Mouse 1 OS retina injected with AAV5GRKL5
- 3-Mouse 2 OD retina injected with AAV5GRKL5
- 4-Mouse 2 OS retina injected with AAV5GRKL5
- 5-Mouse 3 OD retina injected with AAV5GRKL5
- 6-Mouse 3 OS retina injected with AAV5GRKL5
- 7-Mouse 4 OD retina injected with AAV5GRKL5
- 8-Mouse 4 OS retina injected with AAV5GRKL5
- 9-Mouse 5 OD retina injected with AAV5GRKL5
- 10-Mouse 5 OS retina injected with AAV5GRKL5

Figure 15

2016-09-089_178W01_Sequence_Listing
SEQUENCE LISTING

<110> Bartsevich, Victor
Jantz, Derek
Smith, James J.
Nicholson, Michael G.

<120> TREATMENT OF RETINITIS PIGMENTOSA USING ENGINEERED MEGANUCLEASES

<130> 2000706.00178W01

<150> US 62/215,460

<151> 2015-09-08

<160> 278

<170> PatentIn version 3.5

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 1

acgggtgtgg tacgcagcca ct

22

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 1

acgggtgtgg tacgcagcca ct

22

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 2

ccacttcgag taccacagt ac

22

<210> 3

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 3

gggtgtggta cgcagccact tc

22

<210> 4

<211> 22

2016-09-089_178W01_Sequence_Listing

<212> DNA
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 4
gcagccactt cgagtaccca ca

22

<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 5
acgggtgtgg tacgcagccc ct

22

<210> 6
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 6

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His Tyr Ile Arg Leu Thr Phe Thr Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser His Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 7
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 7

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val	Asp	Gly	Asp 20	Gly	Ser	Ile	Tyr	Ala 25	Arg	Ile	Phe	Lys	Gly 30	Gln	His
Trp	Lys	Phe 35	Lys	His	Tyr	Ile	Arg 40	Leu	Thr	Phe	Cys	Val 45	Arg	Gln	Lys
Thr	Gln 50	Arg	Arg	Trp	Phe	Leu 55	Asp	Lys	Leu	Val	Asp 60	Glu	Ile	Gly	Val
Gly 65	Tyr	Val	Thr	Asp	Ser 70	Gly	Ser	Val	Ser	Ala 75	Tyr	Tyr	Leu	Ser	Glu 80
Ile	Lys	Pro	Leu	His 85	Asn	Phe	Leu	Thr	Gln 90	Leu	Gln	Pro	Phe	Leu 95	Lys
Leu	Lys	Gln	Lys 100	Gln	Ala	Asn	Leu	Val 105	Leu	Lys	Ile	Ile	Glu 110	Gln	Leu
Pro	Ser	Ala 115	Lys	Glu	Ser	Pro	Asp 120	Lys	Phe	Leu	Glu	Val 125	Cys	Thr	Trp
Val	Asp 130	Gln	Ile	Ala	Ala	Leu 135	Asn	Asp	Ser	Lys	Thr 140	Arg	Lys	Thr	Thr
Ser 145	Glu	Thr	Val	Arg	Ala 150	Val	Leu	Asp	Ser	Leu 155	Pro	Gly	Ser	Val	Gly 160
Gly	Leu	Ser	Pro	Ser 165	Gln	Ala	Ser	Ser	Ala 170	Ala	Ser	Ser	Ala	Ser 175	Ser
Ser	Pro	Gly	Ser 180	Gly	Ile	Ser	Glu	Ala 185	Leu	Arg	Ala	Gly	Ala 190	Gly	Ser
Gly	Thr	Gly 195	Tyr	Asn	Lys	Glu	Phe 200	Leu	Leu	Tyr	Leu	Ala 205	Gly	Phe	Val
Asp	Gly 210	Asp	Gly	Ser	Ile	Trp 215	Ala	Ser	Ile	Ile	Pro 220	Glu	Gln	Gly	Tyr
Lys 225	Phe	Lys	His	Arg	Leu 230	Arg	Leu	Ser	Phe	Thr 235	Val	Ala	Gln	Lys	Thr 240
Gln	Arg	Arg	Trp	Phe 245	Leu	Asp	Lys	Leu	Val 250	Asp	Glu	Ile	Gly	Val 255	Gly
Tyr	Val	Val	Asp 260	Gln	Gly	Ser	Val	Ser 265	Glu	Tyr	Arg	Leu	Ser 270	Glu	Ile
Lys	Pro	Leu 275	His	Asn	Phe	Leu	Thr 280	Gln	Leu	Gln	Pro	Phe 285	Leu	Lys	Leu

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 8
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 8

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 9

<211> 354

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 9

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 10
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 10

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Met Pro Glu Gln Arg Gln
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Glu Val Cys Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Tyr Asp Gln Gly Ser Val Ser Thr Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 11
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 11

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Asn
20 25 30

Phe Lys Phe Lys His Thr Leu Arg Leu Thr Phe Phe Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Ile Pro Ser Gln Thr Asp
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Ala Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Ile Asp Ser Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 12
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 12

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Gly
20 25 30

Asn Lys Phe Lys His Tyr Leu Arg Leu Thr Phe Asn Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ile Asp Arg Gly Ser Val Ser Asp Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Gln Pro Asp Gln Val Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Arg Phe Ala Val Phe Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Tyr Asp His Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 13
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 13

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val	Asp	Gly	Asp	Gly	Ser	Ile	Tyr	Ala	Arg	Ile	Glu	Pro	Arg	Gln	Thr	20	25	30	
Ala	Lys	Phe	Lys	His	Tyr	Leu	Arg	Leu	Thr	Phe	His	Val	Ser	Gln	Lys	35	40	45	
Thr	Gln	Arg	Arg	Trp	Phe	Leu	Asp	Lys	Leu	Val	Asp	Glu	Ile	Gly	Val	50	55	60	
Gly	Tyr	Val	Val	Asp	Gln	Gly	Ser	Val	Ser	Gln	Tyr	Phe	Leu	Ser	Gln	65	70	75	80
Ile	Lys	Pro	Leu	His	Asn	Phe	Leu	Thr	Gln	Leu	Gln	Pro	Phe	Leu	Lys	85	90	95	
Leu	Lys	Gln	Lys	Gln	Ala	Asn	Leu	Val	Leu	Lys	Ile	Ile	Glu	Gln	Leu	100	105	110	
Pro	Ser	Ala	Lys	Glu	Ser	Pro	Asp	Lys	Phe	Leu	Glu	Val	Cys	Thr	Trp	115	120	125	
Val	Asp	Gln	Ile	Ala	Ala	Leu	Asn	Asp	Ser	Lys	Thr	Arg	Lys	Thr	Thr	130	135	140	
Ser	Glu	Thr	Val	Arg	Ala	Val	Leu	Asp	Ser	Leu	Pro	Gly	Ser	Val	Gly	145	150	155	160
Gly	Leu	Ser	Pro	Ser	Gln	Ala	Ser	Ser	Ala	Ala	Ser	Ser	Ala	Ser	Ser	165	170	175	
Ser	Pro	Gly	Ser	Gly	Ile	Ser	Glu	Ala	Leu	Arg	Ala	Gly	Ala	Gly	Ser	180	185	190	
Gly	Thr	Gly	Tyr	Asn	Lys	Glu	Phe	Leu	Leu	Tyr	Leu	Ala	Gly	Phe	Val	195	200	205	
Asp	Gly	Asp	Gly	Ser	Ile	Tyr	Ala	Ser	Ile	Glu	Pro	Val	Gln	Thr	Tyr	210	215	220	
Lys	Phe	Lys	His	Arg	Leu	Arg	Leu	Ser	Phe	Ala	Val	Ser	Gln	Lys	Thr	225	230	235	240
Gln	Arg	Arg	Trp	Phe	Leu	Asp	Lys	Leu	Val	Asp	Glu	Ile	Gly	Val	Gly	245	250	255	
Tyr	Val	Cys	Asp	Val	Gly	Ser	Val	Ser	Glu	Tyr	Arg	Leu	Ser	Glu	Ile	260	265	270	
Lys	Pro	Leu	His	Asn	Phe	Leu	Thr	Gln	Leu	Gln	Pro	Phe	Leu	Lys	Leu	275	280	285	

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 14
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 14

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Tyr Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Thr Pro Ser Gln Ala Gly
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Glu Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Tyr Asp Gln Gly Ser Val Ser Cys Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 15
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 15

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Tyr Pro Lys Gln Ser
20 25 30

Ser Lys Phe Lys His His Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Ser Gly Ser Val Ser Gln Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Glu Pro Ala Gln Arg Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Lys Phe Ala Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Ala Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 16
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 16

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Glu Gln Thr
20 25 30

Ala Lys Phe Lys His Met Leu Arg Leu Thr Phe Arg Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Asn Asp Ser Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Glu Pro Gln Gln Pro Gly
210 215 220

Lys Phe Lys His Arg Leu Ser Leu Arg Phe Ala Val Tyr Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Tyr Asp Pro Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 17
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 17

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Gly Pro Glu Gln Ser Ser
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Leu Phe Ala Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 18
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 18

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Lys Gln Thr
20 25 30

Ala Lys Phe Lys His His Leu Cys Leu Arg Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp His Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Gln Pro Asp Gln Asn Gln
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Ala Val Tyr Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Tyr Asp Thr Gly Ser Val Ser Arg Tyr Gln Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 19
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 19

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 20
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 20

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Arg
20 25 30

Val Lys Phe Lys His Phe Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 21
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 21

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Gly
20 25 30

Cys Lys Phe Lys His Val Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 22
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 22

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Val
20 25 30

Cys Lys Phe Lys His Ile Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 23
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 23

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Cys
20 25 30

Phe Lys Phe Lys His Cys Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 24
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 24

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Arg
20 25 30

Phe Lys Phe Lys His Cys Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 25
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 25

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val	Asp	Gly	Asp ₂₀	Gly	Ser	Ile	Tyr	Ala ₂₅	Arg	Ile	Glu	Pro	Arg ₃₀	Gln	Phe
Cys	Lys	Phe ₃₅	Lys	His	Ile	Leu	Arg ₄₀	Leu	Thr	Phe	His	Val ₄₅	Ser	Gln	Lys
Thr	Gln ₅₀	Arg	Arg	Trp	Phe	Leu ₅₅	Asp	Lys	Leu	Val	Asp ₆₀	Glu	Ile	Gly	Val
Gly ₆₅	Tyr	Val	Thr	Asp	Trp ₇₀	Gly	Ser	Val	Ser	Gly ₇₅	Tyr	Tyr	Leu	Ser	Glu ₈₀
Ile	Lys	Pro	Leu	His ₈₅	Asn	Phe	Leu	Thr	Gln ₉₀	Leu	Gln	Pro	Phe	Leu ₉₅	Lys
Leu	Lys	Gln	Lys ₁₀₀	Gln	Ala	Asn	Leu	Val ₁₀₅	Leu	Lys	Ile	Ile	Glu ₁₁₀	Gln	Leu
Pro	Ser	Ala ₁₁₅	Lys	Glu	Ser	Pro	Asp ₁₂₀	Lys	Phe	Leu	Glu	Val ₁₂₅	Cys	Thr	Trp
Val	Asp ₁₃₀	Gln	Ile	Ala	Ala	Leu ₁₃₅	Asn	Asp	Ser	Lys	Thr ₁₄₀	Arg	Lys	Thr	Thr
Ser ₁₄₅	Glu	Thr	Val	Arg	Ala ₁₅₀	Val	Leu	Asp	Ser	Leu ₁₅₅	Pro	Gly	Ser	Val	Gly ₁₆₀
Gly	Leu	Ser	Pro	Ser ₁₆₅	Gln	Ala	Ser	Ser	Ala ₁₇₀	Ala	Ser	Ser	Ala	Ser ₁₇₅	Ser
Ser	Pro	Gly	Ser ₁₈₀	Gly	Ile	Ser	Glu	Ala ₁₈₅	Leu	Arg	Ala	Gly	Ala ₁₉₀	Gly	Ser
Gly	Thr	Gly ₁₉₅	Tyr	Asn	Lys	Glu	Phe ₂₀₀	Leu	Leu	Tyr	Leu	Ala ₂₀₅	Gly	Phe	Val
Asp	Gly ₂₁₀	Asp	Gly	Ser	Ile	Trp ₂₁₅	Ala	Ser	Ile	Ile	Pro ₂₂₀	Glu	Gln	Gly	Tyr
Lys ₂₂₅	Phe	Lys	His	Arg	Leu ₂₃₀	Arg	Leu	Ser	Phe	Thr ₂₃₅	Val	Ala	Gln	Lys	Thr ₂₄₀
Gln	Arg	Arg	Trp	Phe ₂₄₅	Leu	Asp	Lys	Leu	Val ₂₅₀	Asp	Glu	Ile	Gly	Val ₂₅₅	Gly
Tyr	Val	Val	Asp ₂₆₀	Gln	Gly	Ser	Val	Ser ₂₆₅	Glu	Tyr	Arg	Leu	Ser ₂₇₀	Glu	Ile
Lys	Pro	Leu ₂₇₅	His	Asn	Phe	Leu	Thr ₂₈₀	Gln	Leu	Gln	Pro	Phe ₂₈₅	Leu	Lys	Leu

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 26
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 26

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ala
20 25 30

Phe Lys Phe Lys His Ala Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 27
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 27

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr
20 25 30

Cys Lys Phe Lys His Ile Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 28
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 28

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Cys
20 25 30

Phe Lys Phe Lys His Gly Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 29
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 29

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ser
20 25 30

Ser Lys Phe Lys His Leu Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 30
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 30

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Tyr Leu Gly Gln His
20 25 30

Trp Lys Phe Lys His Tyr Val Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 31
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 31

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Tyr Leu Gly Gln His
20 25 30

Tyr Lys Phe Lys His Tyr Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 32
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 32

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Tyr Asn Ala Gln Tyr
20 25 30

Tyr Lys Phe Lys His Tyr Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 33
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 33

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Arg Arg Gln Asn
20 25 30

Phe Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 34
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 34

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Arg Arg Gln Cys
20 25 30

Val Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 35
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 35

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Tyr Arg Gln Gly
20 25 30

Ala Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 36
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 36

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ser
20 25 30

Gly Lys Phe Lys His Tyr Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 37
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 37

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ser Asp Thr Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 38
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 38

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Asn Asp Tyr Gly Ser Thr Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 39
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 39

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp His Gly Ser Asn Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 40
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 40

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ser Asp Tyr Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 41
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 41

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Ala Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp His Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 42
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 42

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Gly Asp Tyr Gly Ser Met Ser His Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 43
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 43

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Phe Gly Ser Gln Ser Gln Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 44
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 44

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ser Asp Tyr Gly Ser Ile Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 45
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 45

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ile Asp Tyr Gly Ser Ile Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 46
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 46

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Tyr Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 47
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 47

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Gly Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 48
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 48

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp His Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 49
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 49

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Cys Asp Asn Gly Ser Asn Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 50
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 50

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Tyr Gly Ser Thr Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 51
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 51

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Cys Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Tyr Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 52
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 52

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Met Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His Tyr Ile Arg Leu Thr Leu Cys Val Arg Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Cys Asp Ser Gly Ser Met Ser Ala Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 53
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 53

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Gly Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 54
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 54

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Leu Pro Glu Ser Arg Met
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Gly Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 55
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 55

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Gln Ile Leu Pro Glu Lys Lys Cys
210 215 220

Ala Phe Lys His Arg Leu Arg Leu Trp Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 56
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 56

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Cys Ile Val Pro Glu Lys Ala Ser
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 57
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 57

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Thr Ile Val Pro Glu Lys Ser Ser
210 215 220

Ile Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 58
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 58

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Val Pro Glu Glu Arg Thr
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 59

<211> 354

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 59

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Arg Ile Glu Pro Glu Lys Gly Gly
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 60
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 60

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Ser Pro Glu Val Arg Ala
210 215 220

Pro Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 61
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 61

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Leu Pro Glu Thr Ser Ala
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Phe Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 62
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 62

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ala Ile Leu Pro Glu Gln Ser Tyr
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 63
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 63

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Leu Pro Glu Arg Lys Thr
210 215 220

Lys Phe Lys His Arg Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 64
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 64

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe His Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Cys Ile Glu Pro Glu Arg Gly Tyr
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 65
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 65

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His Tyr Ile Arg Leu Thr Phe Cys Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Asn Asp Ser Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Arg Ile Glu Pro Glu Leu Arg Leu
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Phe Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 66
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 66

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His Tyr Ile Arg Leu Thr Phe Cys Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Asn Asp Ser Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Gln Ile Val Pro Glu Arg Ala Gly
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 67
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 67

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Asn Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Cys Asp Ser Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Thr Pro Glu Pro Thr Ala
210 215 220

Ser Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 68
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 68

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Phe Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Cys Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Asn Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Asn Pro Glu Pro Ser Tyr
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 69
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 69

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Phe Lys Gly Gln His
20 25 30

Trp Lys Phe Lys His His Ile Arg Leu Thr Phe Cys Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val His Asp Tyr Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Leu Pro Glu His Gln Tyr
210 215 220

Arg Phe Lys His Arg Leu Arg Leu Gly Phe Thr Val Ala Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 70
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 70

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ala Ile Asp Pro Asp Gln Lys
20 25 30

Tyr Lys Phe Lys His Arg Leu Arg Leu Ile Phe Ala Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp His Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 71
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 71

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Glu Pro Ala Gln Arg
20 25 30

Tyr Lys Phe Lys His Arg Leu Arg Leu Lys Phe Ala Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 72
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 72

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Asn Pro Asp Gln Thr
20 25 30

Asn Lys Phe Lys His Arg Leu Arg Leu Trp Phe Ala Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Thr Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 73
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 73

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Cys Ile Glu Pro Ala Gln Asn
20 25 30

Ser Lys Phe Lys His Tyr Leu Arg Leu Arg Phe Glu Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Ser Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 74
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 74

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Thr Pro Cys Gln Ser
20 25 30

Tyr Lys Phe Lys His Arg Leu Leu Lys Phe Ser Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Ser Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 75
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 75

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Met Pro Glu Gln Thr
20 25 30

Val Lys Phe Lys His Arg Leu Arg Leu Phe Phe Glu Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Ser Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 76
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 76

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Gln Pro Glu Gln Ala
20 25 30

Pro Lys Phe Lys His Arg Leu Arg Leu His Phe Thr Val His Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 77
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 77

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Trp Ala Thr Ile Glu Pro Ser Gln Thr
20 25 30

Leu Lys Phe Lys His Arg Leu Arg Leu His Phe Ser Val Tyr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Asp Gly Ser Val Ser Arg Tyr Gln Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 78
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 78

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Thr Pro Cys Gln Ser
20 25 30

Tyr Lys Phe Lys His Arg Leu Leu Lys Phe Ser Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Ser Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 79
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 79

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Ile Pro Ser Gln Asn
20 25 30

Leu Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Glu Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Ser Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 80
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 80

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Cys Pro Thr Gln Ala
20 25 30

Ala Lys Phe Lys His Arg Leu Arg Leu His Phe Ala Val Phe Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Cys Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 81
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 81

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Glu Pro Ala Gln Ser
20 25 30

Tyr Lys Phe Lys His Arg Leu Gln Leu Lys Phe Ala Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Cys Asp Ile Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 82
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 82

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ala Ile Met Pro Thr Gln Ser
20 25 30

Tyr Lys Phe Lys His Arg Leu Arg Leu Ala Phe Ser Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Thr Asp Ala Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 83
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 83

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Thr Pro Asn Gln Arg
20 25 30

Thr Lys Phe Lys His Gln Leu Lys Leu Ala Phe Ala Val Tyr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Cys Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 84
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 84

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ala Ile Val Pro Val Gln Ser
20 25 30

Thr Lys Phe Lys His Arg Leu Arg Leu Tyr Phe Thr Val His Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Tyr Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 85
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 85

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Cys Pro Val Gln Ser
20 25 30

Leu Lys Phe Lys His Arg Leu Arg Leu Phe Phe Ala Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp His Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Val Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 86
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 86

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Trp Ala Ser Ile Leu Pro Glu Gln Arg
20 25 30

Asn Lys Phe Lys His Arg Leu Lys Leu Gly Phe Ser Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Val Asp Gln Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 87
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 87

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val	Asp	Gly	Asp 20	Gly	Ser	Ile	Tyr	Ala 25	Thr	Ile	His	Pro	Cys 30	Gln	Cys
Thr	Lys	Phe 35	Lys	His	Arg	Leu	Arg 40	Leu	Tyr	Phe	Glu	Val 45	Tyr	Gln	Lys
Thr	Gln 50	Arg	Arg	Trp	Phe	Leu 55	Asp	Lys	Leu	Val	Asp 60	Glu	Ile	Gly	Val
Gly 65	Tyr	Val	Tyr	Asp	Gln 70	Gly	Ser	Val	Ser	Ser 75	Tyr	Arg	Leu	Ser	Gln 80
Ile	Lys	Pro	Leu	His 85	Asn	Phe	Leu	Thr	Gln 90	Leu	Gln	Pro	Phe	Leu 95	Lys
Leu	Lys	Gln	Lys 100	Gln	Ala	Asn	Leu	Val 105	Leu	Lys	Ile	Ile	Glu 110	Gln	Leu
Pro	Ser	Ala 115	Lys	Glu	Ser	Pro	Asp 120	Lys	Phe	Leu	Glu	Val 125	Cys	Thr	Trp
Val	Asp 130	Gln	Ile	Ala	Ala	Leu 135	Asn	Asp	Ser	Lys	Thr 140	Arg	Lys	Thr	Thr
Ser 145	Glu	Thr	Val	Arg	Ala 150	Val	Leu	Asp	Ser	Leu 155	Pro	Gly	Ser	Val	Gly 160
Gly	Leu	Ser	Pro	Ser 165	Gln	Ala	Ser	Ser	Ala 170	Ala	Ser	Ser	Ala	Ser 175	Ser
Ser	Pro	Gly	Ser 180	Gly	Ile	Ser	Glu	Ala 185	Leu	Arg	Ala	Gly	Ala 190	Gly	Ser
Gly	Thr	Gly 195	Tyr	Asn	Lys	Glu	Phe 200	Leu	Leu	Tyr	Leu	Ala 205	Gly	Phe	Val
Asp	Gly 210	Asp	Gly	Ser	Ile	Tyr 215	Ala	Arg	Ile	Glu	Pro 220	Arg	Gln	Thr	Ala
Lys 225	Phe	Lys	His	Tyr	Leu 230	Arg	Leu	Thr	Phe	His 235	Val	Ser	Gln	Lys	Thr 240
Gln	Arg	Arg	Trp	Phe 245	Leu	Asp	Lys	Leu	Val 250	Asp	Glu	Ile	Gly	Val 255	Gly
Tyr	Val	Thr	Asp 260	Trp	Gly	Ser	Val	Ser 265	Gly	Tyr	Tyr	Leu	Ser 270	Glu	Ile
Lys	Pro	Leu 275	His	Asn	Phe	Leu	Thr 280	Gln	Leu	Gln	Pro	Phe 285	Leu	Lys	Leu

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 88
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 88

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Thr Ile Asp Pro Asp Gln Arg
20 25 30

Gln Lys Phe Lys His Arg Leu Arg Leu Lys Phe Ser Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gly Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Cys Ile Glu Pro Lys Gln Thr Ser
210 215 220

Lys Phe Lys His Arg Leu Cys Leu Arg Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val His Asp Asn Gly Ser Val Ser Gln Tyr Tyr Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 89
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 89

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ala Ile Val Pro Asp Gln Ala
20 25 30

Pro Lys Phe Lys His Arg Leu Arg Leu Phe Phe Ala Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Tyr Pro Gly Gln His Tyr
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Thr Asp Ala Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 90
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 90

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ser Ile Leu Pro Glu Gln Arg
20 25 30

Asn Lys Phe Lys His Arg Leu Lys Leu Ser Phe Ser Val Cys Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Val Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Tyr Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Ile Asp Ala Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 91
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 91

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val Asp Gly Asp Gly Ser Ile Tyr Ala Ala Ile Val Pro Asp Gln Ala
20 25 30

Pro Lys Phe Lys His Arg Leu Arg Leu Phe Phe Ala Val Ser Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Ala Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Cys Ile Glu Pro Lys Gln Thr Ser
210 215 220

Lys Phe Lys His Arg Leu Cys Leu Arg Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val His Asp Asn Gly Ser Val Ser Gln Tyr Tyr Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 92
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 92

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Tyr Ala Cys Ile Cys Pro Asp Gln Gly
20 25 30

Tyr Lys Phe Lys His Arg Leu Thr Leu Lys Phe Ser Val Ala Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Leu Asp Gln Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Pro Gly Ser Val Gly
145 150 155 160

Gly Leu Ser Pro Ser Gln Ala Ser Ser Ala Ala Ser Ser Ala Ser Ser
165 170 175

Ser Pro Gly Ser Gly Ile Ser Glu Ala Leu Arg Ala Gly Ala Gly Ser
180 185 190

Gly Thr Gly Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val
195 200 205

Asp Gly Asp Gly Ser Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala
210 215 220

Lys Phe Lys His Gln Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr
225 230 235 240

Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly
245 250 255

Tyr Val Thr Asp Trp Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln Ile
260 265 270

Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu
275 280 285

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 93
<211> 354
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 93

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Val	Asp	Gly	Asp	Gly	Ser	Ile	Tyr	Ala	Cys	Ile	Leu	Pro	Glu	Gln	Lys	20	25	30
Thr	Lys	Phe	Lys	His	Arg	Leu	Lys	Leu	Ser	Phe	Thr	Val	Cys	Gln	Lys	35	40	45
Thr	Gln	Arg	Arg	Trp	Phe	Leu	Asp	Lys	Leu	Val	Asp	Glu	Ile	Gly	Val	50	55	60
Gly	Tyr	Val	Val	Asp	Gln	Gly	Ser	Val	Ser	Glu	Tyr	Arg	Leu	Ser	Gln	65	70	75
Ile	Lys	Pro	Leu	His	Asn	Phe	Leu	Thr	Gln	Leu	Gln	Pro	Phe	Leu	Lys	85	90	95
Leu	Lys	Gln	Lys	Gln	Ala	Asn	Leu	Val	Leu	Lys	Ile	Ile	Glu	Gln	Leu	100	105	110
Pro	Ser	Ala	Lys	Glu	Ser	Pro	Asp	Lys	Phe	Leu	Glu	Val	Cys	Thr	Trp	115	120	125
Val	Asp	Gln	Ile	Ala	Ala	Leu	Asn	Asp	Ser	Lys	Thr	Arg	Lys	Thr	Thr	130	135	140
Ser	Glu	Thr	Val	Arg	Ala	Val	Leu	Asp	Ser	Leu	Pro	Gly	Ser	Val	Gly	145	150	155
Gly	Leu	Ser	Pro	Ser	Gln	Ala	Ser	Ser	Ala	Ala	Ser	Ser	Ala	Ser	Ser	165	170	175
Ser	Pro	Gly	Ser	Gly	Ile	Ser	Glu	Ala	Leu	Arg	Ala	Gly	Ala	Gly	Ser	180	185	190
Gly	Thr	Gly	Tyr	Asn	Lys	Glu	Phe	Leu	Leu	Tyr	Leu	Ala	Gly	Phe	Val	195	200	205
Asp	Gly	Asp	Gly	Ser	Ile	Tyr	Ala	Arg	Ile	Glu	Pro	Arg	Gln	Thr	Val	210	215	220
Lys	Phe	Lys	His	Met	Leu	Arg	Leu	Thr	Phe	His	Val	Ser	Gln	Lys	Thr	225	230	235
Gln	Arg	Arg	Trp	Phe	Leu	Asp	Lys	Leu	Val	Asp	Glu	Ile	Gly	Val	Gly	245	250	255
Tyr	Val	His	Asp	Asn	Gly	Ser	Val	Ser	Gln	Tyr	Tyr	Leu	Ser	Gln	Ile	260	265	270
Lys	Pro	Leu	His	Asn	Phe	Leu	Thr	Gln	Leu	Gln	Pro	Phe	Leu	Lys	Leu	275	280	285

2016-09-089_178W01_Sequence_Listing

Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro
290 295 300

Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val
305 310 315 320

Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser
325 330 335

Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys Ser
340 345 350

Ser Pro

<210> 94
<211> 163
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 94

Met Asn Thr Lys Tyr Asn Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe
1 5 10 15

Val Asp Gly Asp Gly Ser Ile Ile Ala Gln Ile Lys Pro Asn Gln Ser
20 25 30

Tyr Lys Phe Lys His Gln Leu Ser Leu Ala Phe Gln Val Thr Gln Lys
35 40 45

Thr Gln Arg Arg Trp Phe Leu Asp Lys Leu Val Asp Glu Ile Gly Val
50 55 60

Gly Tyr Val Arg Asp Arg Gly Ser Val Ser Asp Tyr Ile Leu Ser Glu
65 70 75 80

Ile Lys Pro Leu His Asn Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys
85 90 95

Leu Lys Gln Lys Gln Ala Asn Leu Val Leu Lys Ile Ile Trp Arg Leu
100 105 110

Pro Ser Ala Lys Glu Ser Pro Asp Lys Phe Leu Glu Val Cys Thr Trp
115 120 125

Val Asp Gln Ile Ala Ala Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr
130 135 140

2016-09-089_178W01_Sequence_Listing

Ser Glu Thr Val Arg Ala Val Leu Asp Ser Leu Ser Glu Lys Lys Lys
145 150 155 160

Ser Ser Pro

<210> 95
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 95

Leu Ala Gly Leu Ile Asp Ala Asp Gly
1 5

<210> 96
<211> 1047
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 96

atgaatggca	cagaaggccc	taacttctac	gtgcccttct	ccaatgcgac	gggtgtggta	60
cgagagccc	tcgagtaccc	acagtactac	ctggctgagc	catggcagtt	ctccatgctg	120
gccgcctaca	tgtttctgct	gatcgtgctg	ggcttcccca	tcaacttcct	cacgctctac	180
gtcaccgtcc	agcacaagaa	gctgcgacg	cctctcaact	acatcctgct	caacctagcc	240
gtggctgacc	tcttcatggg	cctaggtggc	ttcaccagca	ccctctacac	ctctctgcat	300
ggatacttcg	tcttcggggc	cacaggatgc	aatttgaggg	gcttctttgc	caccctgggc	360
ggtgaaattg	ccctgtgggc	cttggtgggc	ctggccatcg	agcggtagct	ggtggtgtgt	420
aagcccatga	gcaacttccg	cttcggggag	aaccatgcca	tcatgggcgt	tgccctcacc	480
tgggtcatgg	cgctggcctg	cgccgcaccc	ccactcgccg	gctgggtccag	gtacatcccc	540
gagggcctgc	agtgtctgtg	tggaatcgac	tactacacgc	tcaagccgga	ggtcaacaac	600
gagtcttttg	tcattctacat	gttcgtgggc	cacttcacca	tcccatgat	tatcatcttt	660
ttctgctatg	ggcagctcgt	cttcaccgtc	aaggaggccg	ctgccagca	gcaggagtca	720
gccaccacac	agaaggcaga	gaaggaggtc	acccgcatgg	tcatcatcat	ggtcatcgct	780
ttcctgatct	gctgggtgcc	ctacgccagc	gtggcattct	acatcttcac	ccaccagggc	840
tccaacttcg	gtcccatctt	catgaccatc	ccagcgttct	ttgccaagag	cgccgccatc	900
tacaaccctg	tcatttatat	catgatgaac	aagcagttcc	ggaactgcat	gtcaccacc	960
atctgctgcg	gcaagaaccc	actgggtgac	gatgaggcct	ctgctaccgt	gtccaagacg	1020
gagacgagcc	aggtggcccc	ggcctaa				1047

2016-09-089_178W01_Sequence_Listing

<210> 97
 <211> 1047
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 97

atgaatggca	cagaaggccc	taacttctac	gtgcccttct	ccaatgcgac	gggtgtggta	60
cgcagccact	tcgagtaccc	acagtactac	ctggctgagc	catggcagtt	ctccatgctg	120
gccgcctaca	tgtttctgct	gatcgtgctg	ggcttcccca	tcaacttcct	cacgctctac	180
gtcaccgtcc	agcacaagaa	gctgcgacg	cctctcaact	acatcctgct	caacctagcc	240
gtggctgacc	tcttcatggt	cctaggtggc	ttcaccagca	ccctctacac	ctctctgcat	300
ggatacttcg	tcttcggggc	cacaggatgc	aatttgagg	gcttctttgc	caccctgggc	360
ggtgaaattg	ccctgtggtc	cttgggtggc	ctggccatcg	agcgggtacgt	ggtgggtgtgt	420
aagcccatga	gcaacttccg	cttcggggag	aaccatgcca	tcatgggcgt	tgccctcacc	480
tgggtcatgg	cgctggcctg	cgccgcaccc	ccactcgccg	gctgggtccag	gtacatcccc	540
gagggcctgc	agtgctcgtg	tggaatcgac	tactacacgc	tcaagccgga	ggtcaacaac	600
gagtcttttg	tcatctacat	gttcgtggtc	cacttcacca	tcccatgat	tatcatcttt	660
ttctgctatg	ggcagctcgt	cttcaccgtc	aaggaggccg	ctgccagca	gcaggagtca	720
gccaccacac	agaaggcaga	gaaggaggtc	acccgcatgg	tcatcatcat	ggtcatcgct	780
ttcctgatct	gctgggtgcc	ctacgccagc	gtggcattct	acatcttcac	ccaccagggc	840
tccaacttcg	gtcccatctt	catgaccatc	ccagcgttct	ttgccaagag	cgccgccatc	900
tacaaccctg	tcatctatat	catgatgaac	aagcagttcc	ggaactgcat	gctcaccacc	960
atctgctgcg	gcaagaaccc	actgggtgac	gatgaggcct	ctgctaccgt	gtccaagacg	1020
gagacgagcc	aggtggcccc	ggcctaa				1047

<210> 98
 <211> 13706
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 98

gtgggggacc	aggagaaaga	aagccaagga	agaggaggag	gaggaggaga	aggaggagaa	60
ggatgctgac	ctagcagctc	ctctcacagc	agctcctctc	ttgcagaggc	tgaagagcga	120
tttgtgccct	gcaagctaag	cccctaattc	accgaggcaa	aggcaaagcc	cctagccggg	180
ctcccgaggg	ctgggactcg	ggtgccccaa	gatggctgca	tccagccatc	ttggcttaga	240
aagcccccca	catgccagct	tggccaacac	ccacaccatg	ggtttctctg	gactgcccga	300

2016-09-089_178W01_Sequence_Listing

cacaaggtgt	gggtgctggc	caggcctgtg	ttcaaattccc	agctctgcag	aggaactttg	360
accctgcata	ccccagattc	ctcagtggtc	agtggggagt	tagaccctct	tcataggggg	420
caggaggagt	tgttcattca	ttcaacaaat	gtttattgaa	cacctcctat	gggttgtagag	480
ctcagaggca	gcgatgaaca	ggccaggctg	gtcctgcatt	ctagaaatag	atgggaagtc	540
agtcaataag	tagacaaatg	aggccagggtg	tggtggcatg	cctgtagacc	cagttactcg	600
ggatgctgag	gtaggaggat	cacttgagcc	taggacagga	attcaaggct	gcagtaagct	660
atgattgcgc	cactgcactc	cagcctgggc	aacagagcaa	gactcatctc	taaaaaacat	720
ttaaaaattg	ttttaagaag	acaaatgaga	tagtcgctga	tggtaatgac	tgtgtaaaaa	780
ctgaacatgg	ctgggtgtgg	ttgctcacac	ctataatctc	agcacttttg	gaggctgaga	840
ttacagcctc	ccaagtggct	ccaaggcag	gaggatcact	tgagcctggg	agttagagaa	900
cagcttggac	aatatagga	gagcccaact	ctacaaaaat	gaaaataaat	tagccaggca	960
tggtggcaca	caccaatggt	cccagctact	caggggttga	ggtggtggac	cgcttgagcc	1020
caggagggtg	aggctgcagt	gagccatgat	catgccgctg	cactccaacc	tgagtcacag	1080
agtgataccc	tgtctcaaaa	aacaataggc	caggtgtggt	ggctcacgcc	tgtaacccca	1140
gcactttggg	aggccgaggc	ggatggatca	cttgagatca	ggagttagag	accagcctgg	1200
ctaacatggc	aaaatcctgt	ctgtactaaa	aatataaaaa	ttagccaggc	atggcagtac	1260
atgcctgtag	tcctggttac	ttgggaggct	aaggcaggag	aatcgcttga	accaggaag	1320
aggaggttgc	agttagccaa	gatcacacca	ctgcactcca	gcttgggtga	cagagtgaga	1380
ccctgtctca	aaacagctaa	acctggtggg	ggtgcctggt	gtgtaggatg	gtcaggggtg	1440
gtctctccaa	ggacatgagt	gtgagcggag	acctgaagga	gactcaggaa	gagattaata	1500
ctgtcagcaa	caaatatatt	gatcacttac	aagcactccc	aataatccta	ttaggtaggc	1560
actattatca	ttcccatttt	acagagtgga	gaaccgaagc	acactctcgg	gagggcgggg	1620
tagctggctg	caccaggtct	gtgtagcctc	agtccagatg	taaggggtggg	tggaagagag	1680
ccttgcccaa	tgaggagaaa	cagtgaacc	aaggccatag	ggtctaaaga	ttcacgaacc	1740
aggctctcat	ggagaaagca	ggtgaggttt	actgtataga	tgggtgtgcc	cctacccac	1800
actgaggctt	cctcgtctga	gcaaactgag	gccagagag	gggaaggaag	caggactacc	1860
atggtgactc	aaagaccagc	tagaatccag	cctcctctcc	tcgaggcttc	cactgccccca	1920
cgccaggcct	gtgtgactca	gtctagggcc	tttcatttac	cccagctaaa	cctttcttta	1980
gtcatttata	ccatggtgtg	aatggctggc	tggtctttcc	tgagagctat	ctttgatgag	2040
gggagggagg	catagccagg	tttggaagc	tgatacccca	ggaagcccag	ttgactgtgt	2100
gggttatagc	ccaggctgtc	actgatttgt	aacgggacct	gagcaactct	gcagagctag	2160
gcctcagtct	tttcatctgc	aaaatggata	tagcagagat	ggtcagagta	ggtgacttctg	2220
aatgaccctt	ccagctcact	atgagtctgt	tttctgaac	aaagagcatt	ttttgtttaa	2280
aaaaaaattt	cttgggccgg	acacggtggt	tcactcctat	aatcctggca	ctttgggagg	2340

2016-09-089_178W01_Sequence_Listing

ccgaggaggg	tggatcgctt	gagccaggag	ttcaggacca	gcctgggcaa	catagcgaga	2400
ctccaccct	acaaaaata	caaaaactag	tggtgtgcac	ttgtgggtccc	agctactcag	2460
gaggctgagg	tgagaggatc	gcttgagccc	aggaggcaga	ggctacagtg	agctatgatt	2520
gtggcactgc	actccagcct	gggcgacaga	gaccttgtct	caaaactttt	tttttcttcg	2580
tcaagcttta	cagaataaag	agcactgtca	cctcagtgat	ggctgttagt	tccccatcac	2640
cagggctcca	tgaggttgca	attgtgaaac	tcacaaagga	ggaacctgag	acagagaggg	2700
gaagtactga	gatcatctag	gtccattccc	ccactcactc	gttcattcaa	caaataattca	2760
ggagcacctt	ctaggtgcc	ggccctggag	acacatcagt	gaacaaaaca	gacatcatcc	2820
cacctctttc	cactacaggc	caagcaccat	gctgggtctct	gggaaccctg	ttgtgagcaa	2880
gacagacca	ggcttaccct	tgtggactca	tgttacaggc	agggagacgg	gcacaaaaca	2940
caaataaaaa	gcttccatgc	tgtcagaagc	actatgcaaa	aagcaagatg	ctgaggtact	3000
gctaagctgt	gtgggatggg	ggctcagccc	ggccaggagg	gggccagttg	tgggtcagtc	3060
ttgaccaag	gcatccagga	caccctcctt	ctggccatga	gggtccacgt	cagaatcaaa	3120
ccctcacctt	aacctcatta	gcgttgggca	taatcaccag	gccaagcgcc	ttaaactacg	3180
agaggcccca	tcccaccgc	cctgccttag	ccctgccacg	tgtgccaaac	gctgttagac	3240
ccaacaccac	ccaggccagg	tagggggctg	gagcccaggt	gggctgcagg	gaagggggca	3300
ctcttctgag	cagacagatc	tgggaatcct	gggtgggaag	agagacagtg	agagagagat	3360
taagggatat	ttcccaggca	tcagggcttt	gcactctcag	gggtccttcc	gcctggatgt	3420
ccttcccctg	aagcttcctc	ctgttggttc	gttctcagct	caagctccag	cttctcagag	3480
aagcctcctg	tggtgggagt	ggctgcgact	gaactgtccc	tactgttatt	cgctcttcta	3540
tttgtttgtg	gtccctgtgc	cccctcacc	cacaaaaaca	ctggcttctt	gtgagcagga	3600
gcttgctctt	tcgtgtaccc	tgtgtgtccc	caaggaccaa	gcaccttgtc	tgggccacag	3660
taggtgtca	atacacatgt	tggctggaca	gtggctactg	agcgcccgca	cgtcggggcac	3720
tctcagcact	tgcacaggcc	gccccagaca	ccccacttca	ttcctgggag	gtgtcatcat	3780
gttgcttgga	cgacggggag	agggggacct	gccagtgttg	gcctccattt	tccccagtc	3840
atctgcccc	aaggctctga	ctactttctt	tctcacggta	catcctgcta	ttctggaatc	3900
ggccctcgtg	gggccacctg	gtacatggca	tttgaggccc	tcgtggctga	ttaggcctcc	3960
cccaacagt	ccctgtctgc	tgctccagg	gccagcctcc	ccttcagact	ggagtcccct	4020
gaagggttct	gcccctcccc	tgctctggta	gccccctcca	tcctccctcc	ctccactcca	4080
tctttggggg	catttgagtc	acctttctac	accagtgatc	tgcccaagcc	actgctcact	4140
ttcctctgga	taaagccagg	ttccccggcc	tagcgttcaa	gaccattac	aactgcccc	4200
agcccagatc	ttccccacct	agccacctgg	caaactgctc	cttctctcaa	aggcccaaac	4260
atggcctccc	agactgcaac	ccccaggcag	tcaggccctg	tctccacaac	ctcacagcca	4320
ccctggacgg	aatctgcttc	ttccacatt	tgagtcctcc	tcagcccctg	agctcctctg	4380

2016-09-089_178W01_Sequence_Listing

ggcagggctg	tttctttcca	tctttgtatt	cccaggggcc	tgcaaataaa	tgtttaatga	4440
acgaacaaga	gagtgaattc	caattccatg	caacaaggat	tgggctcctg	ggccctaggc	4500
tatgtgtctg	gcaccagaaa	cggaagctgc	aggttgccgc	ccctgccctc	atggagctcc	4560
tcctgtcaga	ggagtgtggg	gactggatga	ctccagaggt	aacttgtggg	ggaacgaaca	4620
ggtaaggggc	tgtgtgacga	gatgagagac	tgggagaata	aaccagaaag	tctctagctg	4680
tccagaggac	atagcacaga	ggcccatggg	ccctatttca	aaccagggcc	accagactga	4740
gctgggacct	tgggacagac	aagtcattgc	gaagttaggg	gaccttctcc	tcccttttcc	4800
tggatcctga	gtacctctcc	tccctgacct	caggcttctc	cctagtgtca	ccttggtccc	4860
tcttagaagc	caattaggcc	ctcagtttct	gcagcgggga	ttaatatgat	tatgaacacc	4920
cccaatctcc	cagatgctga	ttcagccagg	agcttaggag	ggggagggtca	ctttataagg	4980
gtctgggggg	gtcagaacct	agagtcattc	agctggagcc	ctgagtggct	gagctcaggc	5040
cttcgcagca	ttcttgggtg	ggagcagcca	cgggtcagcc	acaagggcca	cagccatgaa	5100
tggcacagaa	ggccctaact	tctacgtgcc	cttctccaat	gcgacgggtg	tggtacgcag	5160
ccccttcgag	taccacagct	actacctggc	tgagccatgg	cagttctcca	tgctggccgc	5220
ctacatgttt	ctgctgatcg	tgctgggctt	ccccatcaac	ttcctcacgc	tctacgtcac	5280
cgtccagcac	aagaagctgc	gcacgcctct	caactacatc	ctgctcaacc	tagccgtggc	5340
tgacctcttc	atggctcctg	gtggcttcac	cagcaccctc	tacacctctc	tgcatggata	5400
cttcgtcttc	gggcccacag	gatgcaattt	ggagggcttc	tttgccaccc	tgggcggtat	5460
gagccgggtg	tgggtggggg	gtgcaggagc	ccgggagcat	ggaggggtct	gggagagtcc	5520
cgggcttggc	ggtggtgggt	gagaggcctt	ctcccttctc	ctgtcctgtc	aatgttatcc	5580
aaagccctca	tatattcagt	caacaaacac	cattcatggg	gatagccggg	ctgctgtttg	5640
tgagggctg	gactgaaca	ctgccttgat	cttatttgga	gcaatatgcg	cttgtctaata	5700
ttcacagcaa	gaaaactgag	ctgagggtca	aagaagtcaa	gcgccctgct	ggggcgctcac	5760
acagggacgg	gtgcagagtt	gagttggaag	ccgcattcta	tctcgggcca	tgtttgccgc	5820
accaagcctc	tgtttccctt	ggagcagctg	tgctgagtca	gaccagggtc	gggactgag	5880
ggagagctgg	gcaagccaga	cccctcctct	ctggggggcc	aagctcaggg	tgggaagtgg	5940
attttccatt	ctccagtcatt	tgggtcttcc	ctgtgctggg	caatgggctc	ggtcccctct	6000
ggcatcctct	gcctcccctc	tcagcccctg	tcctcaggtg	cccctccagc	ctccctgccg	6060
cgttccaagt	ctcctgggtg	tgagaaccgc	aagcagccgc	tctgaagcag	ttcctttttg	6120
ctttagaata	atgtcttgca	tttaacagga	aaacagatgg	ggtgctgcag	ggataacaga	6180
tcccacttaa	cagagaggaa	aactgaggca	gggagagggg	aagagactca	tttagggatg	6240
tggccaggca	gcaacaagag	cctaggtctc	ctggctgtga	tccaggaata	tctctgtctga	6300
gatgcaggag	gagacgctag	aagcagccat	tgcaaagctg	ggtgacgggg	agagcttacc	6360
gccagccaca	agcgtctctc	tgccagcctt	gccctgtctc	ccccatgtcc	aggctgctgc	6420

2016-09-089_178W01_Sequence_Listing

ctcgggtccca	ttctcagggga	atctctggcc	attgttgggt	gtttgttgca	ttcaataatc	6480
acagatcact	cagttctggc	cagaagggtg	gtgtgccact	tacgggtggt	tgttctctgc	6540
agggtcagtc	ccagtttaca	aatattgtcc	ctttcactgt	taggaatgtc	ccagtttggt	6600
tgattaacta	tatggccact	ctccctatgg	aacttcatgg	ggtggtgagc	aggacagatg	6660
tctgaattcc	atcatttcct	tcttcttcct	ctgggcaaaa	cattgcacat	tgcttcatgg	6720
ctcctaggag	aggcccccac	atgtccgggt	tatttcattt	cccgagaagg	gagagggagg	6780
aaggactgcc	aattctgggt	ttccaccacc	tctgcattcc	ttcccaacaa	ggaactctgc	6840
cccacattag	gatgcattct	tctgctaaac	acacacacac	acacacacac	acacaacaca	6900
cacacacaca	cacacacaca	cacacacaca	aaactcccta	ccgggttccc	agttcaatcc	6960
tgaccccctg	atctgattcg	tgtcccttat	gggcccagag	cgctaagcaa	ataacttccc	7020
ccattcccctg	gaatttcttt	gccagctct	cctcagcgtg	tgggtccctct	gccccttccc	7080
cctcctccca	gcaccaagct	ctctccttcc	ccaaggcctc	ctcaaattccc	tctcccactc	7140
ctggttgccct	tcctagctac	cctctccctg	tctagggggg	agtgcaccct	ccttaggcag	7200
tggggctctgt	gctgaccgcc	tgctgactgc	cttgcagggtg	aaattgccct	gtgggtccttg	7260
gtgggtcctgg	ccatcgagcg	gtacgtgggtg	gtgtgtaagc	ccatgagcaa	cttccgcttc	7320
ggggagaacc	atgccatcat	gggcgttgcc	ttcacctggg	tcatggcgct	ggcctgcgcc	7380
gcacccccac	tcgccggctg	gtccaggtaa	tggcactgag	cagaagggaa	gaagctccgg	7440
gggctctttg	tagggctctc	cagtcaggac	tcaaaccag	tagtgtctgg	ttccaggcac	7500
tgaccttgta	tgtctcctgg	cccaaattgcc	cactcagggt	aggggtgtag	ggcagaagaa	7560
gaaacagact	ctaattgttg	tacaagggt	ggtcccatct	cctgagcccc	atgtcaaaca	7620
gaatccaaga	catcccaacc	cttcaccttg	gctgtgcccc	taatcctcaa	ctaagctagg	7680
cgcaaattcc	aatcctcttt	ggtctagtag	cccgggggca	gccccctcta	accttgggcc	7740
tcagcagcag	gggaggccac	accttcctag	tgcagggtggc	catattgtgg	ccccttgga	7800
ctgggtccca	ctcagcctct	aggcgattgt	ctcctaattg	ggctgagatg	agacacagtg	7860
gggacagtgg	tttgacaat	aggactgggtg	actctggtcc	ccagaggcct	catgtccctc	7920
tgtctccaga	aaattcccac	tctcacttcc	ctttcctcct	cagtcttgct	aggggtccatt	7980
tcttaccct	tgctgaattt	gagcccaccc	cctggacttt	ttccccatct	tctccaatct	8040
ggcctagttc	tatcctctgg	aagcagagcc	gctggacgct	ctggggtttcc	tgaggcccgt	8100
ccactgtcac	caatatcagg	aaccattgcc	acgtccta	gacgtgcgct	ggaagcctct	8160
agtttccaga	agctgcacaa	agatccctta	gatactctgt	gtgtccatct	ttggcctgga	8220
aaatactctc	accctggggc	taggaagacc	tcggtttgta	caaacttcct	caaatgcaga	8280
gcctgagggc	tctccccacc	tcctcaccaa	ccctctgcgt	ggcatagccc	tagcctcagc	8340
gggcagtgga	tgctggggct	gggcatgcag	ggagaggctg	ggtggtgtca	tctggtaacg	8400
cagccaccaa	acaatgaagc	gacactgatt	ccacaagggtg	catctgcac	cccatctgat	8460

2016-09-089_178W01_Sequence_Listing

ccattccatc	ctgtcaccca	gccatgcaga	cgtttatgat	ccccttttcc	agggagggaa	8520
tgtgaagccc	cagaaagggc	cagcgctcgg	cagccacctt	ggctgttccc	aagtccctca	8580
caggcagggt	ctccctacct	gcctgtcctc	aggtacatcc	ccgagggcct	gcagtgtctg	8640
tgtggaatcg	actactacac	gctcaagccg	gaggtcaaca	acgagtcttt	tgtcatctac	8700
atgttcgtgg	tccacttcac	catcccatg	attatcatct	ttttctgcta	tgggcagctc	8760
gtcttcaccg	tcaaggaggt	acgggccggg	gggtgggcgg	cctcacggct	ctgaggggtcc	8820
agccccagc	atgcatctgc	ggctcctgct	ccctggagga	gccatggctt	ggacccgggt	8880
cccgtgtcct	gcaggccgct	gccagcagc	aggagtccgc	caccacacag	aaggcagaga	8940
aggaggtcac	ccgcatggct	atcatcatgg	tcatcgcttt	cctgatctgc	tgggtgcctt	9000
acgccagcgt	ggcattctac	atcttcaccc	accagggctc	caacttcggt	cccatcttca	9060
tgaccatccc	agcgttcttt	gccaagagcg	ccgccatcta	caaccctgtc	atctatatca	9120
tgatgaacaa	gcagggtcct	actgcgggtg	ggagggcccc	agtgtccccc	gccacaggcg	9180
ctgcctgcca	aggacaagct	acttcccagg	gcaggggagg	gggctccatc	agggttactg	9240
gcagcagtct	tgggtcagca	gtcccaatgg	ggagtgtgtg	agaaatgcag	attcctggcc	9300
ccactcagaa	ctgctgaatc	tcagggtggg	cccaggaacc	tgcatttcca	gcaagccctc	9360
cacaggtggc	tcagatgctc	actcaggtgg	gagaagctcc	agtcagctag	ttctggaagc	9420
ccaatgtcaa	agtcagaagg	acccaagtcg	ggaatgggat	gggccagctt	ccataaagct	9480
gaataaggag	ctaaaaagtc	ttattctgag	gggtaaaggg	gtaaaggggt	cctcggagag	9540
gtacctccga	ggggtaaaca	gttgggtaaa	cagtctctga	agtcagctct	gccattttct	9600
agctgtatgg	ccctgggcaa	gtcaatttcc	ttctctgtgc	tttgggttcc	tcatccatag	9660
aaaggtagaa	agggcaaac	accaaactct	tggattacaa	gagataattt	acagaacacc	9720
cttggcacac	agagggcacc	atgaaatgtc	acgggtgaca	cagccccctt	gtgctcagtc	9780
cctggcatct	ctaggggtga	ggagcgtctg	cctagcaggt	tccctccagg	aagctggatt	9840
tgagtggatg	gggcgctgga	atcgtgaggg	gcagaagcag	gcaaagggtc	ggggcgaacc	9900
tcactaacgt	gccagttcca	agcacactgt	gggcagccct	ggccctgact	caagcctctt	9960
gccttccagt	tccggaactg	catgtctacc	accatctgct	gcggcaagaa	cccactgggt	10020
gacgatgagg	cctctgctac	cgtgtccaag	acggagacga	gccaggtggc	ccgggcctaa	10080
gacctgccta	ggactctgtg	gccgactata	ggcgtctccc	atcccctaca	ccttccccca	10140
gccacagcca	tcccaccagg	agcagcgctt	gtgcagaatg	aacgaagtca	cataggctcc	10200
ttaatttttt	tttttttttt	aagaaataat	taatgaggct	cctcactcac	ctgggacagc	10260
ctgagaaggg	acatccacca	agacctactg	atctggagtc	ccacgttccc	caaggccagc	10320
gggatgtgtg	cccctcctcc	tcccactca	tctttcagga	acacgaggat	tcttgctttc	10380
tggaaaagtg	tcccagctta	gggataagtg	tctagcacag	aatggggcac	acagtaggtg	10440
cttaataaat	gctggatgga	tgcaggaagg	aatggaggaa	tgaatgggaa	gggagaacat	10500

2016-09-089_178W01_Sequence_Listing

atctatcctc	tcagaccctc	gcagcagcag	caactcatatc	ttggctaata	atatggagca	10560
gttgtttttc	cctccctggg	cctcactttc	ttctcctata	aaatggaaat	cccagatccc	10620
tggtcctgcc	gacacgcagc	tactgagaag	accaaagag	gtgtgtgtgt	gtctatgtgt	10680
gtgtttcagc	actttgtaa	tagcaagaag	ctgtacagat	tctagttaat	gttgtgaata	10740
acatcaatta	atgtaactag	ttaattacta	tgattatcac	ctcctgatag	tgaacatttt	10800
gagattgggc	attcagatga	tggggtttca	cccaaccttg	gggcagggtt	ttaaaaatta	10860
gctaggcatc	aaggccagac	cagggctggg	ggttgggctg	taggcaggga	cagtcacagg	10920
aatgcagaat	gcagtcatca	gacctgaaaa	aacaacactg	ggggaggggg	acggtgaagg	10980
ccaagttccc	aatgagggtg	agattgggcc	tggggtctca	cccctagtgt	ggggccccag	11040
gtcccgtgcc	tccccttccc	aatgtggcct	atggagagac	aggcctttct	ctcagcctct	11100
ggaagccacc	tgctcttttg	ctctagcacc	tgggtcccag	catctagagc	atggagcctc	11160
tagaagccat	gtcacccgc	ccacatttaa	ttaacagctg	agtccctgat	gtcatcctta	11220
tctcgaagag	cttagaaa	aagagtggga	aattccactg	ggcctacctt	ccttggggat	11280
gttcatgggc	cccagtttcc	agtttccctt	gccagacaag	cccatcttca	gcagttgcta	11340
gtccattctc	cattctggag	aatctgctcc	aaaaagctgg	ccacatctct	gaggtgtcag	11400
aattaagctg	cctcagtaac	tgctccccct	tctccatata	agcaaagcca	gaagctctag	11460
ctttaccag	ctctgcctgg	agactaaggc	aaattgggcc	attaaaagct	cagctcctat	11520
gttggtatta	acggtggtgg	gttttgttgc	tttcacactc	tatccacagg	atagattgaa	11580
actgccagct	tccacctgat	ccctgaccct	gggatggctg	gattgagcaa	tgagcagagc	11640
caagcagcac	agagtcccc	ggggctagag	gtggaggagg	cagtcctggg	aatgggaaaa	11700
accccaactt	tggggtcata	gaggcacagg	taaccataa	aactgcaaac	aagctttgtc	11760
acctctcaga	gcttccttat	ctgcaaaaaa	gaatcttaaa	actgaccttg	gctgggcaca	11820
gtggctcaca	cctctaattc	cagcactttg	ggaggccaag	gtgggcagat	cagcaggtca	11880
ggagtttgag	accagcctga	ccaacacggt	gaaaccctgt	ctctactaaa	aatacaaaaa	11940
tcagctgggc	atggtggcgc	gtgcctgtaa	tcccagctat	tcagtgggct	gaggcaggag	12000
aatcgcttga	acctgggagg	tggaggttgc	agtgagccga	gattgcgcca	ctgcactcca	12060
gcctgagcaa	cagagggaca	gtctgtctcc	aaacaaaaca	aaacaaacaa	acaaacaaac	12120
aaacaaacaa	aaaacaacaa	caaaaaaacc	acttgatcct	aaggggatta	gatgcgactg	12180
tggacttta	gtggccagcc	tactgcctgg	catgcagcag	atgagactat	ggcaatactg	12240
ggcttcagct	cagagctggc	cttactagag	accctgtccc	aaaggggaaa	aggatggagc	12300
taaagctccc	gagagtcacc	ccctcctccg	aggtgagaaa	ggagggcagg	agcatgagat	12360
agccgatcct	cggtgccttg	gtgaggctgg	ggcaaatcat	gctgggatct	ctatcattgt	12420
ccctctttac	tgtgactcac	tagataatat	cagtcaggat	acttttggtc	acaagtgata	12480
ggaaatccaa	ctcatttggg	ctgaagcaaa	agggacacat	tgttggctca	catgaacaaa	12540

2016-09-089_178W01_Sequence_Listing

aagcccgggg	cttcaggcac	agggtatcac	catgactgag	atggggatta	attctgtgat	12600
tggccaagtc	taggtcacct	gatcatacgt	aactcattta	tgcctgaggt	tgcaatTTTT	12660
tggatttttg	caatcagacc	ttggcgatga	ccttgagcag	taggatataa	ataactccca	12720
catgcttagc	gttccaataa	tggaatacta	ggcatacgca	ggtctaactg	catcaccatg	12780
gctggaatgg	ggattcatcc	tctgattggg	cagacctagg	tcacatgctc	accctgcagc	12840
ccaagcaggc	tgaatgggga	gaggtagggt	tcacaaagga	aagcccaggt	gctgtttacct	12900
gaagtaggag	ggcaggaggc	agggtgagca	gagccaacat	caaccagag	ggaatggaat	12960
ctaagttagt	gttttctggg	cacgtggctg	gaccaggcct	ccctccctca	tcatctcagg	13020
gacatgaggg	agaagattcc	tatgggtggg	cccgaaggct	tcaccctttg	ttttggatgc	13080
tgtgttgggc	caggggtggca	gtgggtggga	cagtggcatc	ttagctgccc	tgacttgagc	13140
gcagcccatt	ccagctcccc	gccccaaccc	caaccagcc	cactttttct	gagaaatggt	13200
acatttgccc	cagcctcatg	tccagaggaa	aattttactc	taacaccaga	acattctctg	13260
gtttgtcctg	atagacaaga	aagcctccac	ctccttaatt	tacaaatgac	ttgacagctg	13320
cttcgtgggc	acttgcatac	ataaagagaa	ggagctgctg	ccttaagttg	cagcaagttt	13380
ggccccacct	catctccagg	cagccagcag	atgtacagag	tgcctcttgg	gtacaatggc	13440
agctccattc	aaccaaacct	gagcaagctg	accccatgcc	agaatgcact	ggggactcgg	13500
agatgaattg	gagcctagag	accaagtctc	taggctatga	cctgggctgc	ctcacggcca	13560
cagagctctg	tcacgccaag	ggagagatgc	accctgaaa	gcctgaggtg	cccataagg	13620
agagagtggg	tgcccttccc	aactatgtag	cttcagggca	agttctcttt	ctttcttttt	13680
ctttctttct	ctttctttct	ttcttt				13706

<210> 99
 <211> 13706
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 99	
gtgggggacc	aggagaaaga aagccaagga agaggaggag gaggaggaga aggaggagaa 60
ggatgctgac	ctagcagctc ctctcacagc agctcctctc ttgcagaggc tgaagagcga 120
tttgtgccct	gcaagctaag cccctaattc accgaggcaa aggcaaagcc cctagccggg 180
ctcccagggg	ctgggactcg ggtgccccaa gatggctgca tccagccatc ttggcttaga 240
aagcccccca	catgccagct tggccaacac ccacaccatg ggtttctctg gactgcccga 300
cacaagggtg	gggtgctggc caggcctgtg ttcaaattccc agctctgcag aggaactttg 360
accctgcata	ccccagattc ctcatgtgtc agtggggagt tagaccctct tcataggggg 420
caggaggagt	tgttcattca ttcaacaaat gtttattgaa cacctcctat gggttgtgag 480
ctcagaggga	gcgatgaaca ggccaggctg gtctgtcatt ctagaaatag atgggaagtc 540

2016-09-089_178W01_Sequence_Listing

agtcaataag tagacaaatg aggccagggtg tggtagcatg cctgtagacc cagttactcg	600
ggatgctgag gtaggaggat cacttgagcc taggacagga attcaaggct gcagtaagct	660
atgattgctg cactgcactc cagcctgggc aacagagcaa gactcatctc taaaaaacat	720
ttaaaaattg ttttaagaag acaaatgaga tagtcgctga tggtaatgac tgtgtaaaaa	780
ctgaacatgg ctgggtgtgg ttgctcacac ctataatctc agcacttttg gaggctgaga	840
ttacagcctc ccaagtggct cccaaggcag gaggatcact tgagcctggg agttagagaa	900
cagcttggac aatatagga gagcccaact ctacaaaaat gaaaataaat tagccaggca	960
tggtagcaca caccaatggt ccagctact caggggttga ggtggtggac cgcttgagcc	1020
caggaggttg aggctgcagt gagccatgat catgccgctg cactccaacc tgagtcacag	1080
agtgatccc tgtctcaaaa aacaataggc caggtgtggt ggctcacgcc tgtaacccca	1140
gcactttggg aggccgaggc ggatggatca cttgagatca ggagttagag accagcctgg	1200
ctaactggc aaaatcctgt ctgtactaaa aatataaaaa ttagccaggc atggcagtac	1260
atgcctgtag tcctgggttac ttgggaggct aaggcaggag aatcgcttga acccaggaag	1320
aggaggttgc agtgagccaa gatcacacca ctgcactcca gcttgggtga cagagtgaga	1380
ccctgtctca aaacagctaa acctggtggg ggtgcctggt gtgtaggatg gtcaggggtg	1440
gtctctccaa ggacatgagt gtgagcggag acctgaagga gactcaggaa gagattaata	1500
ctgtcagcaa caaatatatt gatcacttac aagcactccc aataatccta ttaggtaggc	1560
actattatca ttccatttt acagagtgga gaaccgaagc acactctcgg gagggcgggg	1620
tagctggctg caccaggtc gtgtagcctc agtccagatg taagggtggg tggaaaagag	1680
ccttgcccaa tgaggagaa cagtgaacc aaggccatag ggtctaaaga ttcacgaacc	1740
aggctctcat ggagaaagca ggtgaggttt actgtataga tgggtgtgcc cctacccac	1800
actgaggctt cctcgtctga gcaaactgag gccagagag ggaaggaag caggactacc	1860
atggtgactc aaagaccagc tagaatccag cctcctctcc tcgaggcttc cactgcccc	1920
cgccaggcct gtgtgactca gtctagggcc tttccattac ccagctaaa ctttcttta	1980
gtcatttata ccatggtgtg aatggctggc tggcttttcc tgagagctat ctttgatgag	2040
gggaggagg catagccagg tttgggaagc tgatacccca ggaagcccag ttgactgtgt	2100
gggttatagc ccaggctgtc actgatttgt aacgggacct gagcaactct gcagagctag	2160
gcctcagtct tttcatctgc aaaatggata tagcagagat ggtcagagta ggtgacttcg	2220
aatgaccctt ccagctcact atgagtctgt tttcctgaac aaagagcatt tttgtttaa	2280
aaaaaaattt cttgggccgg acacggtggt tctactctat aatcctggca ctttgggagg	2340
ccgaggaggg tggatcgctt gagccaggag ttcaggacca gcctgggcaa catagcgaga	2400
ctccaccctt aaaaaaata caaaaactag tgggtgtgcac ttgtggtccc agctactcag	2460
gaggctgagg tgagaggatc gcttgagccc aggaggcaga ggctacagtg agctatgatt	2520
gtggcactgc actccagcct gggcgacaga gaccttgtct caaaactttt ttttcttcg	2580

2016-09-089_178W01_Sequence_Listing

tcaagcttta	cagaataaag	agcactgtca	cctcagtgat	ggctgttagt	tccccatcac	2640
caggggtcca	tgaggttgca	attgtgaaac	tcacaaagga	ggaacctgag	acagagaggg	2700
gaagtactga	gatcatctag	gtccattccc	ccactcactc	gttcattcaa	caaattattca	2760
ggagcacctt	ctaggtgcc	ggccctggag	acacatcagt	gaacaaaaca	gacatcatcc	2820
cacctctttc	cactacaggc	caagcaccat	gctgggtctct	gggaaccctg	ttgtgagcaa	2880
gacagacca	ggcttaccct	tgtggactca	tgttacaggc	agggagacgg	gcacaaaaca	2940
caaataaaaa	gcttccatgc	tgtcagaagc	actatgcaaa	aagcaagatg	ctgaggtact	3000
gctaagctgt	gtgggatggg	ggctcagccc	ggccagggag	gggccagttg	tgggtcagtc	3060
ttgaccaag	gcatccagga	cacctctctt	ctggccatga	gggtccacgt	cagaatcaaa	3120
ccctcacctt	aacctcatta	gcgttgggca	taatcaccag	gccaagcgcc	ttaaactacg	3180
agaggcccca	tcccaccgc	cctgccttag	ccctgccacg	tgtgccaaac	gctgttagac	3240
ccaacaccac	ccaggccagg	tagggggctg	gagcccaggt	gggctgcagg	gaagggggca	3300
ctcttctgag	cagacagatc	tgggaatcct	gggtgggaag	agagacagtg	agagagagat	3360
taagggatat	ttcccaggca	tcagggcttt	gcactctcag	gggtccttcc	gcctggatgt	3420
ccttcccctg	aagcttcctc	ctgttgttcc	gttctcagct	caagctccag	cttctcagag	3480
aagcctcctg	tgttgggagt	ggctgcgact	gaactgtccc	tactgttatt	cgctcttcta	3540
tttgtttgtg	gtccctgtgc	cccctcacc	cacaaaaaca	ctggcttctt	gtgagcagga	3600
gcttgctctt	tcgtgtacct	tgtgtgtccc	caaggaccaa	gcaccttgtc	tgggccacag	3660
taggtgtca	atacacatgt	tggttgaca	gtggtcactg	agcgccgca	cgtcgggcac	3720
tctcagcact	tgcacaggcc	gccccagaca	ccccacttca	ttcctgggag	gtgtcatcat	3780
gttgcttga	cgacggggag	agggggacct	gccagtgttg	gcctccattt	tccccagtc	3840
atctgcccc	aaggctctga	ctactttctt	tctcacggta	catcctgcta	ttctggaatc	3900
ggccctcgtg	gggccacctg	gtacatggca	tttgaggccc	tcgtggctga	ttaggcctcc	3960
cccaacagtg	ccctgtctgc	tgcctccagg	gccagcctcc	ccttcagact	ggagtcccct	4020
gaagggttct	gcccctcccc	tgctctggta	gccccctcca	tcctccctcc	ctccactcca	4080
tctttggggg	catttgagtc	acctttctac	accagtgatc	tgcccaagcc	actgctcact	4140
ttcctctgga	taaagccagg	ttccccggcc	tagcgttcaa	gaccattac	aactgcccc	4200
agcccagatc	ttccccacct	agccacctgg	caaactgctc	cttctctcaa	aggcccaaac	4260
atggcctccc	agactgcaac	ccccaggcag	tcaggccctg	tctccacaac	ctcacagcca	4320
ccctggacgg	aatctgcttc	ttcccacatt	tgagtctctc	tcagcccctg	agctcctctg	4380
ggcagggctg	tttctttcca	tctttgtatt	cccaggggcc	tgcaataaaa	tgtttaatga	4440
acgaacaaga	gagtgaattc	caattccatg	caacaaggat	tgggctcctg	ggccctaggc	4500
tatgtgtctg	gcaccagaaa	cggaagctgc	aggttgcagc	ccctgccctc	atggagctcc	4560
tcctgtcaga	ggagtgtggg	gactggatga	ctccagaggt	aacttgtggg	ggaacgaaca	4620

2016-09-089_178W01_Sequence_Listing

ggtaaggggc	tgtgtgacga	gatgagagac	tgggagaata	aaccagaaag	tctctagctg	4680
tccagaggac	atagcacaga	ggcccatggg	ccctatttca	aaccaggcc	accagactga	4740
gctggggacct	tgggacagac	aagtcacgca	gaagttaggg	gaccttctcc	tcccttttcc	4800
tggatcctga	gtacctctcc	tccctgacct	caggcttctc	cctagtgtca	ccttggcccc	4860
tcttagaagc	caattaggcc	ctcagtttct	gcagcgggga	ttaatgat	tatgaacacc	4920
cccaatctcc	cagatgctga	ttcagccagg	agcttaggag	ggggagggtca	ctttataagg	4980
gtctgggggg	gtcagaaccc	agagtcaccc	agctggagcc	ctgagtggct	gagctcaggc	5040
cttcgcagca	ttcttgggtg	ggagcagcca	cgggtcagcc	acaagggcca	cagccatgaa	5100
tggcacagaa	ggccctaact	tctacgtgcc	cttctccaat	gcgacgggtg	tggtacgcag	5160
ccacttcgag	taccacagct	actacctggc	tgagccatgg	cagttctcca	tgctggccgc	5220
ctacatgttt	ctgctgatcg	tgctgggctt	ccccatcaac	ttcctcacgc	tctacgtcac	5280
cgtccagcac	aagaagctgc	gcacgcctct	caactacatc	ctgctcaacc	tagccgtggc	5340
tgacctcttc	atggctctag	gtggcttcac	cagcaccctc	tacacctctc	tgcatggata	5400
cttcgtcttc	gggcccacag	gatgcaattt	ggagggtctc	tttgccaccc	tgggcggtat	5460
gagccgggtg	tgggtggggg	gtgcaggagc	ccgggagcat	ggaggggtct	gggagagtcc	5520
cgggcttggc	ggtggtggct	gagaggcctt	ctcccttctc	ctgtcctgtc	aatgttatcc	5580
aaagccctca	tatattcagt	caacaaacac	cattcatggt	gatagccggg	ctgctgtttg	5640
tgcagggtctg	gcactgaaca	ctgccttgat	cttatttgga	gcaatatgag	cttgtctaata	5700
ttcacagcaa	gaaaactgag	ctgagggtca	aagaagtcaa	gcgccctgct	ggggcgctcac	5760
acagggtcgg	gtgcagagtt	gagttggaag	ccgcacatcta	tctcgggcca	tgtttgcagc	5820
accaagcctc	tgtttccctt	ggagcagctg	tgctgagtca	gaccagggt	gggcactgag	5880
ggagagctgg	gcaagccaga	cccctcctct	ctggggggccc	aagctcaggg	tgggaagtgg	5940
attttccatt	ctccagtcac	tgggtcttcc	ctgtgctggg	caatgggctc	ggtccctctc	6000
ggcatcctct	gcctcccctc	tcagcccctg	tcctcagggt	cccctccagc	ctccctgccg	6060
cgttccaagt	ctcctggtgt	tgagaaccgc	aagcagccgc	tctgaagcag	ttcctttttg	6120
ctttagaata	atgtcttgca	tttaacagga	aaacagatgg	ggtgctgcag	ggataacaga	6180
tcccacttaa	cagagaggaa	aactgaggca	gggagagggg	aagagactca	tttagggatg	6240
tggccaggca	gcaacaagag	cctaggtctc	ctggctgtga	tccaggaata	tctctgtgta	6300
gatgcaggag	gagacgctag	aagcagccat	tgcaaagctg	ggtgacgggg	agagcttacc	6360
gccagccaca	agcgtctctc	tgccagcctt	gccctgtctc	ccccatgtcc	aggctgtctc	6420
ctcgggtcca	ttctcaggga	atctctggcc	attgttgggt	gtttgttgca	ttcaataatc	6480
acagatcact	cagttctggc	cagaagggtg	gtgtgccact	tacgggtggg	tgttctctgc	6540
agggtcagtc	ccagtttaca	aatattgtcc	ctttcactgt	taggaatgtc	ccagtttggg	6600
tgattaacta	tatggccact	ctccctatgg	aacttcatgg	ggtggtgagc	aggacagatg	6660

2016-09-089_178W01_Sequence_Listing

tctgaattcc	atcatttcct	tcttcttcct	ctgggcaaaa	cattgcacat	tgcttcatgg	6720
ctcctaggag	aggcccccac	atgtccgggt	tatttcattt	cccgagaagg	gagagggagg	6780
aaggactgcc	aattctgggt	ttccaccacc	tctgcattcc	ttcccaacaa	ggaactctgc	6840
cccacattag	gatgcattct	tctgctaaac	acacacacac	acacacacac	acacaacaca	6900
cacacacaca	cacacacaca	cacacacaca	aaactcccta	ccgggttccc	agttcaatcc	6960
tgaccccctg	atctgattcg	tgtcccttat	gggccagag	cgctaagcaa	ataacttccc	7020
ccattccctg	gaatttcttt	gccagctct	cctcagcgtg	tggtccctct	gccccctccc	7080
cctcctccca	gcaccaagct	ctctccttcc	ccaaggcctc	ctcaaattccc	tctcccactc	7140
ctggttgcct	tcctagctac	cctctccctg	tctagggggg	agtgcaccct	ccttaggcag	7200
tggggtctgt	gctgaccgcc	tgctgactgc	cttgcagggt	aaattgccct	gtggctcctg	7260
gtggctcctg	ccatcgagcg	gtacgtgggt	gtgtgtaagc	ccatgagcaa	cttccgcttc	7320
ggggagaacc	atgccatcat	gggcgttgcc	ttcacctggg	tcattggcgct	ggcctgcgcc	7380
gcacccccac	tcgccggctg	gtccaggtaa	tggcactgag	cagaagggaa	gaagctccgg	7440
gggctctttg	tagggctctc	cagtcaggac	tcaaaccag	tagtgtctgg	ttccaggcac	7500
tgaccttgta	tgtctcctgg	cccaaattgcc	cactcagggg	aggggtgtag	ggcagaagaa	7560
gaaacagact	ctaattgttc	tacaagggt	ggtcccatct	cctgagcccc	atgtcaaaca	7620
gaatccaaga	catccaacc	cttcaccttg	gctgtgcccc	taatcctcaa	ctaagctagg	7680
cgcaaattcc	aatcctcttt	ggtctagtac	ccggggggca	gccccctcta	accttggggc	7740
tcagcagcag	gggaggccac	accttcctag	tgcagggtgg	catattgtgg	ccccttgga	7800
ctgggtccca	ctcagcctct	aggcgattgt	ctcctaattg	ggctgagatg	agacacagtg	7860
gggacagtgg	tttggacaat	aggactgggt	actctgggtc	ccagaggcct	catgtccctc	7920
tgtctccaga	aaattcccac	tctcacttcc	ctttcctcct	cagtcttgct	agggctcatt	7980
tcttaccctt	tgctgaattt	gagcccaccc	cctggacttt	ttccccatct	tctccaatct	8040
ggcctagttc	tatcctctgg	aagcagagcc	gctggacgct	ctggggtttc	tgaggcccg	8100
ccactgtcac	caatatcagg	aaccattgcc	acgtccta	gacgtgcgct	ggaagcctct	8160
agtttcaga	agctgcacaa	agatccctta	gatactctgt	gtgtccatct	ttggcctgga	8220
aaatactctc	accctggggc	taggaagacc	tcggtttgta	caaacttcct	caaattgcaga	8280
gcctgagggc	tctccccacc	tcctcaccaa	ccctctgcgt	ggcatagccc	tagcctcagc	8340
gggcagtgga	tgctggggct	gggcattgcag	ggagaggctg	ggtggtgtca	tctggtaacg	8400
cagccaccaa	acaatgaagc	gacactgatt	ccacaagggt	catctgcata	cccatctgat	8460
ccattccatc	ctgtcaccca	gccatgcaga	cgtttatgat	ccccttttcc	aggagaggaa	8520
tgtgaagccc	cagaaagggc	cagcgtcgg	cagccacctt	ggctgttccc	aagtccctca	8580
caggcagggg	ctccctacct	gcctgtcctc	aggtacatcc	ccgagggcct	gcagtgtctg	8640
tgtggaatcg	actactacac	gctcaagccg	gaggtaaca	acgagtcctt	tgtcatctac	8700

2016-09-089_178W01_Sequence_Listing

atgttcgtgg	tccacttcac	catcccatg	attatcatct	ttttctgcta	tgggcagctc	8760
gtcttcaccg	tcaaggaggt	acgggcccgg	gggtgggcgg	cctcacggct	ctgaggggtcc	8820
agcccccagc	atgcatctgc	ggctcctgct	ccctggagga	gccatggtct	ggacccgggt	8880
cccgtgtcct	gcaggccgct	gcccagcagc	aggagtcagc	caccacacag	aaggcagaga	8940
aggaggtcac	ccgcatggtc	atcatcatgg	tcatcgcttt	cctgatctgc	tgggtgccct	9000
acgccagcgt	ggcattctac	atcttcaccc	accagggctc	caacttcggt	cccattctca	9060
tgaccatccc	agcgttcttt	gccaagagcg	ccgccatcta	caaccctgtc	atctatatca	9120
tgatgaacaa	gcaggtgcct	actgcgggtg	ggagggcccc	agtgccccag	gccacaggcg	9180
ctgcctgcc	aggacaagct	acttcccagg	gcaggggagg	gggctccatc	agggttactg	9240
gcagcagtct	tgggtcagca	gtcccaatgg	ggagtgtgtg	agaaatgcag	attcctggcc	9300
ccactcagaa	ctgctgaatc	tcagggtggg	cccaggaacc	tgcatttcca	gcaagccctc	9360
cacaggtggc	tcagatgctc	actcaggtgg	gagaagctcc	agtcagctag	ttctggaagc	9420
ccaatgtcaa	agtcagaagg	acccaagtcg	ggaatgggat	gggccagtct	ccataaagct	9480
gaataaggag	ctaaaaagtc	ttattctgag	gggtaaaggg	gtaaaggggt	cctcggagag	9540
gtacctccga	ggggtaaaca	gttgggtaaa	cagtctctga	agtcagctct	gccattttct	9600
agctgtatgg	ccctgggcaa	gtcaatttcc	ttctctgtgc	tttggtttcc	tcattccatag	9660
aaaggtagaa	agggcaaaac	accaaactct	tggattacaa	gagataattt	acagaacacc	9720
cttggcacac	agagggcacc	atgaaatgtc	acgggtgaca	cagccccctt	gtgctcagtc	9780
cctggcatct	ctaggggtga	ggagcgtctg	cctagcaggt	tccctccagg	aagctggatt	9840
tgagtggatg	gggcgctgga	atcgtgaggg	gcagaagcag	gcaaaggggtc	ggggcgaacc	9900
tcactaacgt	gccagttcca	agcacactgt	gggcagccct	ggccctgact	caagcctctt	9960
gccttccagt	tccggaactg	catgctcacc	accatctgct	gcggcaagaa	cccactgggt	10020
gacgatgagg	cctctgctac	cgtgtccaag	acggagacga	gccaggtggc	cccggcctaa	10080
gacctgccta	ggactctgtg	gccgactata	ggcgtctccc	atcccctaca	ccttccccca	10140
gccacagcca	tcccaccagg	agcagcgcct	gtgcagaatg	aacgaagtca	cataggctcc	10200
ttaatTTTTT	TTTTTTTTTT	aagaaataat	taatgaggct	cctcactcac	ctgggacagc	10260
ctgagaaggg	acatccacca	agacctactg	atctggagtc	ccacgttccc	caaggccagc	10320
gggatgtgtg	cccctcctcc	tcccaactca	tctttcagga	acacgaggat	tcttgctttc	10380
tggaaaagtg	tcccagctta	gggataagtg	tctagcacag	aatggggcac	acagtaggtg	10440
cttaataaat	gctggatgga	tgcaggaagg	aatggaggaa	tgaatgggaa	gggagaacat	10500
atctatcctc	tcagaccctc	gcagcagcag	caactcatac	ttggctaata	atatggagca	10560
gttgTTTTTc	cctccctggg	cctcactttc	ttctcctata	aaatggaaat	cccagatccc	10620
tggtcctgcc	gacacgcagc	tactgagaag	acaaaaagag	gtgtgtgtgt	gtctatgtgt	10680
gtgtttcagc	actttgtaaa	tagcaagaag	ctgtacagat	tctagttaat	gttgtgaata	10740

2016-09-089_178W01_Sequence_Listing

acatcaatta	atgtaactag	ttaattacta	tgattatcac	ctcctgatag	tgaacatttt	10800
gagattgggc	attcagatga	tggggtttca	cccaaccttg	gggcagggtt	ttaaaaatta	10860
gctaggcatc	aaggccagac	cagggctggg	ggttgggctg	taggcaggga	cagtcacagg	10920
aatgcagaat	gcagtcatca	gacctgaaaa	aacaacactg	ggggaggggg	acggtgaagg	10980
ccaagttccc	aatgagggtg	agattgggcc	tgggggtctca	cccctagtgt	ggggccccag	11040
gtcccgtgcc	tccccttccc	aatgtggcct	atggagagac	aggcctttct	ctcagcctct	11100
ggaagccacc	tgctcttttg	ctctagcacc	tgggtcccag	catctagagc	atggagcctc	11160
tagaagccat	gctcacccgc	ccacatttaa	ttaacagctg	agtccctgat	gtcatcctta	11220
tctcgaagag	cttagaaaaca	aagagtggga	aattccactg	ggcctacctt	ccttggggat	11280
gttcatgggc	cccagtttcc	agtttccctt	gccagacaag	cccatcttca	gcagttgcta	11340
gtccattctc	cattctggag	aatctgctcc	aaaaagctgg	ccacatctct	gaggtgtcag	11400
aattaagctg	cctcagtaac	tgctccccct	tctccatata	agcaaagcca	gaagctctag	11460
ctttaccag	ctctgcctgg	agactaaggc	aaattgggcc	attaaaagct	cagctcctat	11520
gttgggtatta	acggtgggtg	gttttgttgc	tttcacactc	tatccacagg	atagattgaa	11580
actgccagct	tccacctgat	ccctgaccct	gggatggctg	gattgagcaa	tgagcagagc	11640
caagcagcac	agagtcccct	ggggctagag	gtggaggagg	cagtcctggg	aatgggaaaa	11700
accccaactt	tgggggtcata	gaggcacagg	taaccataa	aactgcaaac	aagctttgtc	11760
acctctcaga	gcttccttat	ctgcaaaaaa	gaatcttaaa	actgaccttg	gctgggcaca	11820
gtggctcaca	cctctaattc	cagcactttg	ggaggccaag	gtgggcagat	cacgagggtca	11880
ggagtttgag	accagcctga	ccaacacggg	gaaaccctgt	ctctactaaa	aatacaaaaa	11940
tcagctgggc	atggtggcgc	gtgcctgtaa	tcccagctat	tcagtgggct	gaggcaggag	12000
aatcgcttga	acctgggagg	tggaggttgc	agtgagccga	gattgcgcca	ctgcactcca	12060
gcctgagcaa	cagagggaca	gtctgtctcc	aaacaaaaca	aaacaaaca	acaaacaaac	12120
aaacaaaca	aaaacaaca	caaaaaaacc	acttgatcct	aaggggatta	gatgcgactg	12180
tggacttta	gtggccagcc	tactgcctgg	catgcagcag	atgagactat	ggcaatactg	12240
ggcttcagct	cagagctggc	cttactagag	accctgtccc	aaaggggaaa	aggatggagc	12300
taaagctccc	gagagtcacc	ccctcctccg	aggtgagaaa	ggagggcagg	agcatgagat	12360
agccgatcct	cgggtgccttg	gtgaggctgg	ggcaaatcat	gctgggatct	ctatcattgt	12420
ccctctttac	tgtgactcac	tagataatat	cagtcaggat	acttttggtc	acaagtgata	12480
ggaaatccaa	ctcatttggg	ctgaagcaaa	agggacacat	tgttgggtca	catgaacaaa	12540
aagcccgggg	cttcaggcac	agggtatcac	catgactgag	atggggatta	attctgtgat	12600
tggccaagtc	taggtcacct	gatcatacgt	aactcattta	tgcttgaggt	tgcaattttt	12660
tggatttttg	caatcagacc	ttggcgatga	ccttgagcag	taggatataa	ataactccca	12720
catgcttagc	gttccaataa	tggaatacta	ggcatacgca	ggtctaactg	catcaccatg	12780

2016-09-089_178W01_Sequence_Listing

gctggaatgg ggattcatcc tctgattggg cagacctagg tcacatgctc accctgcagc 12840
ccaagcaggc tgaatgggga gaggtagggt tcacaaagga aagcccagggt gctgttacct 12900
gaagtaggag ggcaggaggc agggtaggca gagccaacat caaccagag ggaatggaat 12960
ctaagttggg gttttctggg cacgtggctg gaccaggcct ccctccctca tcattctcagg 13020
gacatgaggg agaagattcc tatgggtggg cccgaagggtc tcaccctttg ttttgatgc 13080
tgtgttgggc cagggtggca gtgggtggga cagtggcatc ttagctgccc tgacttgag 13140
gcagcccatt ccagctcccc gcccacccc caaccagcc cactttttct gagaaatggg 13200
acatttgccc cagcctcatg tccagaggaa aattttactc taacaccaga acattctctg 13260
gtttgtcctg atagacaaga aagcctccac ctcttaatt tacaatgac ttgacagctg 13320
cttcgtgggc acttgcatc ataaagagaa ggagctgctg ccttaagttg cagcaagttt 13380
ggccccacct catctccagg cagccagcag atgtacagag tgcctcttg gtacaatggc 13440
agctccattc aaccaaacct gagcaagctg acccatgcc agaatgcact ggggactcgg 13500
agatgaattg gagcctagag accaagtctc taggctatga cctgggctgc ctcacggcca 13560
cagagctctg tcacgccaag ggagagatgc acccctgaaa gcctgagggtg ccccataagg 13620
agagagtggg tgcccttccc aactatgtag cttcagggca agttctcttt ctttcttttt 13680
ctttctttct ctttctttct ttcttt 13706

<210> 100
<211> 348
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 100

Met Asn Gly Thr Glu Gly Pro Asn Phe Tyr Val Pro Phe Ser Asn Ala
1 5 10 15

Thr Gly Val Val Arg Ser Pro Phe Glu Tyr Pro Gln Tyr Tyr Leu Ala
20 25 30

Glu Pro Trp Gln Phe Ser Met Leu Ala Ala Tyr Met Phe Leu Leu Ile
35 40 45

Val Leu Gly Phe Pro Ile Asn Phe Leu Thr Leu Tyr Val Thr Val Gln
50 55 60

His Lys Lys Leu Arg Thr Pro Leu Asn Tyr Ile Leu Leu Asn Leu Ala
65 70 75 80

Val Ala Asp Leu Phe Met Val Leu Gly Gly Phe Thr Ser Thr Leu Tyr
85 90 95

Thr Ser Leu His Gly Tyr Phe Val Phe Gly Pro Thr Gly Cys Asn Leu
Page 150

2016-09-089_178W01_Sequence_Listing

100

105

110

Glu Gly Phe Phe Ala Thr Leu Gly Gly Glu Ile Ala Leu Trp Ser Leu
115 120 125

Val Val Leu Ala Ile Glu Arg Tyr Val Val Val Cys Lys Pro Met Ser
130 135 140

Asn Phe Arg Phe Gly Glu Asn His Ala Ile Met Gly Val Ala Phe Thr
145 150 155 160

Trp Val Met Ala Leu Ala Cys Ala Ala Pro Pro Leu Ala Gly Trp Ser
165 170 175

Arg Tyr Ile Pro Glu Gly Leu Gln Cys Ser Cys Gly Ile Asp Tyr Tyr
180 185 190

Thr Leu Lys Pro Glu Val Asn Asn Glu Ser Phe Val Ile Tyr Met Phe
195 200 205

Val Val His Phe Thr Ile Pro Met Ile Ile Ile Phe Phe Cys Tyr Gly
210 215 220

Gln Leu Val Phe Thr Val Lys Glu Ala Ala Ala Gln Gln Gln Glu Ser
225 230 235 240

Ala Thr Thr Gln Lys Ala Glu Lys Glu Val Thr Arg Met Val Ile Ile
245 250 255

Met Val Ile Ala Phe Leu Ile Cys Trp Val Pro Tyr Ala Ser Val Ala
260 265 270

Phe Tyr Ile Phe Thr His Gln Gly Ser Asn Phe Gly Pro Ile Phe Met
275 280 285

Thr Ile Pro Ala Phe Phe Ala Lys Ser Ala Ala Ile Tyr Asn Pro Val
290 295 300

Ile Tyr Ile Met Met Asn Lys Gln Phe Arg Asn Cys Met Leu Thr Thr
305 310 315 320

Ile Cys Cys Gly Lys Asn Pro Leu Gly Asp Asp Glu Ala Ser Ala Thr
325 330 335

Val Ser Lys Thr Glu Thr Ser Gln Val Ala Pro Ala
340 345

<210> 101
<211> 348
<212> PRT
<213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 101

```

Met Asn Gly Thr Glu Gly Pro Asn Phe Tyr Val Pro Phe Ser Asn Ala
1      5      10      15

Thr Gly Val Val Arg Ser His Phe Glu Tyr Pro Gln Tyr Tyr Leu Ala
      20      25      30

Glu Pro Trp Gln Phe Ser Met Leu Ala Ala Tyr Met Phe Leu Leu Ile
      35      40      45

Val Leu Gly Phe Pro Ile Asn Phe Leu Thr Leu Tyr Val Thr Val Gln
50      55      60

His Lys Lys Leu Arg Thr Pro Leu Asn Tyr Ile Leu Leu Asn Leu Ala
65      70      75      80

Val Ala Asp Leu Phe Met Val Leu Gly Gly Phe Thr Ser Thr Leu Tyr
      85      90      95

Thr Ser Leu His Gly Tyr Phe Val Phe Gly Pro Thr Gly Cys Asn Leu
      100      105      110

Glu Gly Phe Phe Ala Thr Leu Gly Gly Glu Ile Ala Leu Trp Ser Leu
      115      120      125

Val Val Leu Ala Ile Glu Arg Tyr Val Val Val Cys Lys Pro Met Ser
130      135      140

Asn Phe Arg Phe Gly Glu Asn His Ala Ile Met Gly Val Ala Phe Thr
145      150      155      160

Trp Val Met Ala Leu Ala Cys Ala Ala Pro Pro Leu Ala Gly Trp Ser
      165      170      175

Arg Tyr Ile Pro Glu Gly Leu Gln Cys Ser Cys Gly Ile Asp Tyr Tyr
      180      185      190

Thr Leu Lys Pro Glu Val Asn Asn Glu Ser Phe Val Ile Tyr Met Phe
      195      200      205

Val Val His Phe Thr Ile Pro Met Ile Ile Ile Phe Phe Cys Tyr Gly
210      215      220

Gln Leu Val Phe Thr Val Lys Glu Ala Ala Ala Gln Gln Gln Glu Ser
225      230      235      240

Ala Thr Thr Gln Lys Ala Glu Lys Glu Val Thr Arg Met Val Ile Ile
      245      250      255

```


2016-09-089_178W01_Sequence_Listing

Met Val Ile Ala Phe Leu Ile Cys Trp Val Pro Tyr Ala Ser Val Ala
260 265 270

Phe Tyr Ile Phe Thr His Gln Gly Ser Asn Phe Gly Pro Ile Phe Met
275 280 285

Thr Ile Pro Ala Phe Phe Ala Lys Ser Ala Ala Ile Tyr Asn Pro Val
290 295 300

Ile Tyr Ile Met Met Asn Lys Gln Phe Arg Asn Cys Met Leu Thr Thr
305 310 315 320

Ile Cys Cys Gly Lys Asn Pro Leu Gly Asp Asp Glu Ala Ser Ala Thr
325 330 335

Val Ser Lys Thr Glu Thr Ser Gln Val Ala Pro Ala
340 345

<210> 102
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 102

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 153

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 103
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 103

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 104
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 104

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 154

2016-09-089_178W01_Sequence_Listing

```

1           5           10           15
Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
      50      55      60
Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
145

```

<210> 105
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 105

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1           5           10           15
Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
      50      55      60
Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80

```

2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 106
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 106

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Met Pro Glu Gln Arg Gln Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Glu Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

Gly Ser Val Ser Thr Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

2016-09-089_178W01_Sequence_Listing

145

<210> 107
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 107

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Thr Ile Ile Pro Ser Gln Thr Asp Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Tyr Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ile Asp Ser
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 108
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 108

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Ser Ile Gln Pro Asp Gln Val Tyr Lys Phe Lys His Arg
 Page 157

2016-09-089_178W01_Sequence_Listing

20

25

30

Leu Arg Leu Arg Phe Ala Val Phe Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp His
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 109
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 109

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Glu Pro Val Gln Thr Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Cys Asp Val
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

2016-09-089_178W01_Sequence_Listing

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 110
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 110

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Thr Pro Ser Gln Ala Gly Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Glu Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

Gly Ser Val Ser Cys Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 111

2016-09-089_178W01_Sequence_Listing

<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 111

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Glu Pro Ala Gln Arg Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Lys Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 112
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 112

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Glu Pro Gln Gln Pro Gly Lys Phe Lys His Arg
20 25 30

Leu Ser Leu Arg Phe Ala Val Tyr Gln Lys Thr Gln Arg Arg Trp Phe

2016-09-089_178W01_Sequence_Listing

35

40

45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Pro
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 113
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 113

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Gly Pro Glu Gln Ser Ser Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Leu Phe Ala Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

2016-09-089_178W01_Sequence_Listing

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 114
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 114

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Thr Ile Gln Pro Asp Gln Asn Gln Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Tyr Phe Ala Val Tyr Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Thr
 50 55 60

Gly Ser Val Ser Arg Tyr Gln Leu Ser Gln Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 115
 <211> 147
 <212> PRT
 <213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 115

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 116

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 116

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln

2016-09-089_178W01_Sequence_Listing

50

55

60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 117
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 117

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

2016-09-089_178W01_Sequence_Listing

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 118
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 118

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 119
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 119

2016-09-089_178W01_Sequence_Listing

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 120
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 120

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
Page 166

65

70

75

80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 121
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 121

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

2016-09-089_178W01_Sequence_Listing

Val Leu Asp
145

<210> 122
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 122

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 123
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 123

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 124
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 124

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
Page 169

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 125
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 125

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

2016-09-089_178W01_Sequence_Listing

<210> 126
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 126

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 127
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 127

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

2016-09-089_178W01_Sequence_Listing

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 128
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 128

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
Page 172

2016-09-089_178W01_Sequence_Listing

100

105

110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 129
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 129

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 130
<211> 147
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 130

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 131

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 131

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

2016-09-089_178W01_Sequence_Listing

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 132
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 132

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
Page 175

2016-09-089_178W01_Sequence_Listing

115

120

125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 133
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 133

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 134
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

2016-09-089_178W01_Sequence_Listing

<400> 134

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 135

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 135

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

2016-09-089_178W01_Sequence_Listing

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 136
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 136

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 178

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 137
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 137

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 138
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 138

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 179

2016-09-089_178W01_Sequence_Listing

```

1           5           10           15
Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
      50      55      60
Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
145

```

<210> 139
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 139

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1           5           10           15
Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
      50      55      60
Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80

```

2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 140
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 140

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

2016-09-089_178W01_Sequence_Listing

145

<210> 141
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 141

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 142
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 142

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg

2016-09-089_178W01_Sequence_Listing

20

25

30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 143
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 143

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

2016-09-089_178W01_Sequence_Listing

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 144
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 144

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 145

2016-09-089_178W01_Sequence_Listing

<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 145

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 146
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 146

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe

2016-09-089_178W01_Sequence_Listing

35

40

45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 147
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 147

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

2016-09-089_178W01_Sequence_Listing

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 148
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 148

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 149
<211> 147
<212> PRT
<213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 149

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ile Pro Glu Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 150

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 150

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Leu Pro Glu Ser Arg Met Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Gly Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln

2016-09-089_178W01_Sequence_Listing

50

55

60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 151
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 151

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Gln Ile Leu Pro Glu Lys Lys Cys Ala Phe Lys His Arg
20 25 30

Leu Arg Leu Trp Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

2016-09-089_178W01_Sequence_Listing

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 152
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 152

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Cys Ile Val Pro Glu Lys Ala Ser Arg Phe Lys His Arg
 20 25 30

Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 153
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 153

2016-09-089_178W01_Sequence_Listing

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Thr Ile Val Pro Glu Lys Ser Ser Ile Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 154
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 154

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Val Pro Glu Glu Arg Thr Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
Page 191

65

70

75

80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 155
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 155

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Arg Ile Glu Pro Glu Lys Gly Gly Arg Phe Lys His Arg
 20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

2016-09-089_178W01_Sequence_Listing

Val Leu Asp
145

<210> 156
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 156

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Ser Pro Glu Val Arg Ala Pro Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 157
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 157

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Ile Trp Ala Ser Ile Leu Pro Glu Thr Ser Ala Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Phe Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 158
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 158

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ala Ile Leu Pro Glu Gln Ser Tyr Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
Page 194

85

90

95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 159
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 159

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Ser Ile Leu Pro Glu Arg Lys Thr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

2016-09-089_178W01_Sequence_Listing

<210> 160
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 160

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Cys Ile Glu Pro Glu Arg Gly Tyr Arg Phe Lys His Arg
 20 25 30

Leu Arg Leu Ala Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 161
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 161

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Trp Ala Arg Ile Glu Pro Glu Leu Arg Leu Arg Phe Lys His Arg
 20 25 30

2016-09-089_178W01_Sequence_Listing

Leu Arg Leu Phe Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 162
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 162

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Gln Ile Val Pro Glu Arg Ala Gly Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
Page 197

2016-09-089_178W01_Sequence_Listing

100

105

110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 163
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 163

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Thr Pro Glu Pro Thr Ala Ser Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 164
<211> 147
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 164

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Asn Pro Glu Pro Ser Tyr Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Ser Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 165

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 165

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Leu Pro Glu His Gln Tyr Arg Phe Lys His Arg
20 25 30

Leu Arg Leu Gly Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

2016-09-089_178W01_Sequence_Listing

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 166
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 166

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ala Ile Asp Pro Asp Gln Lys Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ile Phe Ala Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp His
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
Page 200

2016-09-089_178W01_Sequence_Listing

115

120

125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 167
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 167

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Glu Pro Ala Gln Arg Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Lys Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 168
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

2016-09-089_178W01_Sequence_Listing

<400> 168

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Asn Pro Asp Gln Thr Asn Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Trp Phe Ala Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Thr
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 169

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 169

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Cys Ile Glu Pro Ala Gln Asn Ser Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Arg Phe Glu Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

2016-09-089_178W01_Sequence_Listing

Gly Ser Val Ser Ser Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 170
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 170

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Thr Pro Cys Gln Ser Tyr Lys Phe Lys His Arg
20 25 30

Leu Leu Leu Lys Phe Ser Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Ser
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 203

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 171
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 171

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Met Pro Glu Gln Thr Val Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Phe Phe Glu Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

Gly Ser Val Ser Ser Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 172
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 172

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 204

2016-09-089_178W01_Sequence_Listing

```

1           5           10           15
Ile Tyr Ala Thr Ile Gln Pro Glu Gln Ala Pro Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu His Phe Thr Val His Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
      50      55      60
Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
145

```

<210> 173
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 173

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1           5           10           15
Ile Trp Ala Thr Ile Glu Pro Ser Gln Thr Leu Lys Phe Lys His Arg
      20      25      30
Leu Arg Leu His Phe Ser Val Tyr Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Asp
      50      55      60
Gly Ser Val Ser Arg Tyr Gln Leu Ser Gln Ile Lys Pro Leu His Asn
      65      70      75      80

```

2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 174
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 174

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Thr Pro Cys Gln Ser Tyr Lys Phe Lys His Arg
20 25 30

Leu Leu Leu Lys Phe Ser Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Ser
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

2016-09-089_178W01_Sequence_Listing

145

<210> 175
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 175

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Thr Ile Ile Pro Ser Gln Asn Leu Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Tyr Phe Glu Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
 50 55 60

Gly Ser Val Ser Ser Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 176
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 176

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Ser Ile Cys Pro Thr Gln Ala Ala Lys Phe Lys His Arg

2016-09-089_178W01_Sequence_Listing

20

25

30

Leu Arg Leu His Phe Ala Val Phe Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Cys
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 177
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 177

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ser Ile Glu Pro Ala Gln Ser Tyr Lys Phe Lys His Arg
20 25 30

Leu Gln Leu Lys Phe Ala Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Cys Asp Ile
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

2016-09-089_178W01_Sequence_Listing

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 178
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 178

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ala Ile Met Pro Thr Gln Ser Tyr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Ala Phe Ser Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Ala
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 179

2016-09-089_178W01_Sequence_Listing

<211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 179

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Thr Ile Thr Pro Asn Gln Arg Thr Lys Phe Lys His Gln
 20 25 30

Leu Lys Leu Ala Phe Ala Val Tyr Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
 50 55 60

Gly Ser Val Ser Cys Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 180
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 180

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Ala Ile Val Pro Val Gln Ser Thr Lys Phe Lys His Arg
 20 25 30

Leu Arg Leu Tyr Phe Thr Val His Gln Lys Thr Gln Arg Arg Trp Phe
 Page 210

2016-09-089_178W01_Sequence_Listing

35

40

45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 181
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 181

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Cys Pro Val Gln Ser Leu Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Phe Phe Ala Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp His
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

2016-09-089_178W01_Sequence_Listing

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 182
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 182

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Trp Ala Ser Ile Leu Pro Glu Gln Arg Asn Lys Phe Lys His Arg
20 25 30

Leu Lys Leu Gly Phe Ser Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 183
<211> 147
<212> PRT
<213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 183

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile His Pro Cys Gln Cys Thr Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Tyr Phe Glu Val Tyr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Gln
50 55 60

Gly Ser Val Ser Ser Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 184

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 184

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Thr Ile Asp Pro Asp Gln Arg Gln Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Lys Phe Ser Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gly
Page 213

2016-09-089_178W01_Sequence_Listing

50

55

60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 185
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 185

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ala Ile Val Pro Asp Gln Ala Pro Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Phe Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

2016-09-089_178W01_Sequence_Listing

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 186
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 186

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Ser Ile Leu Pro Glu Gln Arg Asn Lys Phe Lys His Arg
 20 25 30

Leu Lys Leu Ser Phe Ser Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 187
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 187

2016-09-089_178W01_Sequence_Listing

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Ala Ile Val Pro Asp Gln Ala Pro Lys Phe Lys His Arg
20 25 30

Leu Arg Leu Phe Phe Ala Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 188
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 188

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Cys Ile Cys Pro Asp Gln Gly Tyr Lys Phe Lys His Arg
20 25 30

Leu Thr Leu Lys Phe Ser Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Leu Asp Gln
50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Glu Ile Lys Pro Leu His Asn
Page 216

65

70

75

80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 189
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 189

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Cys Ile Leu Pro Glu Gln Lys Thr Lys Phe Lys His Arg
 20 25 30

Leu Lys Leu Ser Phe Thr Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Glu Tyr Arg Leu Ser Gln Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

2016-09-089_178W01_Sequence_Listing

Val Leu Asp
145

<210> 190
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 190

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe Thr Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser His Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 191
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 191

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe Cys Val Arg Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Ser
50 55 60

Gly Ser Val Ser Ala Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 192
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 192

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
Page 219

85

90

95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 193
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 193

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
 50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

2016-09-089_178W01_Sequence_Listing

<210> 194
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 194

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 195
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 195

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Asn Phe Lys Phe Lys His Thr
 20 25 30

2016-09-089_178W01_Sequence_Listing

Leu Arg Leu Thr Phe Phe Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 196
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 196

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Gly Asn Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe Asn Val Cys Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ile Asp Arg
50 55 60

Gly Ser Val Ser Asp Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
Page 222

2016-09-089_178W01_Sequence_Listing

100

105

110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 197
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 197

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 198
<211> 147
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 198

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 199

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 199

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Tyr Pro Lys Gln Ser Ser Lys Phe Lys His His
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

2016-09-089_178W01_Sequence_Listing

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp Ser
50 55 60

Gly Ser Val Ser Gln Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 200
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 200

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Glu Gln Thr Ala Lys Phe Lys His Met
20 25 30

Leu Arg Leu Thr Phe Arg Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Asn Asp Ser
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
Page 225

2016-09-089_178W01_Sequence_Listing

115

120

125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 201
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 201

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 202
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

2016-09-089_178W01_Sequence_Listing

<400> 202

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Lys Gln Thr Ala Lys Phe Lys His His
20 25 30

Leu Cys Leu Arg Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp His
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 203

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 203

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

2016-09-089_178W01_Sequence_Listing

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 204
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 204

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Arg Val Lys Phe Lys His Phe
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 228

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 205
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 205

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Gly Cys Lys Phe Lys His Val
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 206
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 206

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 229

2016-09-089_178W01_Sequence_Listing

```

1           5           10           15
Ile Tyr Ala Arg Ile Glu Pro Arg Gln Val Cys Lys Phe Lys His Ile
      20      25      30
Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
      50      55      60
Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
145

```

<210> 207
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 207

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1           5           10           15
Ile Tyr Ala Arg Ile Glu Pro Arg Gln Cys Phe Lys Phe Lys His Cys
      20      25      30
Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
      50      55      60
Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80

```

2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 208
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 208

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Arg Phe Lys Phe Lys His Cys
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

2016-09-089_178W01_Sequence_Listing

145

<210> 209
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 209

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Phe Cys Lys Phe Lys His Ile
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
 50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 210
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 210

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ala Phe Lys Phe Lys His Ala
 Page 232

2016-09-089_178W01_Sequence_Listing

20

25

30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 211
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 211

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Cys Lys Phe Lys His Ile
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

2016-09-089_178W01_Sequence_Listing

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 212
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 212

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Cys Phe Lys Phe Lys His Gly
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 213

2016-09-089_178W01_Sequence_Listing

<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 213

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ser Ser Lys Phe Lys His Leu
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 214
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 214

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Tyr Leu Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Val Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
Page 235

2016-09-089_178W01_Sequence_Listing

35

40

45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 215
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 215

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Tyr Leu Gly Gln His Tyr Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

2016-09-089_178W01_Sequence_Listing

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 216
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 216

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Tyr Asn Ala Gln Tyr Tyr Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 217
<211> 147
<212> PRT
<213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 217

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Arg Arg Gln Asn Phe Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 218

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 218

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Arg Arg Gln Cys Val Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
Page 238

2016-09-089_178W01_Sequence_Listing

50

55

60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 219
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 219

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Tyr Arg Gln Gly Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

2016-09-089_178W01_Sequence_Listing

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 220
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 220

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Ser Gly Lys Phe Lys His Tyr
 20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
 50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 221
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 221

2016-09-089_178W01_Sequence_Listing

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ser Asp Thr
50 55 60

Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 222
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 222

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Asn Asp Tyr
50 55 60

Gly Ser Thr Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
Page 241

65

70

75

80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 223
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 223

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 20 25 30

Ile Arg Leu Thr Phe Asn Val Ala Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp His
 50 55 60

Gly Ser Asn Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

2016-09-089_178W01_Sequence_Listing

Val Leu Asp
145

<210> 224
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 224

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ser Asp Tyr
50 55 60

Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 225
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 225

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Ala Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp His
50 55 60

Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 226
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 226

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Gly Asp Tyr
50 55 60

Gly Ser Met Ser His Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
Page 244

85

90

95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 227
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 227

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Phe
 50 55 60

Gly Ser Gln Ser Gln Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

2016-09-089_178W01_Sequence_Listing

<210> 228
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 228

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 20 25 30

Ile Arg Leu Thr Phe Asn Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ser Asp Tyr
 50 55 60

Gly Ser Ile Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 229
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 229

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 20 25 30

2016-09-089_178W01_Sequence_Listing

Ile Arg Leu Thr Phe Asn Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ile Asp Tyr
50 55 60

Gly Ser Ile Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 230
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 230

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Tyr
50 55 60

Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
Page 247

2016-09-089_178W01_Sequence_Listing

100

105

110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 231
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 231

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Gly
50 55 60

Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 232
<211> 147
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 232

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Tyr Asp His
50 55 60

Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 233

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 233

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

2016-09-089_178W01_Sequence_Listing

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Cys Asp Asn
50 55 60

Gly Ser Asn Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 234
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 234

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Tyr
50 55 60

Gly Ser Thr Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
Page 250

2016-09-089_178W01_Sequence_Listing

115

120

125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 235
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 235

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Cys Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ala Asp Tyr
50 55 60

Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 236
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

2016-09-089_178W01_Sequence_Listing

<400> 236

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Met Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Leu Cys Val Arg Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Cys Asp Ser
50 55 60

Gly Ser Met Ser Ala Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 237

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 237

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Gly
50 55 60

2016-09-089_178W01_Sequence_Listing

Gly Ser Ser Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 238
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 238

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 253

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 239
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 239

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 240
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 240

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 254

2016-09-089_178W01_Sequence_Listing

```

1           5           10           15
Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
      20      25      30
Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
      50      55      60
Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
      145

```

<210> 241
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 241

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1           5           10           15
Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
      20      25      30
Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
      50      55      60
Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80

```

2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 242
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 242

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

2016-09-089_178W01_Sequence_Listing

145

<210> 243
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 243

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
 50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 244
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 244

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
 Page 257

2016-09-089_178W01_Sequence_Listing

20

25

30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 245
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 245

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

2016-09-089_178W01_Sequence_Listing

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 246
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 246

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 247

2016-09-089_178W01_Sequence_Listing

<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 247

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 248
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 248

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
Page 260

2016-09-089_178W01_Sequence_Listing

35

40

45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 249
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 249

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe Cys Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Asn Asp Ser
50 55 60

Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

2016-09-089_178W01_Sequence_Listing

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 250
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 250

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His Tyr
20 25 30

Ile Arg Leu Thr Phe Cys Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Asn Asp Ser
50 55 60

Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 251
<211> 147
<212> PRT
<213> Artificial Sequence

2016-09-089_178W01_Sequence_Listing

<220>

<223> Synthesized

<400> 251

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Asn Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Cys Asp Ser
50 55 60

Gly Ser Gln Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 252

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 252

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Phe Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Cys Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Asn
Page 263

2016-09-089_178W01_Sequence_Listing

50

55

60

Gly Ser Met Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 253
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 253

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Phe Lys Gly Gln His Trp Lys Phe Lys His His
20 25 30

Ile Arg Leu Thr Phe Cys Val Thr Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Tyr
50 55 60

Gly Ser Cys Ser Asn Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

2016-09-089_178W01_Sequence_Listing

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 254
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 254

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 255
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 255

2016-09-089_178W01_Sequence_Listing

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 256
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 256

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile Lys Pro Leu His Asn
Page 266

65

70

75

80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 257
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 257

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Glu Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

2016-09-089_178W01_Sequence_Listing

Val Leu Asp
145

<210> 258
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 258

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 259
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 259

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

2016-09-089_178W01_Sequence_Listing

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 260
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 260

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
Page 269

85

90

95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 261
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 261

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

2016-09-089_178W01_Sequence_Listing

<210> 262
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 262

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
 50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 263
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 263

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
 20 25 30

2016-09-089_178W01_Sequence_Listing

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 264
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 264

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
Page 272

2016-09-089_178W01_Sequence_Listing

100

105

110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 265
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 265

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 266
<211> 147
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 266

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 267

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 267

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

2016-09-089_178W01_Sequence_Listing

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 268
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 268

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
Page 275

2016-09-089_178W01_Sequence_Listing

115

120

125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 269
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 269

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 270
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

2016-09-089_178W01_Sequence_Listing

<400> 270

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Val Asp Gln
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 271

<211> 147

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized

<400> 271

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

2016-09-089_178W01_Sequence_Listing

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 272
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 272

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Cys Ile Glu Pro Lys Gln Thr Ser Lys Phe Lys His Arg
20 25 30

Leu Cys Leu Arg Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Asn
50 55 60

Gly Ser Val Ser Gln Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
Page 278

2016-09-089_178W01_Sequence_Listing

130

135

140

Val Leu Asp
145

<210> 273
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 273

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Tyr Pro Gly Gln His Tyr Lys Phe Lys His Tyr
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Ala
50 55 60

Gly Ser Val Ser Gln Tyr Phe Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 274
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 274

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
Page 279

2016-09-089_178W01_Sequence_Listing

```

1              5              10              15
Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Tyr
      20      25      30
Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Ile Asp Ala
      50      55      60
Gly Ser Val Ser Gly Tyr Tyr Leu Ser Glu Ile Lys Pro Leu His Asn
      65      70      75      80
Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
      85      90      95
Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
      100      105      110
Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
      115      120      125
Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
      130      135      140
Val Leu Asp
      145

```

<210> 275
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 275

```

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1              5              10      15
Ile Tyr Ala Cys Ile Glu Pro Lys Gln Thr Ser Lys Phe Lys His Arg
      20      25      30
Leu Cys Leu Arg Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
      35      40      45
Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Asn
      50      55      60
Gly Ser Val Ser Gln Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
      65      70      75      80

```


2016-09-089_178W01_Sequence_Listing

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp
145

<210> 276
<211> 147
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized

<400> 276

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Ala Lys Phe Lys His Gln
20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val Thr Asp Trp
50 55 60

Gly Ser Val Ser Gly Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
130 135 140

Val Leu Asp

145

<210> 277
 <211> 147
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 277

Lys Glu Phe Leu Leu Tyr Leu Ala Gly Phe Val Asp Gly Asp Gly Ser
 1 5 10 15

Ile Tyr Ala Arg Ile Glu Pro Arg Gln Thr Val Lys Phe Lys His Met
 20 25 30

Leu Arg Leu Thr Phe His Val Ser Gln Lys Thr Gln Arg Arg Trp Phe
 35 40 45

Leu Asp Lys Leu Val Asp Glu Ile Gly Val Gly Tyr Val His Asp Asn
 50 55 60

Gly Ser Val Ser Gln Tyr Tyr Leu Ser Gln Ile Lys Pro Leu His Asn
 65 70 75 80

Phe Leu Thr Gln Leu Gln Pro Phe Leu Lys Leu Lys Gln Lys Gln Ala
 85 90 95

Asn Leu Val Leu Lys Ile Ile Glu Gln Leu Pro Ser Ala Lys Glu Ser
 100 105 110

Pro Asp Lys Phe Leu Glu Val Cys Thr Trp Val Asp Gln Ile Ala Ala
 115 120 125

Leu Asn Asp Ser Lys Thr Arg Lys Thr Thr Ser Glu Thr Val Arg Ala
 130 135 140

Val Leu Asp
 145

<210> 278
 <211> 6214
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 278

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc ccttcccaac agttgcgcag 60

cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggtat ttccatgagc 120

gtttttcctg ttgcaatggc tggcggtaat attgttctgg atattaccag caaggccgat 180

2016-09-089_178W01_Sequence_Listing

agtttgagtt	cttctactca	ggcaagtgat	gttattacta	atcaaagaag	tattgcgaca	240
acgggttaatt	tgcgtgatgg	acagactctt	ttactcgggtg	gcctcactga	ttataaaaac	300
acttctcagg	attctggcgt	accgttcctg	tctaaaatcc	ctttaatcgg	cctcctgttt	360
agctcccgct	ctgattctaa	cgaggaaagc	acgttatacg	tgctcgtcaa	agcaaccata	420
gtacgcgccc	tgtagcggcg	cattaagcgc	ggcgggtgtg	gtgggttacgc	gcagcgtgac	480
cgctacactt	gccagcgcgc	tagcgccgcg	tcctttcgct	ttcttccctt	cctttctcgc	540
cacgttcgcc	ggctttcccc	gtcaagctct	aaatcggggg	ctcccttttag	ggttccgatt	600
tagtgcttta	cggcacctcg	accccaaaaa	acttgattag	ggtgatgggt	cacgtagtgg	660
gccatcgccc	tgatagacgg	tttttcgccc	tttgacgttg	gagtccacgt	tctttaatag	720
tggactcttg	ttccaaactg	gaacaacact	caaccctatc	tcggtctatt	cttttgattt	780
ataagggatt	ttgccgattt	cggcctattg	gttaaaaaat	gagctgattt	aacaaaaatt	840
taacgcgaat	tttaacaaaa	tattaacgct	tacaatttaa	atatttgctt	atacaatctt	900
cctgtttttg	gggcttttct	gattatcaac	cggggtagat	atgattgaca	tgctagtttt	960
acgattaccg	ttcatcgccc	tgcgcgctcg	ctcgtcact	gaggccgccc	gggcaaagcc	1020
cgggcgtcgg	gcgacctttg	gtcgcccggc	ctcagtgagc	gagcgagcgc	gcagagaggg	1080
agtggaattc	acgcgtggat	ctaatagtaa	tcaattacgg	ggtcattagt	tcatagccca	1140
tatatggagt	tccgcgttac	ataacttacg	gtaaattggc	cgcctggctg	accgcccac	1200
gacccccgcc	cattgacgtc	aataatgacg	tatgttccca	tagtaacgcc	aatagggact	1260
ttccattgac	gtcaatgggt	ggagtattta	cggtaaactg	cccacttggc	agtacatcaa	1320
gtgtatcata	tgccaagtcc	gccccctatt	gacgtcaatg	acggtaaattg	gcccgcctgg	1380
cattatgccc	agtacatgac	cttacgggac	tttctactt	ggcagtacat	ctacgtatta	1440
gtcatcgcta	ttaccatggt	gatgcgggtt	tggcagtaca	ccaatgggcg	tggatagcgg	1500
tttgactcac	ggggatttcc	aagtctccac	cccattgacg	tcaatgggag	tttgtttggc	1560
acaaaaatca	acgggacttt	ccaaaatgtc	gtaataaccc	cgccccgttg	acgcaaattg	1620
gcggtaggcg	tgtacggtgg	gaggtctata	taagcagagc	tcgttttagtg	aaccgtcaga	1680
tcactagaag	ctttattgcg	gtagtttatc	acagttaaat	tgctaacgca	gtcagtgcct	1740
ctgacacaac	agtctcgaac	ttaagctgca	gaagttggtc	gtgaggcact	gggcaggtaa	1800
gtatcaaggt	tacaagacag	gtttaaggag	accaatagaa	actgggcttg	tcgagacaga	1860
gaagactctt	gcgtttctga	taggcaccta	ttggctcttac	tgacatccac	tttgcctttc	1920
tctccacagg	tgtccactcc	cagttcaatt	acagctctta	aggctagagt	acttaatacg	1980
actcactata	ggctagccac	catggcaccg	aagaagaagc	gcaagggtgca	tatgaataca	2040
aaatataata	aagagttctt	actctactta	gcagggtttg	tagacgggtga	cggttccatc	2100
tttgcccgtg	tctttaaggg	tcaacattgg	aagttcaagc	actatattcg	tttgaccttc	2160
acgggtggctc	agaagacaca	gcgccgttgg	ttcctcgaca	agctgggtgga	cgagatcggt	2220

2016-09-089_178W01_Sequence_Listing

gtgggttacg	tgactgactg	gggcagcgtg	tcccattact	atctgtccga	gatcaagcct	2280
ttgcataatt	ttttaacaca	actacaacct	tttctaaaac	taaaacaaaa	acaagcaaat	2340
ttagttttaa	aaattattga	acaacttccg	tcagcaaaag	aatccccgga	caaattctta	2400
gaagtttgta	catgggtgga	tcaaattgca	gctctgaatg	attcgaagac	gcgtaaaaca	2460
acttctgaaa	ccgttcgtgc	tgtgctagac	agtttaccag	gatccgtggg	aggtctatcg	2520
ccatctcagg	catccagcgc	cgcctcctcg	gcttcctcaa	gcccgggttc	agggatctcc	2580
gaagcactca	gagctggagc	aggttccggc	actggataca	acaaggaatt	cctgctctac	2640
ctggcgggct	tcgtcgacgg	ggacggctcc	atctgggcct	cgatcattcc	tgagcaaggt	2700
tataagttca	agcacaggct	gcgtctctct	ttcactgtcg	ctcagaagac	acagcgccgt	2760
tggttcctcg	acaagctggg	ggacgagatc	gggtgtgggt	acgtggttga	ccagggcagc	2820
gtctccgagt	acaggctgtc	cgagatcaag	cctctgcaca	acttcctgac	ccagctccag	2880
cccttcctga	agctcaagca	gaagcaggcc	aacctcgtgc	tgaagatcat	cgagcagctg	2940
ccctccgcca	aggaatcccc	ggacaagttc	ctggagggtg	gcacctgggt	ggaccagatc	3000
gccgctctga	acgactccaa	gacccgcaag	accacttccg	aaaccgtccg	cgccgttcta	3060
gacagtctct	ccgagaagaa	gaagtcgtcc	ccctaaggta	ccagcggccg	cgactctaga	3120
tcataatcag	ccataccaca	tttgtagagg	ttttacttgc	tttaaaaaac	ctcccacacc	3180
tccccctgaa	cctgaaacat	aaaatgaatg	caattgttgt	tgttaacttg	tttattgcag	3240
cttataatgg	ttacaaataa	agcaatagca	tcacaaatth	cacaaataaa	gcattttttt	3300
cactgcattc	tagttgtggg	ttgtccaaac	tcatcaatgt	atcttaaggc	gggaattgat	3360
ctgaggaacc	cctagtgatg	gagttggcca	ctccctctct	gcgcgctcgc	tcgctcactg	3420
aggccgggcg	accaaaggtc	gcccgcgccc	cgggcaaagc	ccgggcgctc	ggcgaccttt	3480
ggtcgccccg	cctcagttag	cgagcgagcg	cgcagagagg	gagtggccaa	ccccccccc	3540
cccccccg	cgattctctt	gtttgctcca	gactctcagg	caatgacctg	atagcctttg	3600
tagagacctc	tcaaaaatag	ctaccctctc	cggcatgaat	ttatcagcta	gaacggttga	3660
atatcatatt	gatggtgatt	tgactgtctc	cggcctttct	caccgctttg	aatctttacc	3720
tacacattac	tcaggcattg	catttaaaat	atatgagggt	tctaaaaatt	tttatccttg	3780
cgttgaaata	aaggcttctc	ccgcaaaagt	attacagggt	cataatgttt	ttggtacaac	3840
cgatttagct	ttatgctctg	aggctttatt	gcttaatttt	gctaattctt	tgcttgcct	3900
gtatgattta	ttggatgttg	gaattcctga	tgcggtatth	tctccttacg	catctgtgcg	3960
gtatttcaca	ccgcatatgg	tgactctca	gtacaatctg	ctctgatgcc	gcatagttaa	4020
gccagccccg	acaccgcca	acaccgctg	acgcgccctg	acgggcttgt	ctgctcccg	4080
catccgctta	cagacaagct	gtgaccgtct	ccgggagctg	catgtgtcag	aggttttcac	4140
cgtcatcacc	gaaacgcgcg	agacgaaagg	gcctcgtgat	acgcctatth	ttataggtta	4200
atgtcatgat	aataatgggt	tcttagacgt	cagggtggcac	ttttcgggga	aatgtgcgcg	4260

2016-09-089_178W01_Sequence_Listing

gaacccttat	ttgtttat	ttctaaatac	attcaaatac	gtatccgctc	atgagacaat	4320
aaccctgata	aatgcttcaa	taatattgaa	aaaggaagag	tatgagtatt	caacatttcc	4380
gtgtcgccct	tattcccttt	tttgcggcat	tttgccttcc	tgtttttgct	caccagaaa	4440
cgctggtgaa	agtaaaagat	gctgaagatc	agttgggtgc	acgagtgggt	tacatcgaa	4500
tggatctcaa	cagcggtaag	atccttgaga	gttttcgccc	cgaagaacgt	tttccaatga	4560
tgagcacttt	taaagttctg	ctatgtggcg	cggtattatc	ccgtattgac	gccgggcaag	4620
agcaactcgg	tcgccgata	cactattctc	agaatgactt	ggttgagtac	tcaccagtca	4680
cagaaaagca	tcttacggat	ggcatgacag	taagagaatt	atgcagtgtc	gccataacca	4740
tgagtgataa	cactgcggcc	aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	4800
ccgctttttt	gcacaacatg	ggggatcatg	taactcgcct	tgatcgttgg	gaaccggagc	4860
tgaatgaagc	cataccaaac	gacgagcgtg	acaccacgat	gcctgtagca	atggcaacaa	4920
cgttgcgcaa	actattaact	ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	4980
actggatgga	ggcggataaa	gttgcaggac	cacttctgct	ctcggccctt	ccggctggct	5040
ggtttattgc	tgataaatct	ggagccggtg	agcgtgggtc	tcgcggtatc	attgcagcac	5100
tggggccaga	tggttaagccc	tcccgtatcg	tagttatcta	cacgacgggg	agtcaggcaa	5160
ctatggatga	acgaaataga	cagatcgctg	agatagggtc	ctcactgatt	aagcattggt	5220
aactgtcaga	ccaagtttac	tcatatatac	tttagattga	tttaaaactt	catttttaat	5280
ttaaaaggat	ctaggtgaag	atcctttttg	ataatctcat	gaccaaatac	ccttaacgtg	5340
agttttcgtt	ccactgagcg	tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	5400
ctttttttct	gcgcgtaatc	tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcggtag	5460
tttgtttgcc	ggatcaagag	ctaccaactc	tttttccgaa	ggtaactggc	ttcagcagag	5520
cgcagatacc	aaatactgtc	cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	5580
ctgtagcacc	gcctacatac	ctcgtctctg	taatcctgtt	accagtggct	gctgccagtg	5640
gcgataagtc	gtgtcttacc	gggttggact	caagacgata	gttaccggat	aaggcgcagc	5700
ggtcgggctg	aacggggggg	tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	5760
aactgagata	cctacagcgt	gagctatgag	aaagcgccac	gcttcccga	gggagaaagg	5820
cggacaggta	tccggtaagc	ggcagggtcg	gaacaggaga	gcgcacgagg	gagcttccag	5880
ggggaaacgc	ctggtatctt	tatagtcctg	tcgggtttcg	ccacctctga	cttgagcgtc	5940
gattttttgt	atgctcgtca	ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	6000
ttttacgggt	cctggccttt	tgctggcctt	ttgctcacat	gttctttcct	gcgttatccc	6060
ctgattctgt	ggataaccgt	attaccgcct	ttgagtgagc	tgataaccgt	cgccgcagcc	6120
gaacgaccga	gcgcagcgag	tcagtgagcg	aggaagcgga	agagcgccca	atacgcaaac	6180
cgctctccc	cgcgcttgg	ccgattcatt	aatg			6214

2016-09-089_178W01_Sequence_Listing

<210> 279
 <211> 6214
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 279

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc ctttcccaac agttgcgcag	60
cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggtat ttccatgagc	120
gtttttcctg ttgcaatggc tggcggtaat attgttcttg atattaccag caaggccgat	180
agtttgagtt cttctactca ggcaagtgat gttattacta atcaaagaag tattgcgaca	240
acgggttaatt tgcgtgatgg acagactctt ttactcgggt gcctcactga ttataaaaac	300
acttctcagg attctggcgt accgttcctg tctaaaatcc ctttaatcgg cctcctgttt	360
agctcccgct ctgattctaa cgaggaaagc acgttatacg tgctcgtcaa agcaaccata	420
gtacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac	480
cgctacactt gccagcgcgc tagcgcgcgc tcctttcgtt ttcttccctt cttttctcgc	540
cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttccgatt	600
tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatgggt cacgtagtgg	660
gccatcgccc tgatagacgg tttttcgccc ttgacgttg gagtccacgt tctttaatat	720
tggactcttg ttccaaactg gaacaacact caaccctatc tcgggtctatt cttttgattt	780
ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt	840
taacgcgaat ttttaaaaaa tattaacgct tacaatttaa atatttgctt atacaatctt	900
cctgtttttg gggcttttct gattatcaac cgggggtacat atgattgaca tgctagtttt	960
acgattaccg ttcacgcgcc tgcgcgctcg ctgcgtcact gaggccgccc gggcaaagcc	1020
cgggcgtcgg gcgacctttg gtcgcccggc ctacgtgagc gagcgagcgc gcagagaggg	1080
agtggaattc acgcgtggat ctaatagtaa tcaattacgg ggtcattagt tcatagccca	1140
tatatggagt tccgcgttac ataacttacg gtaaatggcc cgcttggtg accgcccaac	1200
gacccccgcc cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact	1260
ttccattgac gtcaatgggt ggagtattta cggtaaatg cccacttggc agtacatcaa	1320
gtgtatcata tgccaagtcc gcccctatt gacgtcaatg acggtaaatg gcccgctgg	1380
cattatgccc agtacatgac cttacgggac tttcctactt ggcagtacat ctacgtatta	1440
gtcatcgcta ttaccatgtt gatgcggttt tggcagtaca ccaatgggcg tggatagcgg	1500
tttgactcac ggggatttcc aagtctccac ccattgacg tcaatgggag tttgtttggc	1560
acaaaaatca acgggacttt ccaaaatgtc gtaataaccc cgccccgttg acgcaaatgg	1620
gcggtaggcg tgtacggtgg gaggtctata taagcagagc tcgttttagtg aaccgtcaga	1680
tcactagaag ctttattgcg gtagtttatc acagttaaatt tgctaacgca gtcagtgcct	1740

2016-09-089_178W01_Sequence_Listing

ctgacacaac	agtctcgaac	ttaagctgca	gaagttggct	gtgaggcact	gggcaggtaa	1800
gtatcaaggt	tacaagacag	gtttaaggag	accaatagaa	actgggcttg	tcgagacaga	1860
gaagactctt	gcgtttctga	taggcaccta	ttggctcttac	tgacatccac	tttgcctttc	1920
tctccacagg	tgtccactcc	cagttcaatt	acagctctta	aggctagagt	acttaatacg	1980
actcactata	ggctagccac	catggcaccg	aagaagaagc	gcaagggtgca	tatgaatata	2040
aaatataata	aagagttctt	actctactta	gcagggtttg	tagacggtga	cggttccatc	2100
tatgcccgtg	tctttaaggg	tcaacattgg	aagttcaagc	actatattcg	tttgaccttc	2160
tgtgtgcggc	agaagacaca	gcgccgttgg	ttcctcgaca	agctgggtgga	cgagatcggt	2220
gtgggttacg	tgactgactc	tggcagcggt	tccgcttact	atctgtccga	gatcaagcct	2280
ttgcataatt	ttttaacaca	actacaacct	tttctaaaac	taaaacaaaa	acaagcaaat	2340
ttagttttta	aaattattga	acaacttccg	tcagcaaaag	aatccccgga	caaattctta	2400
gaagtttgta	catgggtgga	tcaaattgca	gctctgaatg	attcgaagac	gcgtaaaaca	2460
acttctgaaa	ccgttcgtgc	tgtgctagac	agtttaccag	gatccgtggg	aggtctatcg	2520
ccatctcagg	catccagcgc	cgcctcctcg	gcttcctcaa	gcccgggttc	agggatctcc	2580
gaagcactca	gagctggagc	aggttccggc	actggatata	acaaggaatt	cctgctctac	2640
ctggcgggct	tcgtcgacgg	ggacggctcc	atctgggcct	cgatcattcc	tgagcaaggt	2700
tataagttca	agcacaggct	gcgtctctct	ttcactgtcg	ctcagaagac	acagcgccgt	2760
tggttcctcg	acaagctggt	ggacgagatc	ggtgtgggtt	acgtgggtga	ccagggcagc	2820
gtctccgagt	acaggctgtc	cgagatcaag	cctctgcaca	acttcctgac	ccagctccag	2880
cccttcctga	agctcaagca	gaagcaggcc	aacctcgtgc	tgaagatcat	cgagcagctg	2940
ccctccgcca	aggaatcccc	ggacaagttc	ctggagggtg	gcacctgggt	ggaccagatc	3000
gccgctctga	acgactccaa	gacccgcaag	accacttccg	aaaccgtccg	cgccgttcta	3060
gacagtctct	ccgagaagaa	gaagtcgtcc	ccctaaggta	ccagcggccg	cgactctaga	3120
tcataatcag	ccataccaca	tttgtagagg	ttttacttgc	tttaaaaaac	ctcccacacc	3180
tccccctgaa	cctgaaacat	aaaatgaatg	caattgttgt	tgtttaactg	tttattgcag	3240
cttataatgg	ttacaaataa	agcaatagca	tcacaaattt	cacaaataaa	gcattttttt	3300
cactgcattc	tagttgtggg	ttgtccaaac	tcataaatgt	atcttaaggc	gggaattgat	3360
ctgaggaacc	cctagtgatg	gagttggcca	ctccctctct	gcgcgctcgc	tcgctcactg	3420
aggccggggc	accaaaggtc	gcccgcgccc	cgggcaaagc	ccgggcgtcg	ggcgaccttt	3480
ggtcgccccg	cctcagttag	cgagcgagcg	cgagagagg	gagtggtccaa	cccccccccc	3540
cccccccccg	cgattctctt	gtttgctcca	gactctcagg	caatgacctg	atagcctttg	3600
tagagacctc	tcaaaaatag	ctaccctctc	cggcatgaat	ttatcagcta	gaacggttga	3660
atatcatatt	gatggtgatt	tgactgtctc	cggcctttct	caccggtttg	aatctttacc	3720
tacacattac	tcaggcattg	catttaaaat	atatgagggt	tctaaaaaatt	tttatccttg	3780

2016-09-089_178W01_Sequence_Listing

cggtgaaata	aaggcttctc	ccgcaaaagt	attacaggg	cataatgttt	ttggtacaac	3840
cgatttagct	ttatgctctg	aggctttatt	gcttaatfff	gctaattctt	tgcttgcct	3900
gtatgattta	ttggatgttg	gaattcctga	tgcggtatff	tctccttacg	catctgtcg	3960
gtatttcaca	ccgcatatgg	tgactctca	gtacaatctg	ctctgatgcc	gcatagttaa	4020
gccagccccg	acacccgcc	acacccgctg	acgcgccctg	acgggcttgt	ctgctcccg	4080
catccgctta	cagacaagct	gtgaccgtct	ccgggagctg	catgtgtcag	aggttttcac	4140
cgtcatcacc	gaaacgcgcg	agacgaaagg	gcctcgtgat	acgcctatff	ttataggtta	4200
atgtcatgat	aataatggff	tcttagacgt	cagggtggcac	ttttcgggga	aatgtgcgcg	4260
gaacccctat	ttgtttatff	ttctaaatac	attcaaataf	gtatccgctc	atgagacaaf	4320
aaccctgata	aatgcttcaa	taatattgaa	aaaggaagag	tatgagtatt	caacattttc	4380
gtgtcgccct	tattccctff	tttgcgcat	tttgcccttc	tgtttttgct	caccagaaa	4440
cgctggtgaa	agtaaaagat	gctgaagatc	agttgggtgc	acgagtgggt	tacatcgaac	4500
tggatctcaa	cagcggtaag	atccttgaga	gttttcgccc	cgaagaacgt	tttccaatga	4560
tgagcactff	taaagtcttg	ctatgtggcg	cggattatc	ccgtattgac	gccgggcaag	4620
agcaactcgg	tcgccgcata	cactattctc	agaatgactt	ggttgagtac	tcaccagtca	4680
cagaaaagca	tcttacggat	ggcatgacag	taagagaatt	atgcagtgct	gccataacca	4740
tgagtgataa	cactgcggcc	aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	4800
ccgctttfff	gcacaacatg	ggggatcatg	taactcgcct	tgatcgttgg	gaaccggagc	4860
tgaatgaagc	cataccaaac	gacgagcgtg	acaccacgat	gcctgtagca	atggcaacaa	4920
cgttgcgcaa	actattaact	ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	4980
actggatgga	ggcggataaa	gttgaggac	cacttctgcg	ctcgccctt	ccggctggct	5040
ggtttattgc	tgataaatct	ggagccggtg	agcgtgggtc	tcgcggtatc	attgcagcac	5100
tggggccaga	tggtaaagcc	tcccgtatcg	tagttatcta	cacgacgggg	agtcaggcaa	5160
ctatggatga	acgaaataga	cagatcgctg	agataggtgc	ctcactgatt	aagcattggt	5220
aactgtcaga	ccaagtffac	tcatatatac	tttagattga	tttaaaactt	catttttaaf	5280
ttaaaaggat	ctaggtgaag	atcctttffg	ataatctcat	gaccaaatac	ccttaacgtg	5340
agttttcgff	ccactgagcg	tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	5400
ctttttttct	gcgcgtaatc	tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcggtgg	5460
tttgtttgcc	ggatcaagag	ctaccaactc	tttttccgaa	ggtaactggc	ttcagcagag	5520
cgcagatacc	aaatactgtc	cttctagtgt	agccgtagtt	aggccaccac	ttcaagaact	5580
ctgtagcacc	gcctacatac	ctcgctctgc	taatcctgff	accagtggct	gctgccagtg	5640
gcgataagtc	gtgtcttacc	gggttggaact	caagacgata	gttaccggat	aaggcgcagc	5700
ggtcgggctg	aacggggggg	tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	5760
aactgagata	cctacagcgt	gagctatgag	aaagcgccac	gcttcccga	gggagaaaagg	5820

2016-09-089_178W01_Sequence_Listing

cggacaggta tccggtaagc ggcaggggtcg gaacaggaga gcgcacgagg gagcttccag	5880
ggggaaacgc ctggtatctt tatagtcctg tcggggtttcg ccacctctga cttgagcgtc	5940
gattttttgtg atgctcgtca gggggggcgga gcctatggaa aaacgccagc aacgcggcct	6000
ttttacgggtt cctggccttt tgctggcctt ttgctcacat gttctttcct gcgttatccc	6060
ctgattctgt ggataaccgt attaccgcct ttgagtgage tgataaccgt cgccgcagcc	6120
gaacgaccga gcgcagcgag tcagtgageg aggaagcgga agagcgcca atacgcaaac	6180
cgctctccc cgcggttg cggattcatt aatg	6214

<210> 280
 <211> 5888
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 280

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc cttcccaac agttgcgcag	60
cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggat ttccatgagc	120
gtttttcctg ttgcaatggc tggcggtaat attgttctgg atattaccag caaggccgat	180
agtttgagtt cttctactca ggcaagtgat gttattacta atcaaagaag tattgcgaca	240
acgggttaatt tgcgtgatgg acagactctt ttactcgggtg gcctcactga ttataaaaac	300
acttctcagg attctggcgt accgttcctg tctaaaatcc ctttaatcgg cctcctgttt	360
agctcccgct ctgattctaa cgaggaaagc acgttatacg tgctcgtcaa agcaaccata	420
gtacgcgccc tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac	480
cgctacactt gccagcgcgc tagcgcgcgc tcctttcgtt ttcttccctt cctttctcgc	540
cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctcccttttag ggttccgatt	600
tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatgggt cacgtagtgg	660
gccatcgcgc tgatagacgg tttttcgcgc tttagcgttg gagtccacgt tctttaatag	720
tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgattt	780
ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt	840
taacgcgaat tttaacaaaa tattaacgtt tacaatttaa atatttgctt atacaatctt	900
cctgtttttt gggcttttct gattatcaac cggggtacat atgattgaca tgctagtttt	960
acgattaccg ttcatcgcgc tgcgcgctcg ctcgctcact gaggccgccc gggcaaagcc	1020
cgggcgtcgg gcgaccttg gtcgcccggc ctcagtgage gagcgagcgc gcagagaggg	1080
agtggaaatt acgcgtgggc ccagaagcc tgggtggttg ttgtccttct caggggaaaa	1140
gtgaggcggc cccttgagg aaggggcccg gcagaatgat ctaatcggat tccaagcagc	1200
tcaggggatt gtctttttct agcaccttct tgccactcct aagcgtcctc cgtgaccccg	1260
gctgggattt agcctggtgc tgtgtcagcc ccgggctccc aggggcttcc cagtgggtccc	1320

2016-09-089_178W01_Sequence_Listing

caggaaccct	cgacagggcc	agggcgtctc	tctcgtccag	caagggcagg	gacggggccac	1380
aggccaaggg	caagctttat	tgcggtagtt	tatcacagtt	aaattgctaa	cgcagtcagt	1440
gcttctgaca	caacagtctc	gaacttaagc	tgcagaagtt	ggtcgtgagg	cactggggcag	1500
gtaagtatca	aggttacaag	acaggtttta	ggagaccaat	agaaactggg	cttgctcgaga	1560
cagagaagac	tcttgcgttt	ctgataggca	cctattggtc	ttactgacat	ccactttgcc	1620
tttctctcca	caggtgtcca	ctcccagttc	aattacagct	cttaaggcta	gagtacttaa	1680
tacgactcac	tataggctag	ccaccatggc	accgaagaag	aagcgcaagg	tgcatatgaa	1740
tacaaaatat	aataaagagt	tcttactcta	cttagcaggg	tttgtagacg	gtgacggttc	1800
catctttgcc	cgtatcttta	aggggtcaaca	ttggaagttc	aagcactata	ttcgtttgac	1860
cttcacggtg	gctcagaaga	cacagcgccg	ttggttcctc	gacaagctgg	tggacgagat	1920
cgggtgtggg	tacgtgactg	actggggcag	cgtgtcccat	tactatctgt	ccgagatcaa	1980
gcctttgcat	aattttttta	cacaactaca	accttttcta	aaactaaaac	aaaaacaagc	2040
aaatttagtt	ttaaaaatta	ttgaacaact	tccgtcagca	aaagaatccc	cggacaaatt	2100
cttagaagtt	tgtacatggg	tggatcaa	tgcagctctg	aatgattcga	agacgcgtaa	2160
aacaacttct	gaaaccgttc	gtgctgtgct	agacagttta	ccaggatccg	tgggaggtct	2220
atcgccatct	caggcatcca	gcgccgcac	ctcggcttcc	tcaagcccgg	gttcagggat	2280
ctccgaagca	ctcagagctg	gagcaggttc	cggcactgga	tacaacaagg	aattcctgct	2340
ctacctggcg	ggcttcgtcg	acggggacgg	ctccatctgg	gcctcgatca	ttcctgagca	2400
aggttataag	ttcaagcaca	ggctgctgtc	ctctttcact	gtcgctcaga	agacacagcg	2460
ccgttggttc	ctcgacaagc	tgggtggacg	gatcgggtgtg	ggttacgtgg	ttgaccaggg	2520
cagcgtctcc	gagtacaggc	tgtccgagat	caagcctctg	cacaacttcc	tgaccagct	2580
ccagcccttc	ctgaagctca	agcagaagca	ggccaacctc	gtgctgaaga	tcacgcagca	2640
gctgccctcc	gccaaggaat	ccccggacaa	gttcctggag	gtgtgcacct	gggtggacca	2700
gatcgccgct	ctgaacgact	ccaagaccg	caagaccact	tccgaaaccg	tccgcgccgt	2760
tctagacagt	ctctccgaga	agaagaagtc	gtccccctaa	gcggccgcga	ctctagatca	2820
taatcagcca	taccacattt	gtagaggttt	tacttgcttt	aaaaaacctc	ccacacctcc	2880
ccctgaacct	gaaacataaa	atgaatgcaa	ttgttggtgt	taacttgttt	attgcagctt	2940
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	3000
tgcatcttag	ttgtggtttg	tccaaactca	tcaatgtatc	ttaaggcggg	aattgatcta	3060
ggaaccctta	gtgatggagt	tggccactcc	ctctctgcgc	gctcgtcgc	tactgaggc	3120
cggccgggca	aagccggggc	gtcggggcgac	ctttggctgc	cgggcctcag	tgagcgagcg	3180
agcgcgcaga	gagggagtgg	ccaaccccc	ccccccccc	ccggcgattc	tcttgtttgc	3240
tccagactct	caggcaatga	cctgatagcc	tttgtagaga	cctctcaaaa	atagctaccc	3300
tctccggcat	gaatttatca	gctagaacgg	ttgaatatca	tattgatggg	gatttgactg	3360

2016-09-089_178W01_Sequence_Listing

tctccggcct	ttctcacccg	tttgaatctt	tacctacaca	ttactcaggc	attgcattta	3420
aaatatatga	gggttctaaa	aatTTTTatc	cttgcggtga	aataaaggct	tctcccgcaa	3480
aagtattaca	gggtcataat	gtttttggta	caaccgattt	agctttatgc	tctgaggcct	3540
tattgcttaa	ttttgcta	tctttgcctt	gcctgtatga	tttattggat	gttggaattc	3600
ctgatgcggt	atTTTctcct	tacgcatctg	tgcggtatTT	cacaccgcat	atgggtgact	3660
ctcagtacaa	tctgctctga	tgccgcatag	ttagccagc	cccgacaccc	gccaacaccc	3720
gctgacgcgc	cctgacgggc	ttgtctgctc	ccggcatccg	cttacagaca	agctgtgacc	3780
gtctccggga	gctgcatgtg	tcagaggTTT	tcaccgtcat	caccgaaacg	cgcgagacga	3840
aagggcctcg	tgatacgctt	atTTTTatag	gttaatgtca	tgataataat	ggTTTTcttag	3900
acgtcagggtg	gcactTTTcg	gggaaatgtg	cgcggaaccc	ctatTTgttt	atTTTTctaa	3960
atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaatgct	tcaataatat	4020
tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	ccTTtattcc	ctTTTTtgcg	4080
gcattTTgcc	ttcctgTTTT	tgctcaccca	gaaacgctgg	tgaaagtaaa	agatgctgaa	4140
gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	taagatcctt	4200
gagagTTTTc	gccccgaaga	acgtTTTcca	atgatgagca	ctTTTaaagt	tctgctatgt	4260
ggcgcggtat	tatcccgtat	tgacgccggg	caagagcaac	tcggtcgccg	catacactat	4320
tctcagaatg	acttggttga	gtactcacca	gtcacagaaa	agcatcttac	ggatggcatg	4380
acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataaactgc	ggccaactta	4440
cttctgacaa	cgatcggagg	accgaaggag	ctaaccgctt	TTTTgcacaa	catgggggat	4500
catgtaactc	gccttgatcg	ttgggaaccg	gagctgaatg	aagccatacc	aaacgacgag	4560
cgtgacacca	cgatgcctgt	agcaatggca	acaacgttgc	gcaaactatt	aactggcgaa	4620
ctacttactc	tagcttcccg	gcaacaatta	atagactgga	tggaggcgga	taaagttgca	4680
ggaccacttc	tgcgctcggc	ccttccggct	ggctggTTta	ttgctgataa	atctggagcc	4740
ggtgagcgtg	ggtctcgcgg	tatcattgca	gactggggc	cagatggtaa	gccctcccgt	4800
atcgtagtta	tctacacgac	ggggagtcag	gcaactatgg	atgaacgaaa	tagacagatc	4860
gctgagatag	gtgcctcact	gattaagcat	tggtaaactgt	cagaccaagt	ttactcatat	4920
atactTTaga	ttgatttaaa	acttcatttt	taatttaaaa	ggatctaggt	gaagatcctt	4980
tttgataatc	tcatgaccaa	aatcccttaa	cgtgagTTTT	cgttccactg	agcgtcagac	5040
cccgtagaaa	agatcaaagg	atcttcttga	gatcctTTTT	ttctgcgcgt	aatctgctgc	5100
ttgcaaacaa	aaaaaccacc	gctaccagcg	gtggtttgtt	tgccggatca	agagctacca	5160
actctTTTTc	cgaaggtaac	tggcttcagc	agagcgcaga	taccaaatac	tgtccttcta	5220
gtgtagccgt	agttaggcca	ccacttcaag	aactctgtag	caccgcctac	atacctcgct	5280
ctgctaatac	tgttaccagt	ggctgctgcc	agtggcgata	agtcgtgtct	taccgggttg	5340
gactcaagac	gatagttacc	ggataaggcg	cagcggtcgg	gctgaacggg	gggttcgtgc	5400

2016-09-089_178W01_Sequence_Listing

acacagccca gcttggagcg aacgacctac accgaactga gataacctaca gcgtgagcta	5460
tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg	5520
gtcggaacag gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt	5580
cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg	5640
cggagcctat ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg	5700
ccttttgctc acatgttctt tcctgcgtaa tcccctgatt ctgtggataa ccgtattacc	5760
gcctttgagt gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg	5820
agcgaggaag cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt	5880
cattaatg	5888

<210> 281
 <211> 5888
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthesized

<400> 281

cagcagctgg cgtaatagcg aagaggcccg caccgatcgc ctttcccaac agttgcgcag	60
cctgaatggc gaatggaatt ccagacgatt gagcgtcaaa atgtaggtat ttccatgagc	120
gtttttcctg ttgcaatggc tggcggtaat attgttctgg atattaccag caaggccgat	180
agtttgagtt cttctactca ggcaagtgat gttattacta atcaaagaag tattgcgaca	240
acggttaatt tgcgtgatgg acagactctt ttactcgggtg gcctcactga ttataaaaac	300
acttctcagg attctggcgt accgttcctg tctaaaatcc ctttaatcgg ctcctgtttt	360
agctcccgct ctgattctaa cgaggaaagc acgttatacg tgctcgtcaa agcaaccata	420
gtacgcgccc tgtagcggcg cattaagcgc ggcggtgtg gtggttacgc gcagcgtgac	480
cgctacactt gccagcgcgc tagcgcgcgc tcctttcgtt ttcttccctt cttttctcgc	540
cacgttcgcc ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttccgatt	600
tagtgcttta cggcacctcg accccaaaaa acttgattag ggtgatgggt cagctagtgg	660
gccatcgcgc tgatagacgg tttttcgcgc ttgacgttg gagtccacgt tctttaatag	720
tggactcttg ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgattt	780
ataagggatt ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt	840
taacgcgaat tttacaaaaa tattaacgtt tacaatttaa atatttgctt atacaatctt	900
cctgtttttg gggcttttct gattatcaac cggggtacat atgattgaca tgctagtttt	960
acgattaccg ttcacgcgcc tgcgcgctcg ctcgctcact gaggccgccc gggcaaagcc	1020
cgggcgtcgg gcgacctttg gtcgcccggc ctcagtgagc gagcgagcgc gcagagaggg	1080
agtggaattc acgcgtgggc ccagaagcc tgggtggttgt ttgtccttct caggggaaaa	1140

2016-09-089_178W01_Sequence_Listing

gtgaggcggc	cccttggagg	aaggggcccg	gcagaatgat	ctaatacggat	tccaagcagc	1200
tcaggggatt	gtctttttct	agcaccttct	tgccactcct	aagcgtcctc	cgtgaccccg	1260
gctgggattt	agcctggtgc	tgtgtcagcc	ccgggctccc	aggggcttcc	cagtgggtccc	1320
caggaaccct	cgacagggcc	agggcgtctc	tctcgtccag	caagggcagg	gacggggccac	1380
aggccaaggg	caagctttat	tgcggtagtt	tatcacagtt	aaattgctaa	cgcagtcagt	1440
gcttctgaca	caacagtctc	gaacttaagc	tgcaagaatt	ggtcgtgagg	cactggggcag	1500
gtaagtatca	aggttacaag	acaggtttaa	ggagaccaat	agaaactggg	cttgctcgaga	1560
cagagaagac	tcttgcgttt	ctgataggca	cctattggtc	ttactgacat	ccactttggc	1620
tttctctcca	caggtgtcca	ctcccagttc	aattacagct	cttaaggcta	gagtacttaa	1680
tacgactcac	tataggctag	ccaccatggc	accgaagaag	aagcgcaagg	tgcatatgaa	1740
tacaaaaatat	aataaagagt	tcttactcta	cttagcaggg	tttgtagacg	gtgacggttc	1800
catctatgcc	cgtatcttta	agggtaaca	ttggaagttc	aagcactata	ttcgtttgac	1860
cttctgtgtg	cggcagaaga	cacagcgccg	ttggttcctc	gacaagctgg	tggacgagat	1920
cgggtgtgggt	tacgtgactg	actctggcag	cgtttccgct	tactatctgt	ccgagatcaa	1980
gcctttgcat	aattttttaa	cacaactaca	accttttcta	aaactaaaac	aaaaacaagc	2040
aaatttagtt	ttaaaaatta	ttgaacaact	tccgtcagca	aaagaatccc	cggacaaatt	2100
cttagaagtt	tgtacatggg	tggatcaa	at	aatgattcga	agacgcgtaa	2160
aacaacttct	gaaaccgttc	gtgctgtgct	agacagttta	ccaggatccg	tgggaggtct	2220
atcgccatct	caggcatcca	gcgccgcac	ctcggcttcc	tcaagcccgg	gttcagggat	2280
ctccgaagca	ctcagagctg	gagcaggttc	cggcactgga	tacaacaagg	aattcctgct	2340
ctacctggcg	ggcttcgtcg	acggggacgg	ctccatctgg	gcctcgatca	ttcctgagca	2400
aggttataag	ttcaagcaca	ggctgctgt	ctcttttact	gtcgctcaga	agacacagcg	2460
ccgttggttc	ctcgacaagc	tgggtggacga	gatcgggtgtg	ggttacgtgg	ttgaccaggg	2520
cagcgtctcc	gagtacaggc	tgtccgagat	caagcctctg	cacaacttcc	tgaccagct	2580
ccagcccttc	ctgaagctca	agcagaagca	ggccaacctc	gtgctgaaga	tcacgcagca	2640
gctgccctcc	gccaaaggaat	ccccggacaa	gttcctggag	gtgtgcacct	gggtggacca	2700
gatcgccgct	ctgaacgact	ccaagaccg	caagaccact	tccgaaaccg	tccgcgccgt	2760
tctagacagt	ctctccgaga	agaagaagtc	gtccccctaa	gcggccgcga	ctctagatca	2820
taatcagcca	taccacattt	gtagaggttt	tacttgcttt	aaaaaacctc	ccacacctcc	2880
ccctgaacct	gaaacataaa	atgaatgcaa	ttgttggtgt	taacttgttt	attgcagctt	2940
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	3000
tgcatcttag	ttgtggtttg	tccaaactca	tcaatgtatc	ttaaggcggg	aattgatcta	3060
ggaaccccta	gtgatggagt	tggccactcc	ctctctgcgc	gctcgtcgc	tactgagggc	3120
cgcccgggca	aagcccgggc	gtcgggcgac	ctttggtcgc	ccggcctcag	tgagcgagcg	3180

2016-09-089_178W01_Sequence_Listing

agcgcgcaga	gagggagtg	ccaaccccc	ccccccccc	cggcgattc	tcttgtttgc	3240
tccagactct	caggcaatga	cctgatagcc	tttgtagaga	cctctcaaaa	atagctaccc	3300
tctccggcat	gaatttatca	gctagaacgg	ttgaatatca	tattgatggt	gatttgactg	3360
tctccggcct	ttctcacccg	tttgaatctt	tacctacaca	ttactcaggc	attgcattta	3420
aaatatatga	gggttctaaa	aatttttatc	cttgcgttga	aataaaggct	tctcccgcaa	3480
aagtattaca	gggtcataat	gtttttggta	caaccgattt	agctttatgc	tctgaggctt	3540
tattgcttaa	ttttgcta	tctttgcctt	gcctgtatga	tttattggat	gttggaattc	3600
ctgatgcggt	atcttctcct	tacgcatctg	tgcggtat	cacaccgcat	atggtgcact	3660
ctcagtacaa	tctgctctga	tgccgcatag	ttaagccagc	cccgaacccc	gccaacaccc	3720
gctgacgcgc	cctgacgggc	ttgtctgctc	ccggcatccg	cttacagaca	agctgtgacc	3780
gtctccggga	gctgcatgtg	tcagaggttt	tcaccgtcat	caccgaaacg	cgcgagacga	3840
aagggcctcg	tgatacgctt	atctttatag	gttaatgtca	tgataataat	ggtttcttag	3900
acgtcaggtg	gcacttttcg	gggaaatgtg	cgcggaaccc	ctatttgttt	atctttctaa	3960
atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaatgct	tcaataatat	4020
tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	cccttattcc	cttttttgcg	4080
gcattttgcc	ttcctgtttt	tgctcaccca	gaaacgctgg	tgaaagtaaa	agatgctgaa	4140
gatcagttgg	gtgcacgagt	gggttacatc	gaactggatc	tcaacagcgg	taagatcctt	4200
gagagttttc	gccccgaaga	acgttttcca	atgatgagca	cttttaaggt	tctgctatgt	4260
ggcgcggtat	tatcccgtat	tgacgccggg	caagagcaac	tcggtcgccg	catacactat	4320
tctcagaatg	acttggttga	gtactcacca	gtcacagaaa	agcatcttac	ggatggcatg	4380
acagtaagag	aattatgcag	tgctgccata	accatgagtg	ataaactgc	ggccaactta	4440
cttctgacaa	cgatcggagg	accgaaggag	ctaaccgctt	ttttgcacaa	catgggggat	4500
catgtaactc	gccttgatcg	ttgggaaccg	gagctgaatg	aagccatacc	aaacgacgag	4560
cgtgacacca	cgatgcctgt	agcaatggca	acaacgttgc	gcaaactatt	aactggcgaa	4620
ctacttactc	tagcttccc	gcaacaatta	atagactgga	tggaggcgga	taaagttgca	4680
ggaccacttc	tgcgctcggc	ccttcgggct	ggctggttta	ttgctgataa	atctggagcc	4740
ggtgagcgtg	ggtctcgcgg	tatcattgca	gcactggggc	cagatggtaa	gccctcccgt	4800
atcgtagtta	tctacacgac	ggggagtcag	gcaactatgg	atgaacgaaa	tagacagatc	4860
gctgagatag	gtgcctcact	gattaagcat	tggttaactgt	cagaccaagt	ttactcatat	4920
atactttaga	ttgatttaaa	acttcatttt	taatttaaaa	ggatctaggt	gaagatcctt	4980
tttgataatc	tcatgaccaa	aatcccttaa	cgtgagtttt	cgttccactg	agcgtcagac	5040
cccgtagaaa	agatcaaagg	atcttcttga	gatccttttt	ttctgcgcgt	aatctgctgc	5100
ttgcaaacaa	aaaaaccacc	gctaccagcg	gtggtttgtt	tgccggatca	agagctacca	5160
actctttttc	cgaaggtaac	tggcttcagc	agagcgcaga	taccaaatac	tgctccttcta	5220

2016-09-089_178W01_Sequence_Listing

gtgtagccgt agttaggccca ccacttcaag aactctgtag caccgcctac atacctcgct	5280
ctgctaatacc tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg	5340
gactcaagac gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc	5400
acacagccca gcttggagcg aacgacctac accgaactga gataacctaca gcgtgagcta	5460
tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg	5520
gtcggaaacag gagagcgcac gagggagctt ccagggggaa acgcctggta tctttatagt	5580
cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg	5640
cggagcctat ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg	5700
ccttttgctc acatgttctt tcctgcgtta tcccctgatt ctgtggataa ccgtattacc	5760
gcctttgagt gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg	5820
agcgaggaag cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt	5880
cattaatg	5888